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The purpose of this project was to evaluate the hypothesis that lipid conjugation, with 
and without PEG modification, could stabilize and improve the oral deliverability of 
salmon calcitonin (sCT). Six lipidized sCT conjugates were synthesized, of which 
Lipeo-sCT and REAL-sCT were reversible conjugates; Mal-sCT was a non-reversible 
conjugate; and 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-PL-sCT were Mal-sCT 
conjugates modified with PEG at different sites. Except for REAL-sCT, all were 
novel compounds.  
 
Lipeo-sCT was designed to be similar to REAL-sCT, a bioactive peptide with two 
molecules of the anionic palmitic acids covalently conjugated to sCT via reversible 
inter-disulfide bonds. In Lipeo-sCT, the anionic lipids were substituted with 
triethylene glycol monohexydecyl ether, the hypothesis being that an amphiphilic, 
non-anionic lipid could better enhance the interaction of the peptide with cell 
membrane to promote its permeability. Lipeo-sCT and REAL-sCT were successfully 
synthesized by 4-step reactions, and identified by ESI-MS. These two peptides were 
shown by circular dichroism analysis to have robust helical conformations that were 
independent of the dielectric constant of the solvent. MTT assay further indicated that 
Lipeo-sCT had comparable in vitro cytotoxicity against the Caco-2 cells as REAL-
sCT. Analysis of both conjugates by dynamic light scattering (DLS) and transmission 
electron microscopy (TEM) suggested a propensity to form aggregates over a broad 
concentration range. This aggregation was proposed to cause the trypsin-degradation 
of Lipeo-sCT and REAL-sCT to proceed in a step-wise, unidirectional manner, with 
initial cleavage of the peptide occurring at a position furthest from the conjugated 
lipid sites of cysteine 1 and cysteine 7. In contrast, the monomeric sCT was cleaved 
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simultaneously by trypsin at multiple sites. Lipeo-sCT induced comparable 
hypocalcemia to sCT when injected subcutaneously in female Wistar rats at a dose of 
0.145 mg/kg but, like REAL-sCT, exhibited prolonged activity that lasted for at least 
24 h. Through a novel LC-MS method that was developed in this project to quantify 
the lipidized conjugates and sCT simultaneously in a plasma sample, rats injected 
with Lipeo-sCT (1.90 mg/kg) was found to have sCT but not detectable levels of 
Lipeo-sCT in plasma. The plasma sCT showed a Cmax of 16.2 nM at 90 min 
followed by a relatively constant concentration of 5.9~7.0 nM for at least 480 min. 
Conversely, rats injected with an equivalent dose of REAL-sCT (1.81 mg/kg) had 
detectable plasma levels of both REAL-sCT and sCT, the concentration of sCT 
correlating with that of REAL-sCT for at least 6 h. Unmodified sCT, by comparison, 
persisted in plasma for less than 2h following subcutaneous injection at an equivalent 
dose of 1.50 mg/kg. sCT regeneration in vivo was proposed to occur following liver 
metabolism, as an in-vitro study had shown Lipeo-sCT and REAL-sCT to be reduced 
to sCT by incubation with liver juice. Unlike sCT, which showed some hypocalcemic 
activity after oral administration at a dose of 5.0 mg/kg in the rats, equivalent doses of 
peroral Lipeo-sCT and REAL-sCT failed to elicit statistically significant 
hypocalcemia. The poor oral activity of the lipidized conjugates was attributed to their 
inadequate intestinal stability and permeability.  
 
Mal-sCT was synthesized at a very high yield (83%) using a novel aqueous-based 
lipid conjugation method. It was designed to be a non-reversible sCT conjugate in 
which the lipids (palmitic acid) were conjugated to the peptide by thioether bonds via 
a maleimido-lysine linker. The rationale was that the non-reversible lipid conjugate 
might be better able to fulfill the benefits of lipidization in vivo. Mal-sCT formed 
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smaller aggregates (less than 10 nm mean radii) than REAL-sCT and Lipeo-sCT, 
although it also showed a robust helical structure in aqueous solutions. Mal-sCT had 
significantly higher stability against degradation in rat liver juice than sCT, but the 
two peptides had comparable vulnerabilities to degradation in diluted rat intestinal 
solution. Upon subcutaneous injection into the rats, Mal-sCT (dose of 1.91 mg/kg) 
was shown to persist in the circulation for up to 4 h, while an equivalent dose of sCT 
similarly injected could not be detected after 2.5 h. Yet Mal-sCT, injected at 0.145 
mg/kg, produced a comparable hypocalcemic profile in the rat as sCT. Given that sCT 
was not observed following degradation of Mal-sCT in either the liver or intestinal 
solution, this study demonstrated that Mal-sCT had intrinsic bioactivity. Mal-sCT did 
not, however, exhibit statistically significant hypocalcemic activity upon oral 
administraton despite showing a 2 fold higher cellular uptake than sCT in the Caco-2 
cell model. There was large inter-individual variation in the bioactivity of peroral 
Mal-sCT (6.4 mg/kg), with 2 rats showing up to 40% reduction in plasma calcium 
levels that persisted for up to 10 h while 4 other rats failed to show any response.   
 
PEGylation of the Mal-sCT conjugates was hypothesized to further improve the 
stability and permeability of the peptides in the GIT. The PEGylated Mal-sCTs were 
synthesized by 2 methods. In the first method, 1PEG-Mal-sCT and 2PEG-Mal-sCT 
were synthesized by conjugating PEG (MW 5000 Da) to Mal-sCT at lysine 11 and /or 
lysine 18. Synthesis was observed to proceed in a stepwise manner, with 1PEG-Mal-
sCT first synthesized followed by its reaction with another PEG molecule to give 
2PEG-Mal-sCT. The peptides were identified by MALDI-TOF MS, and the sites of 
conjugation were confirmed by HPLC analysis of tryspin-degraded fragments. 1PEG-
Mal-sCT was found to be a mixture of Mal-sCT conjugated with PEG at lysine 11 or 
 X
lysine 18, the former being favoured at higher ratios of activated PEG-succinimide to 
Mal-sCT used in the synthesis. 2PEG-Mal-sCT consisted of Mal-sCT conjugated with 
PEG at both lysine 11 and lysine 18, its yield also increasing at higher ratios of 
activated PEG-succinimide to Mal-sCT. In the second method, Mal-PL-sCT was 
synthesized by conjugating PEG at the ε-maleimido-lysine linker of Mal-sCT to give 
a triblock system. The synthesis involved the generation of a novel PEG-lipid with a 
maleimido group, which was conjugated to sCT via a thio-ether bond similar to that 
employed in Mal-sCT.  Like Mal-sCT, all 3 PEGylated Mal-sCT conjugates had a 
high tendency to aggregate in aqueous solutions. However, the PEGylated Mal-sCTs 
formed much larger aggregates, evident from Tricine-SDS-PAGE, TEM and DLS 
data, the larger size being attributed to the PEG chains and associated solvent sheath. 
Compared with equivalent doses of sCT and Mal-sCT, subcutaneously injected 
1PEG-Mal-sCT and Mal-PL-sCT showed weaker hypocalcemic activity in the rat, 
while 2 PEG-Mal-sCT was inactive. Peroal 1PEG-Mal-sCT and Mal-PL-sCT were, 
however, ineffective at lowering the plasma calcium level of the rats.  
 
In summary, the project has demonstrated that lipidization was an effective method to 
enhance the stability of sCT against liver and intestinal enzymes without sacrificing 
peptide bioactivity. The higher stability was ascribed to the propensity of the lipidized 
conjugates to form aggregates in aqueous media. Nevertheless, this increase in 
peptide stability appeared inadequate to allow for the peptides to retain their 
bioactivity upon oral administration in the rats. Aggregation of the lipidized peptides 
might have compounded the poor deliverability by impeding intestinal uptake and 
permeability. PEGylation of the lipidized sCT further increased their stability, but was 
not desirable in view of a significantly lower intrinsic hypocalcemic activity. 
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Section  1 Introduction 
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The advent of recombinant biotechnology has generated a wide range of peptides and 
proteins as biopharmaceuticals. Most of the biopharmaceuticals in clinical use are 
delivered by invasive methods, such as intravenous or subcutaneous injection. The 
administration of peptide drugs by the oral route, though intensively sought and much 
better understood than ever before, remains a distant goal at present. This impasse is 
closely related to the failure of pharmaceutical scientists to breach the twin barriers of 
enzymatic degradation and low epithelial permeability encountered in the oral 
delivery of peptide drugs. This is reviewed in the following sections. 
 
1.1 Biological barriers in the oral delivery of peptide drugs                          
1.1.1 Enzymatic degradation 
To be absorbed, a peptide drug following oral administration will have to transit along 
the gastro-intestinal tract (GIT), pass the mucous/glycocalyx layer to cross the 
intestinal epithelium into the portal vein, and finally drain into the general blood 
circulation. Most peptide drugs are susceptible to degradation in the GIT by digestive 
enzymes, such as trypsin, chymotrypsin, elastase, carboxypeptidases and 
aminopeptidases, present in the gastrointestinal fluid (1-5), as well as by di-peptidases 
and tri-peptidases located in the mucous/glycocalyx layers (6-8). Further digestion by 
aminopeptidases present in the brush border membrane (9, 10) can occur during the 
passage across the enterocytes. Some peptides may also be degraded by specific 
enzymes, such as the insulin degradation enzyme present in the cytosol (11, 12). Even 
if a substantial amount of the peptide drug is successfully transported through the 
epithelium, most of it will be broken down by extensive first pass metabolism by liver 
microsomes (13-16). Consequently, most, if not all, of the majority of peptide drugs 
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are degraded during the absorption process in the GIT.  
 
1.1.2 Intestinal Permeability  
The permeability barriers presented to an orally administered peptide drug can be 
equally formidable. One of the first barriers encountered is the mucus/glycocalyx 
layers, which consist of 2 adhesive layers of 10 µm thickness (17) and is regarded as 
both a diffusional barrier as well as an enzymatic barrier. Components in the 
mucus/glycocalyx layers include enzymes (8), glycoproteins, proteins (mostly serum 
albumin), proteoglycans, lipids and electrolytes (18-20). Being generally of higher 
molecular weight (MW) and hydrophilicity compared with components in the 
intestinal epithelium, they present a rate-limiting diffusional barrier to the transport of 
peptide drugs, especially large MW peptide drugs (19, 21, 22). In addition, 
electrostatic repulsion from negatively-charged sugar moieties in the mucus layer is 
believed to hinder close epithelial contact by peptide drugs (19, 23, 24).  
 
The second barrier is the intestinal absorptive epithelium, where drug permeation 
occurs predominantly by one of 4 pathways, namely, intracellular passive diffusion, 
intercellular passive diffusion, endocytosis/transcytosis and active transport. Most 
clinical drugs administered by the oral route are absorbed by intracellular passive 
diffusion, a process favored by high drug permeability and concentration gradient 
across the cell membrane. As the cell membrane is made up of phospholipid bilayers 
(25), absorption by passive diffusion is mainly limited to lipophilic drugs with MW 
below 700 Da (25-27). Most peptide drugs are hydrophilic molecules with MW above 
3000 Da, making it difficult for them to traverse the membrane via this pathway. 
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Permeability is observed to increase proportionally with drug lipophilicity (27, 28), 
but is inversely proportional to the molecular size of the drug (26) and the number of 
polar amides in the drug (29). Therefore, unless the peptide drug is small, like 
cyclosporine (30), peptide drugs are generally poorly absorbed across the intestinal 
absorptive epithelium by intracellular passive diffusion.  
 
Intercellular passive diffusion across the intestinal epithelium is regulated by the tight 
junctions. In the absence of permeation enhancers, peptide drug transport is excluded 
because only very small hydrophilic drugs, with MW less than 200 Da, are effectively 
transported through this route (25). The processes of endocytosis/transcytosis and 
active transport are considered to provide minor pathways for drug absorption 
because of their low transport capacity (31, 32). They are generally not available for 
peptide drug transport as most membrane transporters do not recognize large peptide 
drugs as substrates (25, 32). Consequently, despite the availability of different 
transport pathways, many peptide drugs have low intrinsic intestinal permeability. 
 
1.2 Approaches to the oral delivery of peptide drugs 
The biochemical and physical barriers presented in the GIT combine to make the oral 
delivery of a peptide drug a formidable task. It has not, however, deterred 
pharmaceutical scientists from adopting a host of approaches to explore the viability 
of administering a peptide drug via the oral route. These approaches may generally be 
divided into formulation strategies and drug modification strategies. 
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1.2.1 Formulation strategies 
To overcome the enzymatic barrier in the GIT, peroral peptide drugs have been co-
administered with protease inhibitors, such as the Bowman-Birk inhibitor from 
soybeans, ovomucoid and aprotinin bacitracin (33-37). Mechanisms employed 
included (1) competitive inhibition of enzymes; (2) non-competitive inhibition of 
enzymes, and (3) sequestration of metal ions essential for maintaining enzyme 
structure (38). Although many of the enzyme inhibitors are associated with minimum 
cytotoxicity in the short term (39), long-term administration has been shown to 
interfere with the digestion of nutritive proteins (40), and to cause stimulated protease 
secretion (41), hypertrophy and hyperplasia of the pancreas (42, 43). Of greater 
concern is the development of neoplastic foci following the long-term administration 
of enzyme inhibitors, as these can progress to invasive carcinomas (44). 
 
To increase their intestinal permeability, peptide drugs have been co-administered 
with chemical enhancers, mostly surfactants (e.g. sodium dodecyl sulfate (SDS), 
polysorbate 80, nonylphenoxy(polyoxyethylene) and polyoxyethylene ethers (45-47), 
and Triton®-100 (48)), bile salts (e.g. sodium taurocholate (TC), sodium 
taurodeoxycholate (TDC) (45)), and specific tight junction modifiers, (e.g. chitosan 
(49, 50), its analogue N-trimethyl chitosan chloride (51, 52) and zonula occludens 
toxin (53-55)). The surfactants work by partitioning into the phospholipid bilayer cell 
membrane to disrupt its integrity (39, 45). Tight junction modifiers may modulate the 
function and expression of the paracellular junction proteins, as in the case of chitosan 
and its analogues (56-58), or they may trigger a cascade of events through protein 
kinase C-dependent actin reorganization, e.g. the zonula occludens toxin (59). 
Unfortunately, many of these agents are associated with unacceptable toxicity, such as 
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reduced cell viability (39, 60-62), epithelial damage and histological changes to 
intestinal tissues (45, 63, 64). There is also concern that the indiscriminate disruption 
of protective epithelia by these agents may expose the host to exotic toxins and 
attacks by opportunistic organisms (65). 
 
A more recent strategy, the mechanism of which has not been fully elucidated, 
involved the incorporation of low MW, N-acetylated, non-α, aromatic amino acids, 
such as N-[8-(2-hydroxy-4-methoxy)benzoyl]amino caprylic acid (4-MOAC) and 4-
[4-[(2-hydroxybenzoyl)amino]phenyl]butyric acid, to facilitate the GI absorption of 
macromolecules (66-68). The vector, which has been applied to the recombinant 
human growth hormone (rhGH) (69) and parathyroid hormone 1–34 [PTH], the 34 
residue parathyroid fragment (67), was hypothesized to bind with the peptide drug to 
reversibly destabilize its native structure to a partially unfolded conformation. The 
unfolding of the peptide was proposed to facilitate its permeability across absorptive 
epithelia without affecting the integrity of the epithelial membrane (67). Although 
there is no direct evidence to support the hypothesis, at least one randomized 
crossover double-blinded phase I trial has shown the method to be potentially useful 
for the oral delivery of salmon calcitonin (70). However, the structure-activity 
relationship for these low MW vectors has not been established, and their activity has 
to be empirically assessed on a case-by-case basis. 
 
Several strategies based on mechanical barriers have shown great potential for the oral 
delivery of peptide drugs. One of these involved the use of microtablets as intestinal 
patches (71-74). Coated on one side with ethylcellulose to form an impermeable drug 
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barrier and a mucoadhesive comprising carbopol 934 and pectin, with or without 
sodium carboxylmethylcellulose, on the other end, the microtablets were designed to 
adhere to the intestinal mucosa to provide uni-directional drug release at the 
absorptive site. This system had been tested with insulin and was shown to increase 
the amount of insulin absorbed (72).  
 
Another system involved the use of water-sensitive superporous hydrogels (SPH), 
mainly (meth)acrylic acid/maleic acid copolymers (75), as enteric coated capsules 
(76-78). The delivery system consisted of a shuttle-like SPH conveyer and a drug core, 
which was either inserted into the conveyor system or attached to the surface of the 
conveyor system by edible glue (76). Swelling of the SPH in the intestinal lumen 
would force the drug core to come into intimate contact with the intestinal mucosa 
and cause the immediate release of the drug (77).  This was found to be efficient in 
increasing the oral bioavailability of octreotide, with further enhancement of 
bioavailability achieved through the addition of N-trimethyl chitosan, a permeation 
enhancer, in the drug core (77). The mechanism was multifold, involving the direct 
modulation of tight junction proteins (57), sequestration of calcium ions to modify the 
activity of paracellular junction proteins and intestinal enzymes (76), as well as the 
intimate contact of drug with the absorptive epithelium (78, 79). A peptide drug could 
also be encapsulated within a polymer matrix to shield the drug from enzymatic 
degradation until its release at the absorptive site (80). This strategy has been further 
improved by using mucoadhesive and/or pH-sensitive block polymers, such as the 
poly(methacrylic-g-ethylene glycol) hydrogels (81-84), which can prolong the 
residence time of the drug at the site of absorption.  
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Despite the progress made, strategies based on the formulation approach do not 
resolve the poor intrinsic permeability of peptide drugs. For this reason, some 
pharmaceutical scientists sought to chemically modify the peptide drugs to overcome 
the enzymatic and permeability barriers encountered in the GIT. In the following 
paragraphs, strategies based on the chemical modification of peptide drugs are 
discussed.  
 
1.2.2 Chemical modification strategies 
Chemical modification strategies generally involve the conjugation of a protein drug 
via a chemical bond with certain functional group(s) to stabilize the drug against 
enzymatic degradation and to enhance drug permeability across absorptive epithelia. 
Reported functional groups include transferrin, polyethylene glycol (PEG), 
amphiphilic molecules, and lipids. Peptides, such as insulin and granulocyte colony-
stimulating factor (85-87), when conjugated to transferrin, have been shown to hijack 
the transferrin-mediated endocytosis/transcytosis pathways for effective translocation 
into and across epithelial cells. The strategy has been amply demonstrated by Shen's 
group (85-89), who pioneered the chemical modification strategies, not only with 
transferrin but also with lipids (90-96) as the functional groups. This thesis focused on 
the lipid modification of peptide drugs, with and without the co-conjugation of PEG 
and amphiphilic molecules. Thus, these functional groups are elaborated in the 
following paragraphs.   
 
1.2.2.1 Conjugation with PEG  
PEG modification is an established method to improve the aqueous solubility (97) and 
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decrease the immunogenicity of a peptide drug (98). It has been widely applied to 
prolong the half-life of peptide drugs administered by injections (99). The increased 
circulation time was achieved through enhanced drug stability in vivo (100), reduced 
renal clearance (99) and prolonged local residence at the injection site (101). The 
improved pharmacokinetic properties are often related to the size of the PEG 
molecules, the larger PEG molecules having a greater affinity for water and therefore 
providing a more efficient shield to hinder enzyme degradation and renal filtration 
(101). As each PEG subunit is capable of binding with 2-3 water molecules, a peptide 
drug conjugated with a PEG could be 5-10 fold larger in size compared to the 
unmodified counterpart (99).  
 
On the other hand, the increase in size, which might also be attained by multiple 
conjugation of PEG molecules, could decrease both the permeability and activity of 
the peptide drug (102, 103). In this respect, smaller PEG molecules may be more 
useful, particularly for the non-invasive delivery of peptide drugs. For example, the 
conjugation of insulin with PEG of 750 Da was found to increase peptide stability 
against elastase and pepsin without affecting its biological half-life or Caco-2 cell 
monolayer permeability (103). When formulated into mucoadhesive tablets with 
thiolated poly(acrylic acid) (thiomer)–cysteine as the carrier matrix, the conjugate 
could significantly decrease the blood glucose level of diabetic mice for at least 24 h 
compared with an equivalent dose of unmodified insulin. The prolonged activity of 
the PEG (750)- insulin conjugate was ascribed to its enhanced stability, although the 
thiomer matrix might play a synergistic role by inhibiting interaction with intestinal 
enzymes (104), and prolonging residence time through the formation of covalent 
bonds with the intestinal mucus glycoproteins (105). In another study, salmon 
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calcitonin (sCT) conjugated with a 2000 Da-PEG molecule was shown to cause a 4-
fold increase in hypocalcemic activity after nasal instillation, while sCT conjugated 
with a 12 KDa PEG had decreased hypocalcemic activity in comparison with 
equivalent dose of 2 IU/kg unmodified sCT (102). The superior activity of the sCT 
conjugated with 2000 Da-PEG was again correlated to its stability in the nasal mucosa 
(106).  
 
Recent studies involving poly(caprolactone)-b-poly(ethylene oxide) (PCL-b-PEO), 
however, do not support the supposition that conjugation with larger PEG molecules 
will hinder the absorption of peptides. PCL-b-PEO contained 1 PEG chain 
(approximate MW 2000) surrounding the PCL hydrophobic core, and it formed 
spherical particles of 20~45 nm in aqueous media. Although the PCL-b-PEO 
nanoparticles were much bigger than most molecules modified with a single PEG 
chain, yet the nanoparticles were effectively transported into cell cytoplasm and 
subsequently translocated into cytoplasmic compartments (107). So far, no 
explanation has been offered on the efficient translocation; however, the results did 
show that absorption might not be limited to small PEG molecules as long as the PEG, 
together with other fragments, can form spherical nanoscaled structures. There is, 
however, no evidence that PEG conjugation will promote the aggregation of a peptide 
drug into particles, nor is there evidence to suggest that the conversion of the 
molecular drug into aggregated particles will facilitate its oral delivery.  
 
1.2.2.2 Conjugation with amphiphilic molecule  
Pioneering research on the potential of using amphiphilic moieties to improve peroral 
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peptide bioavailability has been published by the Nobex Corporation (25, 108-111). 
The amphiphilic group contained 1 or more alkyl groups together with 1 or more 
ethylene oxide (also called ethylene glycol) oligomer. Conjugation usually occurred 
via an amide bond between the ε-amine of lysine in the peptide and the carboxyl 
group present in the alkyl or ethylene oxide chains of the amphiphilic molecule (111).  
 
The hexyl-insulin monoconjugate-2 (HIM2) is an example. It consists of insulin 
conjugated with methyl ethylene glycol heptamer modified hexanoic acid at the lysine 
moiety of B29. This conjugate caused a prolonged reduction of postprandial glycemia 
in mongrel dogs  (112), and produced significant activity after oral administration to 
both type 1 and type 2 diabetic patients in Phase 1 and Phase 2 clinical trials (113, 
114). Another example is salmon calcitonin conjugated with a molecule each of 
ethylene glycol heptamer (PEG7) modified hexanoic acid or ethylene glycol hexamer 
(PEG6) modified dodecanoic acid. This conjugate retained osteoclast activity in 
osteoclast cell models (115), and was adequately absorbed following oral 
administration to human volunteers to cause a decrease in plasma calcium ion level 
(108).  
 
A more recent study was conducted with the brain natriuretic peptide (hBNP), a 32-
amino acid peptide with a loop region consisting of 17 residues between 2 cysteine 
intra-disulfide bonds and 3 lysines at positions 3, 14 and 27. Conjugation of this 
peptide at lysine 3 with mPEG7 modified dodecanoic acid did not affect its in vitro 
activity in the human aortic endothelial cell model (111). One hBNP conjugate, 
CONJ-hBNP-021, conjugated with branched mPEG4 urethanyl C6, was found to be 
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orally available at the dose of  350 µg/kg, and was capable of activating the cGMP to 
reduce the mean arterial pressure (MAP) in normal conscious dogs while unmodified 
BNP showed no such bioavailability and activity at the same dose (110, 111).  
 
As with PEG modification, the conjugation of peptides with amphiphilic molecules is 
designed to block interaction with degradative enzymes, and increase the intestinal 
permeability of the peptides (25, 109, 116). There is, however, no report on the 
mechanism by which permeability was enhanced. On the other hand, the amphiphilic 
molecules are conjugated to the peptides by non-reversible bonds, which could result 
in decreased or even complete loss of activity (111). In addition, the activity of the 
amphiphilic peptide conjugates has to be studied on a case-by-case basis due to a lack 
of structure-activity relationship data (111). 
 
1.2.2.3 Conjugation with lipids 
Membrane phospholipids form the skeleton of intestinal epithelium cells and they 
readily interact with exogenous lipids in aqueous media by hydrophobic interactions 
(90). Lipids conjugated to a peptide drug do not lose this capacity to interact with 
membrane phospholipids, yet are able to significantly change the biophysical 
properties of the drug to promote its enzyme stability (117), biodistribution (95), 
pharmacological activity (118) and deliverability across absorptive epithelia (90).  
 
Lipid modification of a peptide drug was first reported by Hashimoto et al. in 1989 
(119) and subsequently by numerous other research groups (90, 119-122). The 
accumulated knowledge has led to this becoming an important method for improving 
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peptide drug delivery. The lipidized peptides are often associated with enhanced 
stability, stronger binding with serum proteins, and prolonged residence at the 
administration site. Collectively, these effects have been proposed to increase and 
prolong the pharmacological activity of the peptides in vivo. The following sections 
discuss the changes in biophysical properties after lipid conjugation of a peptide drug.  
 
(A) Stabilization  
Enhanced stability of a lipidized peptide against degradation by various enzymes in 
the GIT and liver has been widely reported. Delie et al. were among the first to 
demonstrate this, showing the penta-peptide, rennin inhibitor SR 42128, to be more 
stable upon incubation with chemotrypsin and with gastric and intestinal fluids, after 
it was conjugated with 1,3-dipalmitoyl-glycerol (123). More recently, Wang & Shen 
applied lipid modification to prolong the persistence of the Bowman–Birk protease 
inhibitor, a 9 KDa peptide, in the mouse stomach (92). A series of fatty acid 
conjugates of desmopressin has also been reported by Wang et al. to exhibit greater 
stability against hepatic metabolism in vitro, which, after subcutaneous injection, 
translated to up to 250 fold higher in vivo activity compared with unmodified 
desmopressin  (91, 93).  
 
Despite the many reports on the stability of lipidized peptides, the mechanism for the 
enhanced stability remains unknown. Harris & Chess have ascribed the stabilization 
of PEG-conjugated peptides to a ''shielding effect'' that arises from the physical 
boundary imposed by the large and flexible PEG (usually more than 5 KDa) as well 
as the water molecules bound to the hydrophilic PEG (99). This theory cannot, 
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however, be applied to lipidized peptides because the hydrophobic and small lipid 
(normally around 500 Da) will not provide an effective shield in aqueous milieu 
against the degradation enzymes. 
 
(B) Prolonged drug activity 
Prolonged drug activity has been reported for lipidized peptides. While the stability of 
the conjugates may play a role, studies involving subcutaneously administered 
lipidized insulin analogs have suggested the binding of the analogs to tissues at the 
administrative site and to serum albumin to be the predominant factors. In one 
example, Lys (B29) (N-ω-carboxynonadecanoyl)-des(B30) human insulin (O346) was 
found to have extended hypoglycemic activity lasting 25 fold longer than regular 
human insulin after intravenous injection in the dog model (124). Demonstration of a 
strong binding to serum albumin indicated that the bound insulin could serve as a 
depot in the general circulation to slowly release the insulin to target tissues (124). 
Another example is insulin detemir [Lys (B29) (N- ω-carboxytetradecanoyl)-des(B30) 
human insulin, which showed protracted activity and smaller between-subject 
variability in pharmacodynamic profile in human subjects (120, 125). The protracted 
activity was attributed to serum albumin binding, although more recent data suggested 
a local binding of the insulin conjugate to tissues at the injection site, followed by 
slow absorption into the general circulation. On the other hand, the prolonged activity 
of deoxycholic acid-modified insulin in the diabetic rat model was attributed to the 
propensity of the insulin conjugate to aggregate (121). While this was suggested to be 
useful for the oral delivery of insulin, it has not been verified with follow up studies.  
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(C) Reduced or loss of activity 
A problem frequently encountered with lipidized peptides, as with other non-
reversible modification of peptides, is the reduction and, in some cases, loss of 
activity. For example, the palmitoylation of insulin at the phenylalanine 1 and lysine 
29 positions on the B chain resulted in a complete loss of hypoglycemic activity (119). 
To resolve this problem, Shen's group designed a novel lipidization method, which 
they termed reversible aqueous lipidization (REAL). REAL refers to the covalent 
conjugation of a peptide drug with aqueous-soluble fatty acid through a labile inter-
disulfide bond with a thiol containing linker, such as cysteine. As the fatty acids were 
water-soluble, this technique avoided the use of organic solvents, which was the norm 
in peptide lipidization methods and a cause of the deactivation of protein structure and 
activity (90).  The labile inter-disulfide bond was designed to break down after the 
conjugate has been transported into the reductive environment of the cell cytoplasm 
(90, 126). The REAL method has been successfully applied on desmopressin and 
octreotide. I125-labeled desmopressin modified by the REAL technique showed a 250-
fold increase in activity and a 7-fold increase in area under the plasma concentration-
time (AUC) curve in comparison with  non-modified I125-labeled counterpart after 
intravenous injection (91).  As liver was a major site for the reduction of the inter-
disulfide bond to regenerate the parent drug (93), the activity of the conjugate was 
related to its stability in the liver, which in turn was dependent on the chain length of 
the lipid. The REAL method was also shown to increase octreotide activity by the 
same mechanism (95), and to prolong the circulation time of octreotide through serum 
protein binding and local tissue depot effect  (90, 91, 93-95). 
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1.3 Salmon calcitonin 
Salmon calcitonin (sCT) (Figure 1) was the model polypeptide for this project. 
Calcitonin (CT) is secreted mainly by parafollicular (C) cells in the thyroid gland in 
mammals, and in the ultimobranchials body of non-mammals, such as in fish, 
amphibians, reptiles and birds. To date, calcitonins from at least 15 species have been 
isolated, and the calcitonin sequence from the hog, beef, sheep, man, rat, eel and 
salmon have been elucidated. Although all these CT have 32 amino acids, with a 
proline amide at residue 32 and an N-terminal disulfide bridge between residues 1 and 
7, they share only a small degree of sequence similarity (127).   
 
Figure 1 Amino acid sequence in salmon calcitonin 
 
Calcitonin is an endogenous regulator of mineral metabolism, especially calcium 
homoeostasis. The calcitonin receptor is ubiquitous, and is found in the bone, kidney, 
central nervous system (brain) and pituitary gland.  Calcium, as the fifth most 
abundant element in the body, is a major constituent of the physiological milieu and it 
plays a vital role for the proper function of the skeletal and muscular systems. 
Calcium is also involved in the control of cell permeability, neuromuscular 
excitability, muscular contraction, as well as enzyme and ATP activation.  In addition, 
calcium homeostasis controls the movement of other ions, such as phosphate and 
magnesium. Calcitonin regulates calcium homeostasis by inhibiting the resorption of 
osteoclasts and the intestinal absorption of calcium,  as well as by increasing the renal 
excretion of calcium (127).    
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Exogenous calcitonin is used clinically to treat a variety of diseases related to 
increased bone resorption, such as Paget’s disease, osteoporosis and hypocalcaemia 
(127). It has also been used as an analgesic for treating acute vertebral crush fractures 
and metastatic pain (128). Calcitonins from human, pig, salmon, and eel are used 
therapeutically, and are now manufactured by recombinant biotechnology (129). 
Among these, salmon (sCT) and eel (eCT) calcitonins have the highest potency in 
inhibiting bone resorption in human (127), the activity of sCT being about 50 fold that 
of human calcitonin. The potency of sCT has been related to a strong binding affinity 
for the calcitonin receptor, and a strong resistance against enzyme degradation (127). 
 
Although sCT has been widely used as a drug, its rapid degradation by trypsin, 
chymotrypsin and elastase (35, 130) has limited its administration to the subcutaneous 
injection route. The long-term application of sCT is therefore hindered by the 
inconvenience and poor tolerability of the route of administration. It was only in 1995 
that a nasal formulation of calcitonin, Miacalcin Nasal Spray™, was approved by the 
USA Food and Drug Administration (FDA). Considering the chronic nature of the 
treatment of bone diseases, the oral delivery of sCT is still the most preferred method 
of administration for most patients.   
 
Like other peptide drugs, sCT has very low oral bioavailability of less than 0.05% 
relative to iv injection (131, 132). Formulation methods have been exhaustively 
researched to improve the oral delivery of sCT, including formulations with chitosan 
derivative (133-138), phospholipids (139), poly-N-isopropylacrylamide (PNIPAAm) 
(140), and pH-sensitive polymers, such as Eudragit (141). Enhanced bioavailability of 
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sCT delivered by these systems is often ascribed to the encapsulation of the peptide to 
protect it against enzymatic degradation (142), increased permeation via the 
paracellular transport pathway (136, 137), and/or prolongation of residence time (136-
138, 140) and intimate contact of peptide with the intestinal epithelium (137) through 
muco-adhesion  at the absorption site.  
  
In addition to formulation strategies, chemical modifications with PEG, amphiphilic 
or lipid molecules have also been used to improve the intestinal absorption and 
stability of calcitonin. sCT conjugated with PEG (2000 Da) at lysine 18 via amide 
bond showed significantly greater hypocalemic activity in comparison with 
unmodified sCT after intra-colonic or intra-nasal administration at a dose of 5 µg/rat 
(102, 143). The enhancement effect was ascribed to enhanced stability against 
degradation enzymes and prolonged absorption time of intact PEG conjugate (106, 
143). sCT modified with Nobex proprietary amphiphilic molecules (CT-025) also 
lowered to a significant level the baseline plasma calcium level after oral 
administration at equivalent sCT doses of 320 µg and 160 µg to human volunteers 
(108). The plasma concentration of CT-25 was found to correlate with the dose 
administrated. In addition, the acylation of CT with lipid fatty acids, such as acetic 
acid and caproic acid, at lysine 11 to lysine 18, was found to enhance the 
hypocalcemic activity after oral administration, the stability and absorption of the 
peptide being dependent on the length of the conjugated fatty acid (144). Permeability 




In a recent study, Shen's group also demonstrated that REAL can be used to enhance 
the oral delivery of sCT. Based on the detection of a bone resorption marker, 
deoxypyridinoline, in urine, REAL-sCT was shown to be active in inhibiting bone 
resorption in ovariectomized (OVX) rats when administered in Liposyn® (an 
emulsion) at the dose of 50 µg/kg/day while sCT at the same dose did not produce the 
same activity (94). Nevertheless, the emulsion base itself has previously been shown 
to be an effective delivery system for the oral administration of insulin (145, 146). 
Thus, the oral activity of REAL-sCT might be due to the encapsulation of REAL-sCT 
in the oil droplets of the emulsion, and not due to a lipid-induced enhanced 
permeability. Therefore, despite the success of REAL technology in promoting 
peptide bioavailability, there is hardly any report on the effect of lipidization on oral 
peptide delivery without the synergistic effect of formulation.  
 
1.4 Statement of purpose 
The hypothesis for this project was that lipid conjugation, with and without PEG 
attachments, could stabilize and improve the oral deliverability of peptide drugs. 
Lipid conjugation has been shown by several studies to be a promising method for 
increasing the deliverability of a peptide drug (94, 110, 120). The lipid can facilitate 
interaction between the peptide and its binding sites on the cell membrane, and 
promote a depot effect through binding to plasma proteins and the local 
administration site (124, 125). Lipid modification can also increase the enzymatic 
stability of the peptide drug (92, 123). Collectively, these properties may contribute 
towards delayed systemic absorption and increased plasma circulation time, which 
can lead to prolonged or even enhanced efficacy. This is seen with insulin detemir 
[NN-304, also known as Lys B29–tetradecanoyl des–(B30) human insulin], a soluble, 
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long-acting insulin which shows a flat time-action profile over 12h and a long 
clearance rate from its subcutaneous injection site (147). Likewise, stearoyl acylated 
antiviral antibodies have been observed to suppress virus reproduction by 100-fold 
greater than non-modified antibodies because of their capacity for intracellular 
penetration (118).  
 
Besides lipidized peptides, reversible and non-reversible oligo-PEG and PEG-
modified peptides have also been demonstrated to be more stable than unmodified 
drugs in intestinal and other biological fluids (106, 116). The attachment of an 
uncharged, amphiphilic oligo-PEG modified lipid might in fact favor the interaction 
of a peptide drug with the negatively charged intestinal membrane compared with 
conjugation with a negatively charged lipid (19, 23, 24) . Although data had shown 
higher MW PEG to hinder the oral absorption of conjugated peptides (103), recent 
evidence has suggested that high MW PEG conjugation can promote molecular self-
assembly, which can in turn facilitate cellular uptake, very likely by endocytosis (107).  
 
The model drug for this project was salmon calcitonin. As is typical of peptide drugs, 
sCT has very low oral bioavailability, and an orally bioavailable form has not yet 
been developed. The collective results from previous studies have showed that the 
lipidization of sCT has the potential to enhance its oral activity and bioavailability.  
 
Studies designed for this project therefore had the following objectives: 
(1) To determine whether the reversible lipidization of sCT with an amphiphilic, non-
anionic group could enhance its oral activity relative to reversible conjugation of sCT 
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with an anionic lipid via the REAL technique.  
 
(2)  To determine whether the non-reversible lipidization of sCT could enhance its 
oral bioavailability. Oral activity of a reversible lipid-peptide conjugate is presumably 
dependent upon the reversion of the conjugate to the unmodified peptide by reductive 
reactions in the liver (93, 94). However, sCT chemically modified at the disulfide 
bond has previously been demonstrated to retain its bioactivity (148, 149). Since a 
non-reversible lipid conjugate of sCT was likely to be more stable in the physiological 
milieu than the regenerated parent sCT (95), we hypothesized that the lipidization of 
sCT via a non-reversible thio-ether bond might produce a bioactive peptide with 
superior oral bioavailability.  
 
(3) To determine whether the attachment of PEG chains to non-reversible lipidized 
sCT would produce bioactive peptides with enhanced oral deliverability. This study 
was based on the evidence that PEG-modified molecules could form nanoparticles in 
aqueous media, which could promote cellular uptake via endocytosis (107). Data from 
our laboratory and another laboratory had already indicated the tendency of lipidized 
peptides to form aggregates (121), leading us to hypothesize that the attachment of 
PEG molecules might further promote the aggregation of the conjugated peptides into 
nanoparticles that would facilitate oral absorption. There was, however, a concern that 
the multiple modification of sCT could compromise its activity. For this reason, the 
study included the development of novel methods whereby PEG was either 




Section  2 REAL-sCT and Lipeo-sCT:     
Reversible lipidization of sCT for oral delivery 
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2.1 Introduction  
The reversible aqueous lipidization (REAL) method has been shown to be a 
promising tool for improving the deliverability and in vivo activity of peptide drugs 
(90-94). REAL modification resulted in enhanced epithelial uptake and permeability 
(90, 94), sustained release of the parent drug from the lipid conjugate in vivo (91, 93-
95),  improved targeting to the liver to treat hepatocelluluar carcinoma (95), as well as 
increased stability (93) and binding to local tissues (91) for the peptide molecule. 
Using the method of Bjellqvist et al. (150), the isoelectric point (pI) of sCT was 
calculated to be 8.45, suggesting that sCT could be positively charged at the 
physiological pH of 7.4, possibly due to the protonation of the lysine 11, lysine 18 and 
arginine 24 moieties. This net positive charge could be advantageous, as the 
protonated lysine and arginine moieties in cell penetrating peptides were found to 
facilitate the adsorption (151) and subsequent translocation of these peptides across 
cell membranes (152-154). REAL lipidization of sCT could, however, negate this 
advantage as the conjugation of 2 negatively charged lipid chains might result in a 
neutral or negatively charged molecule at physiological pH. Our hypothesis was that 
the conjugation of a neutral or positively charged lipid might result in better cellular 
uptake of sCT in vivo.   
 
The conjugation of small, amphiphilic, oligo-PEG fatty acid conjugate, via a non-
hydrolyzable amide bond at the free ε-amine of the lysine moiety, has been shown in 
clinical trials to be effective in enhancing the oral absorption of peptide drugs, such as 
insulin (113, 114), human brain natriuretic peptide (110) and sCT (108). The 
conjugation method remains, however, to be optimized, because it is frequently 
associated with decreased or loss of activity (111). Our hypothesis was that if the 
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amphiphilic molecules were conjugated with sCT through a reversible bond using the 
REAL method, it could minimize the loss of activity.  
 
The purpose of the study in this section was to synthesize and evaluate a novel 
lipidized sCT, namely Lipeo-sCT (Figure 2 A), which was obtained by conjugating a 
triethylene glycol monohexyldecyl ether (C16E3OH, E: ethylene glycol) group to sCT 
via disulfide bonds. Unlike REAL-sCT, Lipeo-sCT might retain a positive charge at 
physiological pH as it involved the modification of sCT with amphiphilic lipids. The 
physiochemical properties of the peptide, together with its stability and reversibility in 
biological fluids were studied. In addition, the capacity of the peptide to lower plasma 
calcium level following subcutaneous injection and oral gavage was examined in the 
rat model. REAL-sCT (Figure 2B) was also synthesized and, together with sCT, used 






































Figure 2 Chemical structure of (A) salmon calcitonin-triethylene glycol monohexadecyl ether 
conjugate (Lipeo-sCT) and (B) Reversible Aqueous Lipidized salmon calcitonin (REAL-sCT)  
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2.2 Materials and Methods 
sCT from Unigene Laboratory (NJ, USA); cysteine hydrochloride, 3,3'-dithiobis-
pyridine (dithiodipyridine) (DTDP), 3-mercapto-propanoic acid (3-MPA), 
dicyclohexylcarbodiimide (DCC), triethylene glycol monohexyldecyl ether 
(C16E3OH), trifluoroacetic acid (TFA), succinimide palmitate (Suc-Pal), sodium 
dodecyl sulfate (SDS), N,N,N′,N′-tetramethyl-ethylenediamine (TEMED), 
peroxydisulphate, trypsin (TPCK treated, bovine), N,N'-methylene bis-acrylamide, 
D2O and CDCl3 from Sigma-Aldrich (St. Louis, MO, USA); 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) from BDH Chemicals Ltd. (Poole, 
England). N-tris(hydroxymethyl)methylglycine (Tricine) was from Amersham 
Biosciences (Little Chalfont, Buckinghamshire, England). Polyacrylamide gel (40% 
stock solution with 38:1 w:w ratio of acrylamide to N,N'-methylene bis-acrylamide) 
and dithiothreitol (DTT) were from Bio-Rad (Hercules, CA, USA). MicroBCA 
Protein Assay Kit was from Pierce Biotechnology (Rockford, IL, USA).  Acetonitrile 
and isopropanol of High Pressure Liquid Chromatography (HPLC) grade, 
cyclohexane, chloroform and acetone of analytical grade were supplied by Fisher 
Scientific (Irvine, CA, USA). Milli-Q water was used in the mobile phase for HPLC 
analysis. Silica-gel (15–40 µm) was from Merck (Darmstadt, Germany).   
 
Finnegan MAT LCQ mass spectrometer, equipped with an Electrospray Ionization 
(ESI) or Atmospheric Pressure Chemical Ionization (APCI) source, and coupled with 
Xcalibur LCQ Tune Plus Version 1.0 SR software (San Jose, CA, USA), was used for 
mass spectrometry analysis. The MS spectrometer settings were as follows: capillary 
temperature 270 °C; shealth gas 75 unit/min; auxiliary gas 20 unit/min, spray voltage 
4 kV, capillary voltage 10 V. LC flow rate: 0.5 ml/min (50% methanol). Injection 
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volume: 20 µl.  Bruker 300M NMR was used for all the NMR analyses. Plasma 
samples in the pharmacokinetic study were analyzed using the Q-TRAP LC-MS/MS 
system (Applied Biosystems Inc. CA, USA). 
 
Caco-2 cells were from American Type Culture Collection (Rockville, MD, USA). 
Minimal essential medium (MEM), fetal bovine serum (FBS), non-essential amino 
acids (NEAA) and Opti MEM were from Gibco BRL Life Technology (Grand Island, 
NY, USA) while the cell culture flasks (75 cm2) were from NUNC (Rochester, NY, 
USA). 
 
2.2.1 Synthesis  
Lipeo-sCT  
Synthesis of 3-(2-(pyridin-2-yl)disulfanyl)propanoic acid (I) (Figure 3) was 
performed according to a published method (155) with slight modification. 2.05 g of 
DTDP (9.32 mmol) dissolved in water (containing 15 ml of acetic acid) was reacted 
with 675 μl of 3-mercaptopropanoic acid (7.76 mmol, added stepwise) at ambient 
condition for 4 h. The target product was separated from the reaction mixture in a C-
18 HPLC semi-preparative (10×250mm) column with gradient elution from 30% to 
70% methanol (containing 0.1% TFA) in 20 min. The fractions containing the target 
compound were collected, the solvent was evaporated and the residue was dried in a 
desiccator under vacuum. The yield was 0.996 g (49.7%). ESI-MS (MH+): 
experimental m/z: 215.4 (calculated 216.0). 1H-NMR (D2O) δ (ppm): 8.63 (d, 1H, 
Pyridyl-6'H), 7.90(m, 2H, Pyridyl-4', 5' H), 7.39(m, 1H, Pyridyl- 3'H), 3.10(t, 2H, -
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Figure 3 Synthesis Pathway of Lipeo-sCT 
 
2-(2-(2-(hexadecyloxy)ethoxy)ethoxy)ethyl 3-(2-(pyridin-2-yl)disulfanyl) propanoate  
(II) (Figure 3) was synthesized by condensing 748.6 mg of  C16E3OH (2.0 mmol) and 
446.9 mg of 3-(2-(pyridin-2-yl)disulfanyl) propanoic acid  (I) (2.08 mmol) in 17 ml of 
CH2Cl2 with 482.6 mg (2.34 mmol) of DCC at ambient conditions for 1.5 h. The 
reaction mixture was flushed stepwise in a silica-gel column with cyclohexane-
acetone mixture at volume to volume ratio of 100: 1 to 100: 4. Fractions containing 
the target were pooled and dried in rotary evaporator. The yield was 513.3 mg 
(44.9%). ESI-MS (MH+: experimental m/z 572.3 (calculated 572.3) and MNa+: 
experimental m/z 594.3 (calculated 594.3).  1H-NMR (CDCl3) δ (ppm): 8.47 (d, 1H, 
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pyridyl-6'H), 7.66 (m, 2H, pyridyl-4'H , 5'H), 7.10 (t, 1H, pyridyl-6'H), 4.25 (t, 2H, -
COOCH2CH2O-), 3.63 (m, 10H, -
COOCH2CH2OCH2CH2OCH2CH2OCH2CH2(CH2)13CH3), 3.44 (t, 2H, -
OCH2CH2(CH2)13CH3), 3.07 (t, 2H, -SSCH2CH2COO), 2.79 (t, 2H, -
SSCH2CH2COO-),  1.55 (m, 2H, -OCH2CH2(CH2)13CH3), 1.28 (m, 26H, -(CH2)13-), 
0.88 (t, 3H, -CH3). 13C-NMR (CDCl3) δ (ppm): 171.51, 149.69, 137.02, 120.74, 
119.72, 71.54, 70.64, 70.57, 70.02, 69.00, 63.92, 33.76, 33.34, 31.88, 29.66, 29.60, 
29.59, 29.47, 29.32, 26.07, 22.65, 14.08.  
 
Synthesis of Lipeo-sCT (IV) was adapted from published methods (91, 155). 22.45 
mg of sCT dissolved in 5 ml of water was reduced with 67.8 mg of dithiothreitol 
(DTT) at 2~8°C over 4 h. The reduced calcitonin, identified by ESI-MS and separated 
by HPLC, was reacted under argon with compound II in 50% ethanol for about 16 h, 
and the target product, Lipeo-sCT, was isolated in a C-18 semi-preparative column 
(10 × 250mm) by gradient elution of ACN-IPA (1:1, with 0.1% TFA) from 0% to 
100% in water (with 0.1% TFA) in 45 min at a flow rate of 2 ml/min. Fractions 
containing the target conjugate were pooled and the organic solvent removed in the 
rotary evaporator at ambient temperature. The residue was freeze-dried (Dynavac 
FD8 Freeze Drier, Australia) and labeled as Lipeo-sCT (yield 40~50%). 
 
REAL-sCT  
REAL-sCT was synthesized according to published methods (90, 155), with slight 
modification (Figure 4). 3.816 g of DTDP (0.0173 mol) was dissolved in a mixture 
containing 20 ml of water and 34 ml of acetic acid before the stepwise addition of 
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1.881 g cysteine (0.0155 mol). The mixture was stirred overnight (16 h) and side 
products generated were extracted by 50 ml of chloroform. The aqueous layer was 
separated, dried and mixed with 5.2 g of silica-gel. The silica-gel mixture was 
desiccated and packed into a 40-g silica-gel column, and eluted stepwise with 
chloroform, 10% of methanol in CHCl3, and 20% of methanol in CHCl3. Fractions 
containing the target product, cysteinyl pyridyl disulfide (CPD), identified with mass 






















































Figure 4 Synthesis pathway for REAL-sCT 
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Palmitoyl derivative of cysteinyl pyridyl disulfide (Pal-CPD) was synthesized 
according to a reported method (90).  277.0 mg of CPD dissolved in 13.85 ml of 
dimethylformamide (DMF) was mixed with 750 µl of triethylamine and 567.0 mg of 
succinimide palmitate (Suc-Pal). The reaction proceeded for 5 h at ambient 
temperature and was terminated by the addition of 300 ml of water. The pH of the 
solution was adjusted to pH 3.0 with 2~3ml of 1N HCl. The precipitate was isolated 
by filtration, desiccated and dissolved in CHCl3 before it was eluted stepwise in a 32 g 
silica-gel column with CHCl3, followed by combination of CHCl3 and CH3OH in the 
volume ratios of 50:1, 30:1 and 10:1.  Fractions containing the pure target compound, 
Pal-CPD, identified via ESI-MS and NMR, were pooled together and evaporated to 
dryness to yield the target product Pal-CPD.  
 
22.76 mg of sCT was reduced with 105.0 mg of DTT and isolated in a semi-
preparative C-18 column (10×250mm). Fractions containing the reduced sCT were 
pooled together and reacted with 39.8 mg of Pal-CPD in a pH 7.0 ammonium acetate 
buffer solution. The reaction mixture was concentrated by rotary evaporator and the 
target REAL-sCT was separated in a semi-preparative column and dried, as described 
for Lipeo-sCT.  
 
2.2.2 Purity and lipophilicity  
Purity of the lipidized peptides was characterized by Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (Tricine-SDS-PAGE) using a Hoefer miniVE 
electrophoresis system (Hoefer Inc, San Francisco, USA), according to the method of 
Schagger and von Jagow (156). Tricine-SDS-PAGE is a gel electrophoresis method 
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for the separation of proteins in the range of 1 to 100 KDa.  10 µl sample solution was 
mixed with equal volume of loading buffer (4% SDS, 12% glycerol, 50 mM Tris, 
0.01% Coomassie Brilliant Blue adjusted to pH 6.8) without 2-mercaptoethanol and 
loaded onto the wells of the gel plate. The stacking gel comprised of 4% T (T was the 
total concentration of acrylamide and N,N'-methylene bis-acrylamide) and 3% C (C 
was the total content of N,N'-methylene bis-acrylamide in the mixture of acrylamide 
and N,N'-methylene bis-acrylamide), the spacer gel consisted of 10% T and 3% C, 
while the separating gel was prepared with 16.5% T and 6% C. The gel was then fixed 
with a solution containing 50% methanol, 40% water and 10% acetic acid.  After 0.5 
h, the gel was stained with Coomassie Brilliant Blue in 10% acetic acid and then 
destained with 10% acetic acid. The image was recorded with HP Scanjet 5550c 
scanner (Hewlett-Packard Development Company).   
 
Purity of the peptides was further characterized by HPLC analysis (Hewlett Packard 
1050 HPLC system equipped with Hewlett Packard 1100 auto-sampler and a Jupiter 
4.6×250 C-4 column). The parent compound, sCT, and the lipidized sCT products 
were separately dissolved in water to prepare 1.0 mM (3~5 mg/ml) solutions. HPLC 
conditions were as follows: injection volume = 5 μl; λ= 214 nm; flow rate = 1 ml/min. 
The mobile phase consisted of an organic phase of 1:1 v/v ACN-IPA with 0.1% of 
TFA and an aqueous phase of 0.1% of TFA in water. A gradient elution was adopted, 
the organic:aqueous phase volume ratio being increased from 30:70 to 97:3 in 30 min 




The micro-structure of sCT and its conjugates were visualized under a transmission 
electron microscope (TEM) (JEOL JEM-2010, (JEOL Ltd, Tokyo, Japan). Samples 
were prepared by dissolving each peptide in distilled water at a concentration of 0.5 
mM and mixing 2 µl of the solution with 1 µl of 1% phosphotungstic acid solution for 
about 1 min on a TEM grid. Excess solution was blotted with fiber-free tissue paper 
and the samples were dried under ambient conditions.  
 
2.2.4 Particle size 
Particle size was determined using the Protein SolutionsTM DynaProTM Dynamic Light 
Scattering Instrument (Wyatt Technology Corporation, Santa Barbara, CA) at a laser 
wavelength of 825.8 nm, detector angle of 90º, and typical sample volume of 20 µl 
(157). Each light scattering experiment consisted of 20 or more independent 
measurements, and the data were analyzed using the DynaProTM software, 
DYNAMICS (version 5.26.60). Samples were dissolved in distilled water at 
concentrations of 2.5, 11, 50, 220 and 1000 µM. To minimize dust interference, all 
solutions were freshly prepared and centrifuged at 2000 rpm for 2 min (Eppendorf 
centrifuge 5417, Hamburg, Germany) immediately prior to analysis.  
 
2.2.5 Stability  
Stability of the peptides was measured in three environments. To establish the 
stability of the peptides against degradation by proteinases, the peptides were 
incubated with trypsin according to protocols reported in the literature (3, 35). Each 
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peptide (50 μM) was incubated separately with 0.25 μM of trypsin in 50 mM Tris 
buffer (pH 7.25) containing 1 mM calcium chloride. The mixture was shaken at 50 
rpm in a water bath maintained at 37ºC. Aliquots of 200 μl were sampled at 0, 1, 2, 5, 
15 and 30 min, and the enzyme activity was immediately quenched by adding 400 µl 
of urea solution (12.4 M in water). Trypsin-digested samples were analyzed by HPLC 
and LC-MS. 
 
Stability of the peptides in intestinal fluid was determined according to a published 
method (143), with slight modification. To obtain the intestinal fluid, 3 female Wistar 
rats (9 weeks, about 220 gram) which had been fasted for 24 h, were euthanatized by 
intraperitoneal (IP) injection of ketamine (150 mg/kg) and xylazine (20 mg/kg). The 
intestine was exposed by an abdominal incision, and 30-40 cm of the small intestine, 
beginning from the duodenum, was excised and the luminal content flushed out with 
7.5-9.0 ml of phosphate buffer solution (PBS) at pH 6.6 using a syringe (actual 
intestinal fluid was approximately 0.5-1.5 ml). The protein content in the intestinal 
fluid was determined by the MicroBCA Protein Assay Kit (Pierce Biotechnology, 
Rockford, IL USA). This Kit quantified total protein based on the colorimetric 
detection of bicinchoninic acid chelated with Cu+1, the latter being generated by the 
reduction of Cu+2 by proteins in an alkaline environment. Protein contents in the 
intestinal fluids of the 3 rats were found to be 1.32, 1.27 and 1.47 mg/ml respectively. 
The intestinal fluids were further diluted with 0.1 M pH 6.6 PBS to yield a final 
protein content of 0.9 mg/ml. The degradation experiments were initiated by adding 
30 µl of intestinal fluid (0.9 mg/ml) to 566 µl of peptide (43 µM) in pH 6.6 PBS at 
37ºC to yield final intestinal protein content of 45 µg/ml. At specific time points, 
aliquots of the digested mix were withdrawn and the enzyme activity was quenched 
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by lowering the pH to 2.5 through the addition of acetic acid at an acetic acid:digested 
mix volume ratio of 1:15. The mixture was then analyzed using the HPLC.  
 
To determine the stability of the peptides against hepatic metabolism, a study was 
conducted using a previously described in vitro metabolic system (93) with slight 
modification. A fresh liver (7.5 g), harvested from a euthanized normal Wistar female 
rat (240g), was soaked in normal saline, then triturated and mixed with 7.5 ml of 
MEM solution containing 5% FBS. The mixture was centrifuged at 2000 rpm at 4 °C 
(Hettich Zentrifugen, Tuttlingen, Germany) for about 2 min, and the supernatant was 
collected. Lyophilized sCT and sCT conjugates were separately added to aliquots of 
the supernatant to give final concentrations of 0.10 mM, and the mixtures were 
incubated in a water bath operating at 37ºC and a shaking frequency of 60 rpm. The 
reacting mixtures were sampled at 0, 15, 30, 45, 60, 90, and 120 min. Ethanol (125 µl) 
was immediately added, under vortex, to each withdrawn sample (50 µl) to quench 
the reaction, and the supernatant fractions (120 µl), isolated by centrifugation of the 
samples, were analyzed by HPLC. 
 
Peptide digestion was monitored through HPLC and/or LC-MS analyses, the samples 
being analyzed either immediately or upon storage at -80ºC. HPLC analysis was 
carried out in a Waters symmetry C-18 column (300 Å) with an injection volume of 
100 µl and a detection wavelength of 214 nm. The elution time profile was from 
100% A (distilled water with 0.1% of TFA) to 100% B (1:1 v/v isopropanol and 
acetonitrile with 0.1% of TFA) in 40 min, and holding at 100% B for 5 min. Due to 
baseline drift, all HPLC spectra were adjusted for baseline values to better present the 
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data. Peptide concentration, calculated from the HPLC peak area, was expressed as % 
remaining relative to the concentration measured at 0 min.  
 
LC-MS analysis was carried out with a Finnegan MAT LCQ mass spectrometer 
equipped with an Electrospray Ionization (ESI) source. LC settings were the same as 
those listed for the HPLC assay. The MS spectrometer settings were the same as 
described under Section 2.2. The digested fragments were identified through a 
comparison of MW with values calculated using ChemDraw Ultra 8.0 
(CambridgeSoft Corporation. MA. USA).  
 
2.2.6 Peptide conformation 
Peptide conformation was determined by circular dichroism (CD). CD spectra were 
obtained with a Jasco Circular Dichroism System 810 over a scanning range of 190 to 
260 nm. The N2 flow rate was set at 5L/min. The sample cuvette (200µl) was cleaned 
until blank samples (0, 20, and 50% of trifluoroethanol (TFE) in water) showed 
optical density of less than 0.5 mDeg. The spectra of test samples, which comprised 
of 0.10 mM of sCT or sCT conjugate dissolved in distilled water containing 0 – 50% 
of TFE , were recorded with the corresponding solvents serving as blanks. 
 
2.2.7 In vivo hypocalcemic activity 
Pharmacodynamic response of sCT and the sCT conjugates was evaluated by analysis 
of plasma calcium concentration and the area above the intensity curve (AAIC) in the 
rat model (132). Wistar female rats weighing 170~220 g (about 8 weeks old) were 
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purchased from the National University of Singapore (NUS) Centre for Animal 
Resources, and housed at the NUS Animal Holding Unit. All experimental protocols 
involving animals were approved by the Animals Ethics Committee of the National 
University of Singapore. The rats were divided randomly into groups of 6 after 3 days 
of acclimatization, and the pharmacodynamic response was assessed following 
subcutaneous and oral administration of the peptides. 
 
For subcutaneous administration, sCT, REAL-sCT and Lipeo-sCT (0.145 mg/ml) 
were separately dissolved in distilled water and injected under the dorsal skin of the 
rat using a 27-gauge needle at a dose of 0.145 mg/kg for every group.  For oral 
administration, the peptides were separately dissolved in distilled water to give 2.5 
mg/ml sCT equivalent solutions. The rats were fasted for 12-16 h before they were 
administered by intragastric gavage via an 18-gauge gavage needle with 5.0 mg/kg of 
sCT or 6.1 mg/kg of REAL-sCT or 6.4 mg/kg of Lipeo-sCT (equivalent to 5.0 mg/kg 
sCT). Control rats were administered with water. Immediately before, and at 1, 2, 4, 8, 
12, 18, 24, 36, 48 h after administration, blood samples (120-150 μl) were collected 
either via tail vein (after subcutaneous injection) or saphenous vein (after gastric 
gavage) puncture with a Microvette® CB300LH (Sarstedt, Germany). Blood plasma 
was obtained by centrifuging the samples at 5000 rpm (Eppendorf Centrifuge 5145D) 
for 5 min at 15ºC.   
 
Plasma calcium level was assayed by atomic absorption spectrometry (Perkin Elmer 
AAnalyst 100, MA, US) using a hollow calcium lamp at λ=422.7 Ǻ as the light source 
(158). Slit width was 0.7 nm and pure ethyne/compressed air flame was used. 
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Calibration was performed using standard solutions that contained 5.0, 10.0 and 15.0 
mg/dL of calcium, together with 140 mM of NaCl and 5 mM of KCl. Blank solutions 
comprised of 140 mM of NaCl and 5 mM of KCl without calcium. The standard and 
blank solutions, as well as all plasma samples, were diluted 50-fold with a solution 
containing 10mM of LaCl3 and 37mM of HCl before they were analyzed. Average 
recovery of calcium using this method was 100.3% (RSD=3.8%, n=3) over the 
concentration range of 5.55 to 13.3 mg/dL.  
 
2.2.8 Pharmacokinetics profile  
Introduction 
Pharmacokinetic (PK) profiles of sCT, REAL-sCT and Lipeo-sCT were established in 
the rat model following subcutaneous injection. In most PK studies involving 
calcitonin, plasma calcitonin has been quantified by a highly specific and sensitive 
immunological method, such as the Radioimmunoassay (RIA) (159-162) or Enzyme 
Linked Immuno-Sorbent Assay (ELISA) (142, 163, 164). These assays are, however, 
expensive and detect with certainty only the intact, unmodified sCT. Successful 
detection of chemically modified sCT is subject to the availability of appropriate 
antibodies (70), and erroneous data could be generated from poor peptide-antibody 
binding and binding to calcitonin fragments (165). An alternative method is to 
radiolabel the peptide, such as through the process of iodination. Iodinated sCT 
conjugates cannot, however, be differentiated from the regenerated sCT by measuring 
the radioactivity level in plasma samples. Nor can any dynamic change between the 
concentrations of reversible sCT conjugates and sCT be monitored. Moreover, 
experiments involving iodinated compounds are associated with considerable safety 
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risks and will have to be carried out in a dedicated laboratory facility. 
 
Recently, a Liquid Chromatograph-Electrospray Ionization-Mass Spectrometry (LC-
ESI-MS) method based on selected ion monitoring (SIM) of the triply charged ion 
1144.9 (M+3H+) has been developed for the assay of plasma sCT (166). Although this 
method is attractive because of its specificity, it requires the collection of a large 
volume (350µl) of blood samples by cannulation and complex sample processing, 
which involves lyophilization and reconstitution. In addition, this method cannot be 
used to detect sCT  prodrugs, such as Lipeo-sCT and REAL-sCT, due to the high 
specificity required for monitoring both sCT and its conjugates. To address these 
challenges, we have developed a simple LC-MS method which required only small 
blood samples and routine LC-MS apparatus. It also had the added advantage of 
quantifying sCT and its conjugates simultaneously in one plasma sample. 
 
LC-MS method development 
The LC-MS method required the extraction of peptides by precipitation of the plasma 
with organic solvent followed by centrifugation. Unlike sCT, however, Lipeo-sCT 
and REAL-sCT were observed to form pellets when solutions of the peptides at 4 – 10 
mg/ml in water were centrifuged at 12000 × g (Appendorf ® Microcentrifuge 5415 R) 
for 1 h. Since the pelletization of peptide precipitates could adversely affect the 
extraction efficiency, preliminary experiments were conducted to investigate the 
effects of centrifugation speed at 2000, 5000 and 10000 rpm (370, 2320 and 9270 × g 
respectively) on peptide recovery.  
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To optimize the solvent system for the extraction of the peptides in plasma, 30 µl 
plasma samples from female Wistar rats were mixed with 30 µl of Lipeo-sCT, REAL-
sCT or sCT (0.10 mM in water) under vortex and the mixtures were precipitated by 
addition of 120 µl of ACN or ACN-IPA. Controls were similarly prepared, using 
distilled water instead of rat plasma. All samples were centrifuged at 5000 rpm (2320 
×g) (Hettich Zentrifugen, Tuttlingen, Germany) for 2 min. The supernatants were 
decanted into 200 µl-HPLC glass insert and 30 μl was immediately injected into the 
HPLC (HP 1050 coupled with HP1100 autosampler) to determine the peptide content.  
The recovery was calculated according to Equation 1. 
% Recovery =
PlasmaithoutConjugateWItsorsCTofAreaPeak
PlasmaWithConjugateItsorsCTofAreaPeak ×100           (1)  
To ascertain whether the peptides remained stable in the supernatant, HPLC analysis 
was repeated at 93, 188 and 282 min after precipitation of plasma protein by ACN-
IPA. Relative peptide recovery at different time points was calculated based on the 
HPLC peak area with reference to that of the freshly prepared samples at 0 min. There 
was no apparent sCT peak for the Lipeo-sCT and REAL-sCT samples, indicating that 
the disulfide bond in the lipidized sCT was not reduced in plasma. The study was 
repeated thrice, using plasma from 3 different rats, and the data are presented as 
percent peptide remaining in the samples. 
 
For the LC-MS analysis, the LC-MS settings consisted of a Q-TRAP instrument 
(Applied Biosystems Inc. US) coupled with Agilent 1100 dual pumps, oven and 
autosampler (Agilent Technologies, US). Initially, a Waters Symmetry® 300 C-18 
(2.1×150 mm, particle size 5µm, 300Å) column was used. However, minor peaks at 
22.82 min and 22.97 min respectively were found after the major peaks were eluted 
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out at 16.46 min and 17.05 min respectively for REAL-sCT and Lipeo-sCT. 
Adjustment of the mobile phase gradient could not resolve the problem. When the 
column was switched to a Waters Symmetry® 300 C-4 (2.1×150 mm, particle size 
5µm, 300Å) column, both of these 2 peptides gave only one peak. For this reason, the 
C-4 column was employed for subsequent analysis. The final gradient elution profile 
employed is shown in Table 1 with A being 0.1% of formic acid (FA) in water and B 
consisting of 1:1 v/v of acetonitrile and isopropanol with 0.1% of FA. The LC 
gradient was from 10% B to 90% B in 12 min and further to 100% B in another 3 min. 
The LC gradient was then returned to 10% in 19 min as post-run. The column oven 
was set at 35 º C and the eluent before 8 min and after 16 min was diverted to waste 
container. Under these conditions, the peaks of sCT, REAL-sCT and Lipeo-sCT were 
readily detected and resolved for the plasma samples.  
Table 1  LC gradient elution settings for analysis of sCT and its conjugates with LC-MS 
Step Total time(min) A (%) B (%) 
0 0.0 90.0 10.0 
1 12.0 10.0 90.0 
2 15.0 0.0 100.0 
3 17.0 0.0 100.0 
4 19.0 90.0 10.0 
5 27.0 90.0 10.0 
 A: water containing 0.1% of formic acid (FA) 
 B: Acetonitrile and isopropanol mixture (1:1 v/v) containing 0.1% of FA 
 
The MS Mutiple Reaction Monitoring (MRM) signals were optimized to give the 
strongest response; the final settings employed are detailed Table 2. The m/z ratios for 
the parent ion of sCT, REAL-sCT and Lipeo-sCT were, respectively, 858.60, 1038.00 
and 972.0. Daughter ions for all 3 peptides had m/z ratio of 115.1. 
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Table 2 Optimum setting parameters for the determination of sCT, REAL-sCT and Lipeo-sCT 
with MRM mode   
  Q1 Mass (amu) Q3 Mass (amu) Dwell(msec) DP EP CEP CE 
sCT 858.6 (M+4H+)  115.1 150 138 4.5 43.15 39
REAL-sCT 1038.0 (M+4H+) 115.1 150 130 6.0 49.07 47
Lipeo-sCT 871.8 (M+5H+) 115.1 150 102 4.5 43.58 38
DP: declustering potential; EP: exiting potential; CEP: collision cell entrance potential; CE: collision energy  
  
Standard curve 
Blank plasma samples (20 µl) were diluted with an equal volume of water containing 
sCT or its conjugates in the concentration range of 0.5 to 500 nM, then precipitated 
with 80µl of ACN-IPA, and centrifuged for 2 min at 5000 rpm. Thirty µl of the 
supernatant solutions were injected into the LC-MS system to be eluted according to 
the conditions prescribed in Table 1 and Table 2. The concentration at which the 
height of signal/noise ratio was approximately 3 was deemed to be the detection limit 
for sCT and its conjugates. Plots of peak area against concentration yielded linear 
graphs for all 3 peptides as stardard curve for the calculation of the concentration of 
actual plasma samples.  
 
Drug administration and blood sampling  
Wistar female rats weighing 180 to 220 g were randomly assigned to 3 groups. The 
treatment groups were injected subcutaneously (27-gauge needle) with 0.44 µmol/kg 
of sCT (1.50 mg/kg, 1.50 mg/ml), REAL-sCT (1.81 mg/kg, 1.81 mg/ml) or Lipeo-
sCT (1.90 mg/kg, 1.90 mg/ml) in normal saline. At 0, 10, 30, 50, 70, 90, 120, 150, 
240 and 360 min, 50 µl of blood was withdrawn from each rat by saphenous vein 
puncture and collected with a Microvette® CB300LH (Sarstedt, Germany). The blood 
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samples were immediately centrifuged at 3340 × g for 5 min to obtain 20 µl of 
plasma. Plasma samples were stored at -80ºC until analysis. Samples to be analyzed 
by LC-MS were thawed at ambient temperature, diluted with an equal volume (20 µl) 
of water and then mixed with 80 µl of ACN-IPA under vortex to precipitate the 
plasma protein. The precipitate was pelleted by centrifugation at 2320 × g, and the 
clear supernatant (30 µl) was immediately injected into the LC-MS for peptide 
analysis. 
 
2.2.9 In vitro cytotoxicity  
In vitro cytotoxicity of the conjugates was determined by the MTT (3-(4,5-
dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) assay (167). MTT is reduced 
by dehydrogenase enzymes in the mitochondria of living and metabolically active 
cells to generate formazan, a purple colored product quantifiable by colorimetric 
measurement after cell lysis. The amount of formazen generated is directly 
proportional to the number of live cells in many cell models (167). This assay has 
been used to determine cell activation (168), cell proliferation and in vitro 
cytotoxicity (167, 169). The beauty of this method over others is its precision, rapidity 
and reproducibility (167, 169).  Because of these reasons, the MTT assay has been 
widely used in evaluating the efficacy of anticancer drug delivery systems (170, 171), 
antiproliferative activity of chemical libaries (172, 173) and the cytotoxicity of 
polymers (170, 174, 175), surfactants (62) and drug conjugates (176-178). 
 
In this study, Lipeo-sCT, REAL-sCT and sCT were separately dissolved at 
concentrations ranging from 3.2 to 1000 µM in Hanks Balanced Salt Solution (HBSS) 
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containing 10 mM of N-2-hydroxyethylpiperazine-N′-2-ethansulfonic acid (HEPES) 
and adjusted to pH 7.2. Caco-2 cells from American Type Culture Collection (ATCC, 
Rockville, MD) at passage 59 were seeded onto 96-well plates at a density of 20,000 
cells/well and cultured in 100 µl of culture medium in 5% CO2/95% air at 37°C for 48 
h  in a CO2 incubator (NuAire, Plymouth, MN USA). The culture medium, which 
comprised of Minimum Essential Medium supplemented with 10% of fetal bovine 
serum, 1% of non-essential amino acids, 100 U/mL of penicillin, and 100 µg/mL of 
streptomycin, was exchanged for 100 µL of sample solutions and the cells were 
incubated for a further 4 h at 37°C. Cell viability was determined by incubating the 
cells for 4 h at 37°C with 100 µL of MTT solution (1mg/mL of MTT in HBSS, pH 
7.1). Intracellular formazan crystals were extracted into 100 µL of dimethyl sulfoxide, 
and quantified by measuring the absorbance of the cell lysate at 590 nm (Spectra 
Fluor plate reader, Tecan, Austria). Cell viability was calculated as a percent based on 
the absorbance measured relative to the absorbance obtained from cells exposed only 
to the HBSS/HEPES solution. Experiments were conducted eight times, and the 
difference between sample mean value and that of 0.1% dextran in HBSS/HEPES 
(negative control) were analyzed using one-way ANOVA (SPSS 11.0, SPSS Inc., 
Chicago, IL) ) with post-hoc Tukey’s tests at  p = 0.05. 
 
2.3 Results  
2.3.1 Synthesis and identification 
Similar synthesis pathways, via disulfide exchange reactions, were employed to 
generate 3-(2-(pyridin-2-yl)disulfanyl)propanoic acid (Compound I) (Figure 3) and 
CPD (Figure 4), the precursors for the production of activated lipids in the synthesis 
of Lipeo-sCT and REAL-sCT, respectively. Further generation of activated lipids was 
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achieved either through condensation (Figure 3) or nucleophilic substitution (Figure 
4). Lipeo-sCT and REAL-sCT were obtained by reaction of the corresponding 
activated lipids with reduced sCT. 
 
The identities of Lipeo-sCT and REAL-sCT were confirmed by ESI-MS mass 
spectrometry (Figure 5). In the case of Lipeo-sCT (calculated MW 4355.3), the 
observed m/z peaks of 872.3, 1089.9 and 1452.9 (Figure 5 A) corresponded closely to 





m +=  (n: the number of protons). Similarly, the observed 
peaks of 830.6, 1038.3 and 1384.1 matched well with the m/z values of 830.8 
(M+5H+), 1038.3 (M+4H+), and 1384.0 (M+3H+) calculated on the basis of a 
theoretical MW of 4149.0 for REAL-sCT (Figure 5 B). 
 
To confirm that the lipid molecules were conjugated to sCT via disulfide bonds, 
Lipeo-sCT and REAL-sCT (0.05 µM) were separately incubated under reductive 
conditions with 30-fold its molar concentration of DTT at ambient temperature for 1 h 
(Figure 6). The products were subjected to ESI-MS analysis without separation. The 
MS spectrum (Figure 7 A) for the reduced product of Lipeo-sCT showed peaks at 
859.3, 1145.7 and 1717.5, which respectively matched the calculated m/z values of 
M+4H+, M+3H+ and M+2H+ for reduced sCT (MW 3433.9). Additional peaks at 
480.2 and 485.2 corresponded to the calculated m/z values of the ammonium and 
sodium adduct  (V + NH4+ and V + Na+) of the detached lipid, C16E3OH modified 3-









m ×+=  with n=1. These data further confirmed that Lipeo-sCT was 
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REAL-sCT after reduction with DTT did not show peaks at 830.8, 1038.3 and 1384.0. 
Instead, new peaks were observed at m/z values of 687.6, 859.2, 1145.0 and 1718.4 
(Figure 7 B), which corresponded with the calculated m/z values for M+4H+, M+3H+ 
and M+2H+ of reduced sCT (MW 3433.9). The mass spectrum of reduced REAL-sCT 
was comparable to that of sCT (MW 3431.9) (Figure 5 C), except that the former 
tended to exhibit peaks at higher m/z values, e.g. the M+2H+ peak was observed at 
1718.4 for reduced REAL-sCT compared to 1716.5 for sCT (Figure 5 C). Assuming 
that REAL-sCT had been converted to reduced sCT by incubation with DTT, this 
result could be attributed to the reduced sCT having a MW 2 Da higher than sCT. 
However, the difference in m/z values might be obscured by the spontaneous 
formation of disulfide bond in the reduced sCT to generate sCT, and by the resolution 
of the MS instrument. The data nevertheless confirmed that REAL-sCT was 
successfully synthesized through disulfide conjugation bonds. 
 
2.3.2 Purity and hydrophobicity  
Tricine-SDS-PAGE analysis showed sCT to be positioned at the forefront of the gel, 
with Lipeo-sCT taking up the rear (Figure 8). The relative positions of sCT, REAL-
sCT and Lipeo-sCT following denatured gel electrophoresis were in agreement with 
their calculated MW. HPLC analyses of the Lipeo-sCT and REAL-sCT samples 
yielded single peaks (Figure 9),  suggesting that they were highly purified (>95%). 
sCT had the shortest retention time (tR) of 11.051 min, while REAL-sCT and Lipeo-
sCT were eluted at 22.338 and 24.937 min, respectively. Based on a lipophilic index 




ttR −  , and t0 was the retention 
time of the solvent (3.40 min), the lipophilicity of the peptides would be ranked in the 
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order of sCT (Log k' = 0.35) < REAL-sCT (Log k' = 0.74) < Lipeo-sCT(Log k' = 
0.80). 
 
1     2     3     4  
Figure 8 Tricine-SDS-PAGE for (1) sCT, (2) REAL-sCT, (3) Lipeo-sCT and (4) a mixture of sCT, 







Figure 9 HPLC chromatographs of (A) Lipeo-sCT (B) REAL-sCT and (C) sCT. Analysis was 
performed with 1.0 mM solution; injection volume = 5 μl; λ = 214nm; Jupiter 4.6×250 C-4 
column; flow rate = 1 ml/min. Gradient elution was set  at  30% to 97% acetonitrile-isopropanol 
mixture (1:1 v/v) in water (0.1% TFA) in 30 min, and holding the final concentration for another 
5 min.   
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2.3.3 Morphology 
Figure 10 shows the TEM micrographs of sCT, Lipeo-sCT and REAL-sCT. The 
peptides in water (0.5 mM) were stained with phosphotungstic acid and dried prior to 
viewing under the TEM. At the magnification of 10,000×, sCT appeared as a 
relatively homogeneous dispersion (Figure 10 C). Lipeo-sCT (Figure 10 A) and 
REAL-sCT (Figure 10 B) samples, on the other hand, were not homogeneously 
distributed, with evidence of widespread clumping of the peptides. While this was 
suggestive of a greater propensity of the two lipidized peptides to form agglomerates, 
it should be noted that the samples were viewed in the dried state, and that artefacts 
could have been introduced during sample drying.  
 
2.3.4 Particle size 
To measure the propensity of the peptides to agglomerate in solution, particle size of 
the lipidized peptides was determined using dynamic light scattering. sCT (MW 3.43 
KDa) at the concentrations of 224 and 1000 µM in distilled water showed dominant 
peaks corresponding to mean radii of 0.99 and 1.1 nm (Table 3), which translated to 
MW of 3.25 and 4.20 KDa (DYNAMICS® Version 5.26.60), respectively. These MW 
values were comparable with the calculated MW of sCT, suggesting that sCT in 
distilled water existed mainly as monomers. Although sCT also exhibited 3 other 
peaks corresponding to particle radii of more than 10 nm, the actual mass of particles 
contributing to these peaks was negligible (Table 3). The implication was that sCT 
showed negligible tendency to aggregate when dissolved in water at these two 
concentrations. Further dilution of the sCT solution to 50 and 2.5 µM resulted in very 
low photon counts of less than 20 kcps, comparable to that of distilled water, which 
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made it difficult to take measurements against the background noise. As the dilution 
of sCT was not likely to cause peptide fragmentation, the implication is that the 









Figure 10 TEM micrographs of (A) Lipeo-sCT, (B) REAL-sCT and (C) sCT. Samples were 
prepared by mixing 2 µl of peptide solution (0.5 mM in water) with 1 µl of 1% phosphotungstic 
acid solution for 1 min in a TEM grid. Magnification 10,000x; scale bar, 500 nm. 
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Table 3 Particle size of sCT in water as determined by dynamic light scattering 
Concentration 
(uM) 












1000 166 Peak  1 1.10 0.1  100.0  4.20
  Peak  2 13.1 0  0.0  1.37E+03
  Peak  3 104.5 14.6  0.0  1.79E+05
  Peak  4 1157.0 306.4  0.0  4.95E+07
224 33 Peak  1 0.99 0.2  100.0  3.25
  Peak  2 65.9 7.7  0.0  6.07E+04
    Peak  3 2740.0 0  0.0  3.72E+08
 
 
 By comparison, the Lipeo-sCT (MW 4.36 KDa) particles had radii of 63.9 to 126.8 
nm over the concentration range of 54 to 2.5 µM in water (Table 4). As these mean 
sizes were far larger than the expected particle size of 1.2 nm based on the theoretical 
MW of Lipeo-sCT, aggregation of the lipidized peptide in water was implicated. 
Moreover, unlike the micellization of surfactants, which is not favored at dilute 
concentrations, the particle size of Lipeo-sCT was observed to double when the 
solution was diluted from 11 to 2.5 μM, although there was a small decrease in 
particle size from 76.3 to 63.9 nm following a 5-fold dilution from 54 to 11 μM. The 
changes in particle size might be due to inter-batch variation rather than to any 
specific bonding between the molecules. Disulfide bond exchange reaction was not 
likely because of the absence of a reductive environment. The particle size of Lipeo-
sCT could not be determined at the high concentration of 1.0 mM as the photon count 




Table 4 Particle size of Lipeo-sCT in water as determined by dynamic light scattering 
Concentration 
(uM) 










MW      
(K Da) 
54 368 Peak  1        76.3 35.6  100.0  1.68E+4
  Peak  2        2628.0 250.3  0.0  5.72E+8
11 568 Peak  1        63.9 38.9  100.0  6.94E+4
  Peak  2        2578.0 287.8  0.0  5.46E+8
2.5 38 Peak  1        126.8 42.8  99.0  3.66E+5




REAL-sCT showed similar aggregation behavior as Lipeo-sCT, exhibiting dominant 
peaks that corresponded to mean radius of 105.6 to 211.1 nm over the wide 
concentration range of 2.5 to 224 µM in water (Table 5). As these radii were larger 
than the expected radius of 1.1~1.2 nm based on the calculated MW of the REAL-sCT 
monomer, aggregation of the lipidized peptide in water was again implicated. Like 
Lipeo-sCT, there was no evidence of REAL-sCT undergoing disaggregation upon 
dilution from 224 to 2.5 µM.  
 
Table 5 Particle size of REAL-sCT in water as determined by dynamic light scattering 
Concentration 
(µM) 










MW        
(KDa) 
224 3453 Peak  1 134.3  103.5 98.9  4.21E+5  
  Peak  2 2607.0  267.5 1.1  5.61E+8  
54 1135 Peak  1 211.1  135.7 98.8  1.26E+6  
  Peak  2 2598.0  274.6 1.2  5.56E+8  
11 198 Peak  1 105.6  54.5 100  2.35E+5  
2.5 80.7 Peak  1 135.6  18.2 99.1  4.30E+5  








2.3.5 Stability  
Stability against trypsin digestion 
Compared with sCT, the two lipidized sCT showed significant resistance against 
trypsin digestion (Figure 11). While more than 90% of the sCT sample was digested 
within a minute, with complete degradation observed at 2 min, about 50% of Lipeo-
sCT and REAL-sCT were detected in the enzyme mix after 1 min and at least 10% of 
the lipidized peptides remained at 2 min. Lipeo-sCT did not show significantly 




















sCT REAL-sCT Lipeo-sCT 
 
Figure 11 Degradation profiles of sCT, REAL-sCT and Lipeo-sCT upon digestion by trypsin. 
Samples at 50 μM were incubated under agitation (50 rpm) with  0.25 μM of trypsin in 50 mM 
Tris buffer containing 1 mM calcium chloride (pH 7.25) at 37ºC. 200 μl-aliquots were withdrawn 
for peptide analysis by HPLC following immediate quenching with 400 µl  of urea (12.4 M) .Data 
represent mean ± SD, n = 3. 
  
Analysis of the degradation products suggested that the peptides were cleaved at 
different sites by the enzyme. Trypsin is known to cleave peptide and protein 
molecules predominantly at the C-terminal of the amino acids, lysine and arginine 
(180, 181). HPLC chromatographs of the sCT digestion mixture at 1 min showed 7 




was simultaneously cleaved at Lys11, Lys18 and Arg24 by the enzyme (Figure 13 A), 
the final degradation peaks and their chromatographic behavior were consistent with 
other people's work (182). In contrast, the digestion mix for Lipeo-sCT and REAL-
sCT showed comparatively fewer peaks over 30 min, with only 2 new peaks observed 
at 1 min (Figure 12 B and Figure 12 C). Identification of the degradation products by 
LC-MS analysis (Finnegan MAT LCQ mass spectrometer) suggested step-wise 
degradation of the lipidized peptides by the enzyme (Figure 13 B and C). For both 
Lipeo-sCT and REAL-sCT, trypsin digestion first occurred at Arg24, followed by 
cleavage at Lys18, suggesting that the enzyme degradation proceeded from a site 
furthest removed from the conjugated lipid, then along the peptide chain towards the 
conjugated lipid (Figure 13 B and C). Thus, while lipidization per se could not totally 
arrest trypsin digestion, the degradation profiles affirmed the conjugated lipid to be an 
effective steric barrier against enzyme approach. The proposed degradation pathways 
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Figure 12 HPLC chromatographs of trypsin digestion mix with sCT(A), Lipeo-sCT(B) and 
REAL-sCT(C) at different incubation time points.  HPLC analysis was carried out with a Waters 
symmetry C-18 column (300 Å). Elution time profile was from 100% A: 0.1% TFA in water to B: 
1:1 v/v isopropanol and acetonitrile with 0.1% TFA in 40 min and maintaining at B for 5 min. 






C S N L S T C V L G K11 L S Q E  L H K18 L QT Y P R 24 T25 N T G S G T P32
After 1 minute
C1 S N L S T C V L G K11 L S Q E  L H K18 L QT Y P R 24 T25 N T G S G T P32




C S N L S T C V L G K11 L S Q E  L H K18 L QT Y P R 24+ + + T25 N T G S G T P32  
-------------------------------------------------------------------------------------------- 
C1(Lipeo) S N L S T C(Lipeo) V L G K11 L S Q E  L H K18 L QT Y P R 24 T25 N T G S G T P32
After 5 minutes
  T25 N T G S G T P32
L QT Y P R 24+
C1(Lipeo) S N L S T C(Lipeo) V L G K11 L S Q E  L H K18 L QT Y P R 24
C1(Lipeo) S N L S T C(Lipeo) V L G K11 L S Q E  L H K18
After 15 minutes




C1(REAL) S N L S T C(REAL) V L G K11 L S Q E  L H K18 L QT Y P R 24 T25  N T G S G T P32
After 5 minutes
T25 N  T G S G T P32+
L QT Y P R 24+
C1(REAL) S N L S T C(REAL) V L G K11 L S Q E  L H K18 L QT Y P R 24
C1(REAL) S N L S T C(REAL) V L G K11 L S Q E  L H K18
After 15 minutes
T25  N T G S G T P32+  





Figure 13 Proposed degradation pathways of sCT (A), Lipeo-sCT (B) and REAL-sCT(C) by 






Stability against intestinal metabolism 
Figure 14 shows the degradation profiles of sCT, Lipeo-sCT and REAL-sCT in the 
rodent intestinal fluid. Incubation of sCT with the intestinal fluid resulted in less than 
1% of the peptide remaining at 5 min, the degradation-time profile following 1st order 
kinetics (Y = 100e-1. 15x, R2 = 0.99). In contrast, the corresponding degradation data of 
Lipeo-sCT and REAL-sCT did not fit into first order kinetics (R2<0.65). The lipidized 
peptides showed rapid degradation in the initial 2 min, in which more than 60% of the 
peptides were digested, followed by slower rates of degradation over the next 18 min. 
Lipeo-sCT and REAL-sCT had comparable initial degradation rates, but Lipeo-sCT 



















Figure 14 Degradation of REAL-sCT and Lipeo-sCT in rat intestinal solution. sCT and its 
conjugates (40 µM) were separately incubated with diluted rat intestinal fluid (45 µg protein /ml) 
at 37ºC at agitation rate of  50 rpm 
 
Stability against hepatic metabolism 
To understand how the liver contributed towards the degradation of lipidized sCT, 




rodent liver. Control experiments showed sCT to be degraded immediately upon 
contact with liver juice, with about 99% of sCT being degraded in 15 min (Figure 15). 
sCT was not detectable after 30 min of incubation in the liver juice. In the case of 
Lipeo-sCT and REAL-sCT, HPLC analysis of the digestion mix showed that sCT was 
generated from both peptides immediately upon incubation with the liver juice. The 
peak area for sCT released from Lipeo-sCT and REAL-sCT were respectively 1249.4 
and 474.2. In contrast, the peaks corresponding to REAL-sCT and Lipeo-sCT were 
comparatively small and were in fact difficult to differentiate from the noise signals. 
A comparison of the sCT peak area suggests that Lipeo-sCT might be more labile, as 
it released the parent peptide at a faster rate than an equimolar concentration of 
REAL-sCT. Significantly, the sCT peak area declined at a slower rate for Lipeo-sCT 
and REAL-sCT than for unmodified sCT (Figure 15), alluding to a continuous release 
of sCT from the lipidized peptides to replace the sCT that was metabolized by the 
liver enzymes. This was in spite of the lack of definitive peaks for either lipidized 


















Figure 15 sCT levels as measured by HPLC when sCT, REAL-sCT and Lipeo-sCT were 
incubated with fresh liver juice. Liver juice was the turbid supernatant obtained by centrifuging 





2.3.6 Peptide conformation  
The CD spectra of sCT in water showed no apparent secondary structure (Figure 16 
A). Upon the addition of TFE, an organic solvent with low dielectric constant, sCT 
showed a positive peak at 192 nm and 2 negative peaks at 208 nm and 222 nm, 
respectively, suggesting the presence of a helical structure. This structure became 
more evident at higher TFE concentrations. In contrast, Lipeo-sCT (Figure 16 B) and 
REAL-sCT (Figure 16 C) exhibited comparable CD spectra whether they were 
dissolved in water or in aqueous solutions of TFE. The CD spectra of the lipidized 
peptides indicate that lipid conjugation of sCT resulted in a helical structure which 














































Figure 16 Circular dichroism spectra of (A) sCT, (B) Lipeo-sCT and (C) REAL-sCT in aqueous 





2.3.7 In vivo hypocalcemic activity 
The hypocalcemic activity of subcutaneously administered Lipeo-sCT was evaluated 
in the rat model with sCT and REAL-sCT as controls. Rats in all groups, including 
those administered with water, did not show significantly different baseline plasma 
calcium levels (10.30~10.48 mg/dL) (Figure 17). Neither did the plasma calcium level 
vary significantly from baseline level for 48 h after the subcutaneous administration of 
water. In contrast, there was a sustained lowering of plasma calcium level over 18 h 
for rats in the sCT treatment group. This plasma calcium profile was in agreement 
with published data (127). Rats administered subcutaneously with equal concentration 
of Lipeo-sCT or REAL-sCT had comparable plasma calcium levels to those in the 
sCT treatment group in the initial 18 h (p>0.3). However, the two lipidized peptides 
showed longer duration of action than sCT, as they continued to produce substantially 
lower plasma calcium levels (p<0.01) 24 h after administration in comparison with 
sCT and water groups. Plasma calcium levels reverted to baseline levels by 36 h in all 
3 treatment groups. At all time points sampled, there were no significant differences 

























Water sCT REAL-sCT Lipeo-sCT
 
Figure 17 Plasma calcium level of Wistar female rats administered with sCT, REAL-sCT and 
Lipeo-sCT by subcutaneous injection. sCT and the conjugates were administered as 0.145 mg/ml  
in distilled water at the dose of 145 µg/kg . Data represent mean ± SD( n = 6). 
 
The biological activities of peroral sCT, REAL-sCT and Lipeo-sCT were also 
compared. All 6 rats administered with sCT (dose 5.0 mg/kg) by intragastric gavage 
showed significantly lower plasma calcium levels at 1 to 2 h post-administration 
(p<0.001), and a return of the calcium levels to baseline at 4h post-administration 
(Figure 18). In contrast, the mean plasma calcium data obtained for peroral Lipeo-sCT 
and REAL-sCT were not statistically different from baseline levels. However, unlike 
the consistent outcomes observed for the sCT group, significant differences in inter-
individual outcomes were obtained for the Lipeo-sCT treatment group (Figure 19). 
While the majority of the rats (4 out of 6) administered with peroral Lipeo-sCT did 
not exhibit lower plasma calcium level, rat #4 did show a dip in plasma calcium level 
(7.62 mg/dL) at 2 h post-administration, while rat #3 showed a sustained lowering of 
plasma calcium level to values in the range of 7.06 to 9.09 mg/dL over the period of 1 




select individuals. Such inter-individual variation was not observed in the REAL-sCT 
group (Figure 20). The in vivo data for REAL-sCT also indicate that, without the aid 
of pharmaceutical excipients (94), REAL-sCT was not effective in lowering plasma 





























Figure 18 Plasma calcium level of 6 individual Wistar female rats after intragastric gavage with 





























Figure 19 Plasma calcium level of 6 individual Wistar female rats after intragastric gavage with 
Lipeo-sCT. Lipeo-sCT was administered as 3.17 mg/ml (equivalent to as 2.5 mg/ml of sCT) 































Figure 20 Plasma calcium level of 6 individual Wistar female rats after intragastric gavage with 
REAL-sCT. REAL-sCT was administered as 3.04 mg/ml (equivalent to as 2.5 mg/ml of sCT) 
solutions in water at the dose of 6.06 mg/kg of REAL-sCT (equilavent to 5.0 mg/kg of sCT). 
 
 
2.3.8 Pharmacokinetics profile after subcutaneous injection 
LC-MS method development  
The LC-MS method required efficient peptide extraction from the plasma samples. As 
the centrifugation-induced precipitation of Lipeo-sCT and REAL-sCT might affect 
peptide recovery, preliminary experiments were conducted to investigate the effects of 
centrifugation and extraction solvent on peptide extraction efficiency. Using 
acetonitrile as the extraction solvent, peptide recovery was found not to be 
significantly affected by centrifugation at the speed of 2000 rpm (370 ×g), 5000 rpm 
(2320 ×g) and 10,000 rpm (9270 ×g) for 2 min (Figure 21).  sCT recovery was 
generally satisfactory, within the range of 85.3 % to 110.4 %, but the recovery of 
REAL-sCT and, in particular, Lipeo-sCT were low, in the ranges of 40.8% to 42.2%, 





















Figure 21 Effect of centrifugation speed on the recovery of sCT, REAL-sCT and Lipeo-sCT from 
plasma samples. Plasma samples were diluted 1:1 v/v with water, followed by the precipitation of 
plasma components by addition of 4 times its volume of acetonitrile. 
 
To increase the extraction efficiency for Lipeo-sCT and REAL-sCT, ACN-IPA was 
used as the extraction solvent instead of ACN, and the centrifugation process was 
conducted at 5000 rpm (2320 ×g) for 2 min. As shown in (Figure 22), the change in 
solvent resulted in greater recovery of REAL-sCT and Lipeo-sCT from the plasma, 
the recovery rates being 65.6% and 62.9%, respectively. Mean recovery rate for sCT 
remained high at 118.7%. The improved recovery of Lipeo-sCT and REAL-sCT in 
ACN-IPA might be due to the higher solubility of the lipidized sCT in ACN-IPA than 
in ACN. The recovery rates of 62.9% and 65.6%, though low when compared with the 
usual reported range of 80%~120% for small molecules (183), were deemed 
satisfactory in view of the relatively poor solubilities of the lipid (non-ionizable parts) 

























Figure 22 Effect of extraction solvent on the recovery of sCT, Lipeo-sCT and REAL-sCT from 
plasma samples. ACN - acetonitrile alone; ACN-IPA - acetonitrile and isopropanolol in the 
volume ratio of 1:1. Plasma samples were diluted with equal volume of water and precipitated 
with 4 times its volume of extraction solvent.  Data represent mean ± SD, n=3.  
  
The rates of recovery of sCT, Lipeo-sCT and REAL-sCT from the plasma samples 
were also dependent on the time lapse between extraction and LC-MS analysis. Figure 
23 shows a diminishing relative recovery rate with increasing time lapse, suggesting 
that sCT, Lipeo-sCT and REAL-sCT were unstable in the extraction media. The 
recovery profiles underpin rapid degradation, with 50% of the extracted peptides 
degraded in about 90 min, and complete degradation in 300 min. It was therefore 
critical that the LC-MS analysis is performed immediately on the extracted peptides to 
obtain reproducible results. The uniform susceptibility of the 3 peptides to degradation 
in the extraction media was unlike their differential degradation rates in trypsin, liver 
and intestinal fluids, suggesting that the aggregation of lipidized sCT might be 
compromised in the extraction media. Moreover, any enzymes in the media would 
have been partially deactivated by the experimental conditions employed, in particular 
the precipitation of plasma proteins, the high content of organic solvents (ACN-IPA) 
































Figure 23 Effect of incubation time on the relative recovery of sCT, Lipeo-sCT and REAL-sCT 
from the extraction media at room temperature (23ºC). The samples were obtained as clear 
supernatant after centrifugation from the plasma samples, which were diluted with equal volume 
of water and precipitated with 4 times its volume of IPA-ACN (v/v 1:1). Data represent mean ± 
SD, n=3. 
 
On the basis of these results, the following method was adopted for the processing of 
plasma samples for the LC-MS analysis. Plasma samples with and without peptide (20 
µl) were diluted with an equal volume of distilled water under vortex, and precipitated 
with 2 times its volume of ACN-IPA (v/v: 1:1) (80 µl). The supernatant was 
recovered by centrifugation at 5000 rpm (2320 ×g) for 2 min, and 30 µl of the 
supernatant was injected immediately for LC-MS analysis. Under the LC-MS 
operational conditions set out in Section 2.2.8, in which sCT was detected with the 
ion-pair (a pair of parent ion and daughter ion) of 858.6→115.1 (parent ion →
daughter ion), Lipeo-sCT with the ion pair 871.8→115.1 and REAL-sCT with 1038.0
→115.1, blank plasma samples showed a clean baseline with the tandem MS mode. 
Using the same tandem MS mode for plasma samples spiked with the peptides, the 
elution times for sCT, Lipeo-sCT and REAL-sCT were found to be about 9.9 min, 




Lipeo-sCT and REAL-sCT showed similar retention times, which differed from the 
HPLC results (Figure 9). This discrepancy could be due to the sharp gradient increase 
employed for elution in the LC-MS column, which allowed the relatively more 
lipophilic Lipeo-sCT to be eluted at comparable rates with REAL-sCT. For plasma 
samples that contained sCT and a lipidized sCT, there was no interference of peaks, 
indicating that the concentrations of sCT and Lipeo-sCT (or sCT and REAL-sCT) 
could be simultaneously determined in the same sample. This is a huge advantage for 









Figure 24 Chromatograms of (A) sCT, (B) Lipeo-sCT and (C) REAL-sCT in rat plasma. sCT was 
detected by monitoring the reaction 858.6→115.1, Lipeo-sCT was detected by monitoring 871.8→
115.1, and REAL-sCT was detected by monitoring 1038.0→115.1.  
 
The detection limit for sCT, Lipeo-sCT and REAL-sCT, based on peak height that 




25). The detection limit for sCT was comparable to that reported by Song et al. (166), 
who used the selected ion monitoring (SIM) method. However, compared with the 
SIM method, the method developed in this project was advantageous as it involved 
smaller volume of plasma samples, simpler sample processing techniques, and higher 
specificity. The detection of the fragmented daughter ion as an ion pair with the parent 
ion produced greater specificity for this method whereas the SIM method allowed 











Figure 25 Chromatograms of  (A) 1.25 nM of sCT, (B) 5.0 nM of Lipeo-sCT and (C) 2.5nM of 
REAL-sCT in plasma. sCT was detected by monitoring 858.6→115.1, Lipeo-sCT was detected by 
monitoring 871.8→115.1, and REAL-sCT was detected by monitoring 1038.0→115.1.  
 
Calibration of the LC-MS was performed with plasma samples spiked with known 
quantities of sCT or lipidized sCT. There was good linearity between peak area and 




(Figure 26 A) 5.0 to 200 nM for Lipeo-sCT (Figure 26 B) and 2.5 to 500 nM for 
REAL-sCT (Figure 26 C).  However, the RSD were relatively wide, reaching values 
of 42.9% (n = 2 – 5) for sCT, 36.1% (n = 2 – 5) for REAL-sCT and 46.6% (n = 2 – 4) 
for Lipeo-sCT. The instability of peptides in the extraction fluid, as well as 
aggregation of the lipidized peptides in aqueous media, might have contributed to the 
variability in results obtained. Nevertheless, most of the RSD values were within the 
acceptable range (RSD < 20%) for biological assay methods (166), and together with 
the linearity of calibration plots, indicated that the LC-MS method could be used for 
the quantification of sCT, Lipeo-sCT and REAL-sCT in plasma samples.  
 
Pharmacokinetic profiles   
Figure 27 shows the plasma concentration of sCT following SC injection of a 1.50 
mg/ml solution of sCT in normal saline at a dose of 1.50 mg/kg into Wistar female 
rats. The pharmacokinetic profile suggests a rapid elimination of the peptide from the 
circulatory system, with complete elimination observed at 150 min. 
 
In contrast, rats injected subcutaneously with a single equivalent dose of REAL-sCT 
showed gradually increasing REAL-sCT plasma concentration that reached a mean 
peak value of 419 nM at 150 min (Figure 28). This concentration appeared to be 
sustained (a dip at 240 min was likely due to the loss of a blood sample for the rat 
which had shown high plasma concentrations of REAL-sCT and sCT at other time 
points), for the mean plasma REAL-sCT concentration at 360 min was 473 nM. The 
rat plasma samples also recorded a concomitant rise in sCT concentration over the 



































































Figure 26 Plot of LC-MS peak area against the concentration of standard solutions of  (A) sCT, 






























Figure 27 Plasma sCT concentration in Wistar female rats after a single SC injection of 1.50 
mg/kg of sCT in normal saline at the concentration of 1.50 mg/ml. Data represents mean ± SD, 
n=3~4.  
 
site, sCT was being regenerated from the lipidized peptide. Mean plasma sCT 
concentration was 13.0 nM at 10 min post-administration, and ranged between 16 to 
32 nM for up to 360 min. Since the plasma REAL-sCT concentration was around 10-
fold higher than the sCT concentration, it was probable that the parent drug was 
regenerated from the lipidized peptide only after absorption into the systemic 
circulation. Since blood plasma is an oxidative environment (126, 184), it is 
conceivable that the regeneration of sCT from plasma REAL-sCT occurred 
predominantly by hepatic metabolism. The conversion of REAL-sCT to sCT by 
hepatic metabolism has been demonstrated by the data in Section 2.3.5. The plasma 
mean REAL-sCT concentration was also more than 2-fold higher than the sCT 
concentration observed in rats administered with sCT by subcutaneous injection.  The 
greater persistence of REAL-sCT in the circulatory system was probably due to its 
stronger resistance against hepatic metabolism compared to sCT. There was wide 
inter-individual variation in plasma REAL-sCT concentration, which might be 

































































Figure 28 Plasma REAL-sCT and sCT concentration in Wistar female rats after a single SC 
injection of REAL-sCT at the dose of 1.81mg/kg  (equivalent to 1.50 mg/kg  of sCT) in normal 
saline at the concentration of 1.81 mg/ml (equivalent to 1.50 mg/ml  of sCT)  Data represents 
mean ± SD (n=3~4) 
  
Unlike REAL-sCT, Lipeo-sCT could not be quantified with certainty in the plasma of 
rats injected with a single subcutaneous dose of 1.91 mg/kg of Lipeo-sCT (equivalent 
to 1.50 mg/kg sCT). Although the Lipeo-sCT peak was discernible in the 
chromatograms of a few plasma samples, the height of these peaks was below 3 times 
the height of noise, suggesting that the Lipeo-sCT concentration was below the 
detection limit of 5 nM. This failure to quantify could not be attributed to plasma 
protein binding since Lipeo-sCT can be extracted from standard solutions of Lipeo-
sCT in blank plasma. The highly lipophilic Lipeo-sCT could, however, have bound to 
the local tissue at the site of injection, where it was then slowly absorbed into the 
general circulation. Another possibility was that the ester bond between C16E3OH and 




in the plasma (16, 185, 186),  and the resultant peptide conjugate in the absence of 
C16E3 was not detectable with the current LC-MS settings.  
 
Conversely, sCT was present at quantifiable concentrations in all the plasma samples 
of rats administered with Lipeo-sCT (Figure 29),  although the concentrations were 
lower at all time points analyzed compared with the plasma sCT level measured in 
rats administered with an equivalent dose of REAL-sCT. The plasma sCT level in rats 
injected with Lipeo-sCT showed a gradual increase to reach 16.2 nM in the first 90 
min post-administration. This level was maintained for up to 150 min before 
decreasing to 7.0 nM at 240 min. The pharmacokinetic profile probably reflected the 
different rates of release of sCT from Lipeo-sCT aggregates, with a faster release of 
the parent peptide from smaller sized aggregates and the larger sized aggregates 
maintaining the sustained release profile. The slower release of sCT from Lipeo-sCT 
in comparison with that from REAL-sCT could be accounted for by a stronger binding 
of Lipeo-sCT with the adipose tissue at the subcutaneous injection site due to lipid-

























Figure 29 Plasma sCT concentration in Wistar female rats after a single SC injection of Lipeo-
sCT at the dose of 1.91 mg/kg  (equivalent to 1.50 mg/kg  of sCT) in normal saline at the 





2.3.9 Cytotoxicity  
The determination of cell viability is a common assay to evaluate the in vitro 
cytotoxicity of biomaterials. To test the cytotoxicity of the lipidized sCT conjugates, 
sCT was used as a control. The MTT results indicated that sCT was not cytotoxic 
against the Caco-2 cells at all the concentrations evaluated (up to 1000 µM or 3.43 
mg/ml) (Figure 30). These results corroborated with its LD50 value of >72800 U/ml, 
about 12 mg/ml for iv, sc and ip administration in mice (187). Compared with the 
negative control (dextran 0.1%) and sCT, REAL-sCT was slightly more cytotoxic in 
that it caused the cell viability to fall to 60% at a concentration of 1000 µM (Figure 
31). Nevertheless, the exposed cells retained relatively high viability (≥ 85%) at up to 
320 µM of REAL-sCT. Similarly, the Caco-2 cells were more sensitive to Lipeo-sCT, 
which lowered cell viability to 76% at 320 µM (Figure 32), but Lipeo-sCT was again 
benign at lower concentrations. As the cytotoxicity profile of Lipeo-sCT was similar 
to that of REAL-sCT, the cytotoxicity of the peptides might be attributed to the 
affiliation to the cell membrane rather than to the chemical structure of the conjugated 
lipid. The cytotoxicity profile of Lipeo-sCT also did not support a previous report that 
































Figure 30 In vitro cytotoxicity of sCT on Caco-2 cells as measured by the MTT assay. Cell 





























Figure 31 In vitro cytotoxicity of REAL-sCT on Caco-2 cells as measured by the MTT assay. Cell 

































Figure 32 In vitro cytotoxicity of Lipeo-sCT on Caco-2 cells as measured by the MTT assay. Cell 
viability is expressed as mean ± SD (n = 8)  
 
2.4 Discussion 
In this section, we described the synthesis and extensive characterization of a novel 
lipid conjugate of sCT, denoted as Lipeo-sCT (Figure 2 A). Lipeo-sCT was similar to 
REAL-sCT (Figure 2 B), another lipidized sCT first synthesized in the laboratory of 
Shen (94), in possessing a reversible disulfide bond. However, while sCT was 
conjugated with 2 molecules of a negatively charged lipid in REAL-sCT, Lipeo-sCT 
contained two copies of a non-ionic C16E3OH group. Our hypothesis was that the 
conjugation of a non-ionic lipid group would better enhance the bioavailability of 
peroral sCT than the conjugation of a negatively charged lipid. To prove the 
hypothesis, the evaluation of Lipeo-sCT was carried out with both sCT and REAL-
sCT as controls.  
 
Lipeo-sCT was synthesized by a 4-step process (Figure 3), similar to that reported for 
REAL-sCT. To obtain the activated lipid for reaction with sCT, DTDP was reacted 




acid, which was then condensed with C16E3OH. Lipeo-sCT was synthesized via a 
disulfide exchange reaction between the activated lipid and reduced sCT. Positive 
identification of Lipeo-sCT and REAL-sCT was attained by ESI-MS analyses, which 
also showed both peptides to be readily reversible to the parent sCT under a reducing 
environment provided by incubation with DTT. Both lipidized peptides were 
confirmed to be highly purified by Tricine-SDS PAGE and HPLC data, which also 
suggest Lipeo-sCT to possess a higher lipophilicity than REAL-sCT.  
 
The amphiphilic nature of Lipeo-sCT and REAL-sCT underpin a propensity to form 
aggregates in aqueous solutions. This was shown directly by TEM micrographs, and 
further confirmed by particle size measurement using DLS. Unlike most 
pharmaceutical surfactants, however, Lipeo-sCT and REAL-sCT did not appear to 
dissociate into monomers at dilute concentrations. The implication is that the 
hydrophobic bonding between the long lipid molecules of the lipidized peptides, 
which gave rise to the aggregates, was stronger than those encountered in surfactants 
that possess smaller lipid moieties.  
 
The aggregation behavior of Lipeo-sCT might account for its lower than expected 
cytotoxicity against the Caco-2 cells. This study was the first to elaborate on the in 
vitro cytotoxicity of lipidized sCT in comparison with sCT. Taking cytotoxicity to be 
associated with a reduction of cell viability to lower than 80% (174), Lipeo-sCT and 
REAL-sCT might be regarded to be cytotoxic only at concentrations at or higher than 
0.32 mM (1.39 and 1.33 mg/ml, respectively). Considering that sCT is administered 




toxic at equivalent doses. Therefore, both lipidized sCT analogs may be regarded to 
have low toxicity. These results are surprising because Lipeo-sCT was conjugated 
with 2 molecules of C16E3OH, a non-ionic surfactant whose clinical application as an 
absorption enhancers (65) had been limited because of its toxicity (61). Yet the 
cytotoxicity of this molecule was not manifested when it was conjugated to sCT. 
Instead, Lipeo-sCT was almost comparable in cytotoxicity to REAL-sCT, despite the 
latter being designed specifically to be non-toxic through the selection of endogenous 
ligands, such as palmitic acid and cysteine (90), for conjugation. The anomaly could 
be explained by the aggregation of the lipidized peptides in aqueous media. 
Aggregation would congregate the lipid chains of Lipeo-sCT into a hydrophobic core 
that is shielded from the aqueous bulk by the sCT peptide chains, thereby reducing 
contact between the lipids and the cells and causing a downgrade in cytotoxicity. The 
shielding of the conjugated lipids, which chemically differentiated Lipeo-sCT and 
REAL-sCT, would also cause the peptides to present with similar surface properties, 
and therefore cytotoxicity profiles.  
 
The higher stability of REAL-sCT and Lipeo-sCT might also be attributed to their 
propensity to aggregate in aqueous media. Lipeo-sCT and REAL-sCT were observed 
to possess higher stability than sCT against trypsin, intestinal and hepatic metabolism. 
sCT, which existed as monomers in solutions, was rapidly degraded by trypsin, which 
cleaved the peptide simultaneously at multiple sites (lysine 11, lysine 18 and arginine 
25). In contrast, trypsin degradation of Lipeo-sCT and REAL-sCT proceeded in a 
step-wise, unidirectional manner, with initial cleavage of the peptide occurring at a 




degradation profile is envisaged to be facilitated by peptide aggregation, as the 
orientation of conjugated lipids towards the core of the aggregates would direct the 
sCT backbone chain outwards, making the amino acids in the chain furthest from the 
lipid conjugation sites to be the most exposed and therefore vulnerable to enzyme 
approach. Aggregation would also restrict chain flexibility and enable enzyme 
degradation to proceed in a sequential manner.  
 
The different degrees of structural flexibility between sCT and the lipidized peptides 
were demonstrated in the circular dichroism spectra. sCT, which existed as monomers 
in the concentrations analyzed, exhibited a conformation that was strongly influenced 
by the solvent, varying from a random structure in water to a helical structure in 
solvent of lower dielectric constant. REAL-sCT and Lipeo-sCT, on the other hand, 
showed helical structures that were independent of solvent composition.  
 
Lipidization of sCT with the non-ionic C16E3OH did not negate the efficacy of the 
peptide to lower plasma calcium level following subcutaneous injection in the rats. 
Lipeo-sCT was observed to lower the rodent plasma calcium to similar levels as 
unmodified sCT. However, the bioactivity of Lipeo-sCT was extended by at least 6 h 
relative to that of sCT. To our knowledge, this is the first report to demonstrate a 
prolongation of sCT activity by lipid modification. Subcutaneously administered 
REAL-sCT exhibited comparable intensity and duration of bioactivity as Lipeo-sCT, 
suggesting that the calcium lowering activity of the lipidized peptides was 
independent of their lipidization chemistry. This conclusion should, however, be 




formulation showed both to have similar hypocalcemic activities after subcutaneous 
administration, yet the REAL-sCT formulation was more potent in inhibiting bone 
resorption, as measured by urinary deoxypyridinoline (DPD) level, after oral 
administration (94). The discrepancy was ascribed to a ‘ceiling effect’ of 
hypocalcemic drugs administered at doses greater than the saturable dose, where the 
maximum plasma calcium lowering effect reached a threshold level due to 
homeostasis and feedback mechanisms (132). It is therefore possible that Lipeo-sCT 
and REAL-sCT might well have different bioactivity profiles when injected at lower 
doses.  
 
The pharmacokinetic study provided an explanation for the prolonged hypocalcemic 
activity observed of REAL-sCT and Lipeo-sCT in the rat model. sCT after 
subcutaneous injection at a dose of 1.5 mg/kg showed immediate availability and a 
rapid elimination rate, the plasma sCT level decreasing from 150 nM at 10 min to 
undetectable level (<1.3 nM) at 150 min. The rapid elimination of systemic sCT was 
not surprising given its instability in media containing liver enzymes or plasma. In 
contrast, subcutaneous injection of equivalent doses of Lipeo-sCT and REAL-sCT 
produced sustained plasma sCT levels in the rats. In the case of Lipeo-sCT, the 
lipidized peptide was not present at measurable levels in the blood at all time points 
examined, but the presence of systemic sCT underscores a successful conversion of 
the injected Lipeo-sCT to the parent drug in vivo. Since plasma does not offer a 
reductive environment, the systemic regeneration of sCT from Lipeo-sCT was likely 
to occur in the liver. Degradation studies in the liver juice had demonstrated an 




(Section 2.3.5). The ratio of plasma Lipeo-sCT to sCT levels implied an immediate 
conversion of absorbed Lipeo-sCT to sCT, although it was more likely for C16E3OH                     
to be eliminated through the hydrolysis of the ester bonds, yielding an intermediate 
compound that subsequently was converted to sCT in the liver. Lipeo-sCT might also 
had been so poorly absorbed that it formed a depot at the injection site, from which 
only very a small portion of Lipeo-sCT was absorbed into circulation and converted to 
sCT. On the other hand, both sCT and REAL-sCT were detected in the blood 
following the subcutaneous injection of REAL-sCT, indicating that REAL-sCT 
readily penetrated the systemic circulation from the injection site. However, the 
significantly lower plasma sCT concentration indicated that only a small portion of 
the systemic REAL-sCT was converted to sCT, although the plasma sCT 
concentration correlated with the REAL-sCT concentration at all time points analyzed. 
Despite these differences in their pharmacokinetic profiles, both Lipeo-sCT and 
REAL-sCT produced persisting plasma sCT levels upon subcutaneous injection into 
the rats. Rats injected with REAL-sCT exhibited plasma sCT level of 16~32 nM for at 
least 360 min while sustained plasma sCT level of 5.9~ 7.0 nM was observed for up to 
at least 480 min for rats injected with Lipeo-sCT. The sustained plasma sCT levels 
accounted for Lipeo-sCT and REAL-sCT having prolonged hypocalcemic activity 
compared with the parent drug upon subcutaneous injection in the rats.   
 
“Regeneration of sCT from Lipeo-sCT and REAL-sCT could be mediated by disulfide 
exchange reactions with the glutathione and thioredoxin enzymes in the liver (184), 
possibly in the liver endothelial cells and Kupffer cells, as these cells are mainly 




                                                                                                                                     
was unlikely to occur in the general circulation, as it required a reductive environment 
that would be provided for by the high level of glutathione (GSH) coupled with low 
levels of oxidized glutathione (GSSG) in the cytosol (184). To date, the subcellular 
locations of the putative reduction sites and the mechanisms by which the 
endocytosed macromolecules were reduced remained poorly understood (190). 
However, transportation of sCT and its analogs into the cytosol could take place via 
scavenger receptor mediated endocytosis/transcytosis (189, 191). In addition, binding 
of the highly lipophilic sCT conjugates with plasma albumin (95, 124, 147) could 
result in these molecules being endocytosed as a complex, despite their existence as 
aggregates at the subcutaneous injection site. 
 
It is not inconceivable that REAL-sCT and Lipeo-sCT themselves might also possess 
hypocalcemic activity. Lipeo-sCT and REAL-sCT exhibited a robust helical structure, 
and the active form of sCT has been predicted to assume this conformation (148, 192). 
If the lipidized peptides possessed inherent hypocalcemic activity, they would 
influence the plasma calcium level. The consequent would be a greater fall in plasma 
calcium level than that expected had the hypocalcemic activity resulted only from the 
conversion of the lipidized to sCT in vivo. This appeared to be the case in Figure 17. 
Unlike sCT, REAL-sCT and Lipeo-sCT also produced larger inter-individual 
variation in plasma calcium level, in particular at 24, 36 and 48 h after subcutaneous 
injection. Peroral administration of Lipeo-sCT resulted in even more extreme 
variation in outcome. Such variation might be reflective of the individual rat’s 




effect is the summation of effects from sCT and lipidzed peptides if the latter were 
active. However, the potency of the lipidized peptides could not be ascertained in this 
study due to the the high dose used in the pharmacokinetics study, which made it 
difficult to correlate hypocalcemic activity with pharmacokinetic profile because of a 
potential ceiling effect (132). Moreover, the continuous release of sCT from the 
lipidized peptides made it difficult to apportion any hypocalcemic effect to the 
lipidized peptides even if they were active. 
 
Unlike sCT, which showed hypocalcemic activity after oral administration at a dose of 
5.0 mg/kg, equivalent doses of peroral Lipeo-sCT did not produce statistically 
significant hypocalcemic activity. Surprisingly, although REAL-sCT was successfully 
absorbed following subcutaneous injection, this lipidized peptide also failed to exhibit 
significant hypocalcemic activity when administered by intragastric gavage to the rats. 
The poor efficacy of peroral REAL-sCT could be attributed to its instability in the 
GIT. Although Lipeo-sCT and REAL-sCT possessed greater stability in rodent 
intestinal fluid compared to sCT, only 15.2% and 3.2% of the of Lipeo-sCT and 
REAL-sCT doses, respectively, were detected after 20 min of incubation with diluted 
intestinal fluid (Figure 14). Given that a typical GIT transit time is in the range of 
more than 1 h (193) and the concentration of enzymes in the GIT was much higher 
than that used in the in vitro experiments, it was unlikely for sufficient intact Lipeo-
sCT and REAL-sCT to remain in the GIT for absorption into the systemic circulation. 
Thus, it might be concluded that peptide stability might not be the most critical factor. 
Moreover, the aggregation of these lipid conjugates in vivo could result in very large 




size-dependent passive diffusion pathway (25) unless the monomeric lipidized peptide 
was released. Although absorption via the transcytosis pathway, which was 
independent of of the MW of the conjugate as long as the aggregates had diameter of 
≤ 100 nm (142, 194), was a possibility, this did not appear to occur to a significant 
extent as peroral Lipeo-sCT showed inconsistent results while peroral REAL-sCT was 
not active.  
 
The data for peroral REAL-sCT contrasted with the findings of a published study (94) 
in which REAL-sCT administered subcutaneously as a solution in Liposyn® (an 
intravenous emulsion) was reported to exhibit similar hypocalcemic activity as sCT 
This formulation of REAL-sCT was even shown to be more potent in inhibiting bone 
resorption, as measured by urinary  deoxypyridinoline (DPD) level, than sCT after 
subcutaneous and oral administration. This discrepancy between the findings in the 
present study and that in the earlier study underpin the importance of formulation on 
the oral bioavailability of REAL-sCT. Further study is therefore necessary to establish 





Section  3 Mal-sCT: aqueous soluble, non-






Lipid conjugation is a promising method for increasing the deliverability of a peptide 
drug. However, lipidization frequently results in reduced or, in some cases, loss of 
bioactivity of a pharmaceutical (119, 195). To confer the benefits of lipidization 
without sacrificing efficacy, Shen's group designed a novel method, known as 
reversible aqueous lipidization (REAL), in which water-soluble lipid groups were 
conjugated to a peptide drug via inter-disulfide bonds (90, 91, 93, 94). This method 
has been shown to be particularly useful for potentiating the activity of peptide drugs 
with an intra-disulfide bond, such as desmopressin (91, 93), calcitonin (94) and 
octreotide (95). The potentiated activities appeared to be related to the enhanced 
stability of the conjugates and their capacity to bind to local tissues and plasma 
proteins. For these reversible conjugates, activity in vivo was associated with the 
regeneration of the parent drug after oral or subcutaneous administration. There was 
evidence, however, that the REAL-peptide conjugate itself might be active (94). 
 
On that basis, we examined the structure-activity relationships of peptide drugs with 
intra-disulfide bonds, and found further evidence that the intra-disulfide bond is 
frequently not essential for activity. For example, the replacement of the disulfide 
moiety in desmopressin with a sulfide-methylene group resulted in a longer duration 
of activity (196). An analogue of octreotide, PTR 3173, which did not have an intra-
disulfide bond, was shown to be as potent as octreotide in inhibiting forskolin-




calcitonin (sCT) analogues without an intra-disulfide bond also possessed intact 
hypocalcemic activity in the rat model (149). More recently, the sCT S-sulfonated 
analog was shown to have a more potent activity than sCT in rats (148). These 
findings led us to hypothesize that the disulfide bond in peptide drugs might be a 
potential site for non-reversible lipidization. The argument for non-reversible 
lipidization is that it maintains greater conjugate stability, and therefore greater 
assurance of realizing the lipid-mediated advantages in vivo compared to a labile lipid 
conjugate.    
 
To date, there is no report on a non-reversible aqueous-based lipid modification 
method targeted at the intra-disulfide bond of a peptide drug. This section describes a 
novel non-reversible, aqueous-based lipid conjugation method developed in this 
project that was targeted at the intra-disulfide bond of salmon calcitonin. The method 
was unique compared to other non-reversible lipidization methods (121, 199, 200) 
because it utilized an aqueous medium, which was environmentally friendlier than 
noxious organic solvents, and gave very high yield. It may therefore be a useful 
generic tool for the lipidization of peptide drugs with sulfide-ether bonds. 
 
3.2 Materials and Methods 
N-α-(tert-butoxycarbonyl)-L-lysine (N-Boc-lysine), methylpyrrolecarboxylate, tris(2-
carboxyethyl) phosphine (TCEP), trifluoroacetic acid (TFA) and fluorescein-5-
isothiocyanate (FITC) were from Sigma-Aldrich (St. Louis, MO, USA). All other 






N-ε-maleimido α-Boc-L-lysine  
N-ε-maleimido α-Boc-L-lysine (II) was synthesized according to published methods 
(201, 202) with slight modification, as shown in (Figure 33 A). Briefly, 1.56 g (10 
mmol) of methylpyrrolecarboxylate and 2.46 g (10 mmol) of N-Boc-L-lysine (I) were 
mixed in saturated aqueous NaHCO3 at 0ºC for 2 h. The solution was acidified to pH 
3 with 20% of H2SO4 before extraction with ethyl acetate. The organic layers were 
combined and the residue after solvent evaporation was isolated by silica-gel column 
flushing with chloroform-methanol stepwise gradient.  The target was pooled together 
and solvent was evaporated. This reaction resulted in 2.70 g of N-ε-maleimido α-Boc-
L-lysine (II) (yield 84.5%).  
 
1H-NMR (CDCl3) δ ppm: 1.30-1.95 (6H, m, (CH2)3), 1.44 (9H, s, Boc(COCCH3)3), 
3.52 (2H, t, NCH2), 4.28 (1H, m, α-CH), 5.08 (1H, d, -NHCO-), 6.69 (2H, s, 
maleimido-H). ESI-MS (MNa+): m/z 348.3 (calculated 349.3). 13C-NMR  (CDCl3) δ 
ppm: 22.5 (lysine-γ-CH2), 27.8 (lysine-β-CH2), 28.1 (Boc-CH3), 31.6 (lysine-δ-CH2) , 
37.2 (lysine-ε-CH2), 52.9 (31.6 (lysine-α-CH2), 81.5 (Boc-C-), 133.9  (maleimido-CH), 




































































Figure 33 Schematic diagram showing the synthesis pathway of (A) ε-Maleimido Lysine 
Derivative of Palmitic acid (Pal-Lys-Mal, IV) and (B) conjugation of Pal-Lys-Mal to sCT. 
 
ε-Maleimido lysine derivative of palmitic acid (Pal-Lys-Mal) 
Pal-Lys-Mal (IV) was synthesized based on a previous report (202) with slight 
modification. N-ε-maleimido α-Boc-L-lysine (II) (0.81 g, 0.24 mmol) was reacted 
with 8 ml of saturated HCl in dry ethyl acetate (prepared by flushing dry HCl with 
ethyl acetate, the dry HCl was generated by heating NaCl with concentrated H2SO4) 
for 30 min at room temperature before addition of 3 ml of dry ether at 0ºC. HCl salt of 




precipitation and filtration.  
 
N-ε-maleimido-L-lysine HCl (III) (0.47 g, 1.78 mmol) was added without further 
purification to 0.71 g (2.02 mmol) of Pal-Suc and 493 µl (3.56 mmol) of triethyl 
amine in 15 ml of dimethylformamide (DMF). The reaction mixture was stirred at 
room temperature for 0.5 h, then diluted with 100 ml of water. The precipitate was 
collected via filtration and dried in vacuo. The residue was eluted in a silica-gel 
column using a mixture of chloroform, methanol and acetic acid (100:2:0.01) as 
eluent to produce the target Pal-Lys-Mal (IV) (0.282 g, 34.2% yield).  
 
APCI-MS (MH+): experimental m/z: 465.0 (calculated: 465.6). 1H-NMR (CDCl3) δ  
ppm: 0.84 (3H, CH3), 1.22 (26H, m, (CH2)13), 1.58 (4H, m, lysine-γ,δ- CH2), 1.70-
1.94(2H, m, lysine-β-CH2), 2.23 (2H, t, COCH2), 3.48 (3H, t, CH3), 4.51 (1H, q, 
lysine-α-CH), 6.46 (1H, d, CONH), 6.67 (2H, d, maleimido-H), 9.33 (1H, broad, 
COOH). 13C-NMR (CDCl3) δ ppm: 174.91, 174.33, 170.85, 134.02, 52.06, 37.14, 
36.32, 31.81, 31.16, 29.60, 29.57, 29.55, 29.43, 29.24, 29.18, 27.94, 25.57, 22.57, 
22.22, 13.99.  
 
Conjugation of Pal-Lys-Mal with sCT  
Conjugation of Pal-Lys-Mal with sCT generated the conjugate, Mal-sCT (V), as 
shown in (Figure 33 B).  Mal-sCT was prepared by mixing, with stirring, 31.12 mg of 
sCT and 27.0 mg of Pal-Lys-Mal (IV), together with 30 mg of tris(2-




protection at 0ºC for about 20 h.  
 
Mal-sCT was separated from the reaction mixture in a C-18 semi-preparative column 
(10×250mm) with the elution system: A: 0.1% TFA in water and B: isopropanol and 
acetonitrile (1:1 v/v) mixture containing 0.1% TFA; from 50% B to 90% B in 40 min 
at a flow rate of 2 ml/min. The fractions containing the target were collected and 
pooled together, and after the evaporation of the organic solvent in a rotary evaporator, 
the concentrated target was lyophilized and identified with ESI-MS by comparing the 
experimental and calculated m/z values based on an exact mass of 4360.4 Dalton for 
MW of Mal-sCT. 
  
The purity of Mal-sCT was confirmed with HPLC. HPLC analysis was carried out 
using a Waters Symmetry 300 C-18 column (4.6×250mm). Elution time profile was 
from 100% A: water (0.1% TFA) to 100% B: 1:1 v/v mixture of isopropanol and 
acetonitrile (0.1% TFA) in 40 min and maintaining at 100% B for another 5 min. 
Volume of sample injected was 100 µl and the sample was detected at λ=214 nm. 
 
3.2.2 Morphology  
The morphology of Mal-sCT was observed under a TEM using protocols previously 






3.2.3 Particle size 
Particle size was determined using the Protein SolutionsTM DynaProTM Dynamic 
Light Scattering Instrument as previously described in Section 2.2.4. 
 
3.2.4 Stability  
Stability of Mal-sCT in rodent intestinal fluid and liver juice was determined 
according to the methods described in Section 2.2.5. 
 
3.2.5 Peptide conformation 
Peptide conformation was determined in a CD spectrophotometer as described in 
Section 2.2.6.  
 
3.2.6 Uptake by Caco-2 Cells  
sCT and Mal-sCT were labeled with the fluorophore, FITC, to allow for their 
quantification in cellular uptake experiments. Synthesis of FITC-sCT and FITC-Mal-
sCT was based on the reaction between the isothiocyanate group of FITC and the 
primary amino groups of lysine and N-terminal amine in the peptides (203) (Figure 
34). The conjugation reaction, at a drug to FITC molar ratio of 1:2, was carried out in 
pH 9.0 NaHCO3 solution at 0-4ºC for 3 h. The reactions were quenched by adding 5 
ml of pH 4.0 ammonium acetate solutions. Fractions containing the FITC-labeled 
peptides were isolated by elution in a semi-preparative HPLC column and lyophilized. 




unlabeled and labeled peptides obtained from the MS measurements. Labeling 
efficiencies for 1 FITC- and 2 FITC-labeled sCT were 56.9% and 7.1%, respectively. 
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Figure 34 Scheme of  labeling sCT and Mal-sCT with fluorescein isothiocyanate (FITC) 
 
Cellular uptake experiments were conducted according to the established protocols in 
our laboratory (204). Freeze-dried FITC-labeled samples were dissolved in the uptake 
medium (HBSS containing 10 mM HEPES and buffered to pH 7.4) to give 5.0 µM 
sCT or Mal-sCT solution. Caco-2 cells (passage 56, American Type Culture 
Collection, Rockville, MD) were cultured for 10 days on 96-well polycarbonate plates 
(NuncTM, Nalge Nunc International, Denmark) at a seeding density of 2×104 
cells/well. The cells were washed thrice with pre-warmed uptake medium and 
equilibrated for 1h with 100 µl of the medium at 37°C. After the uptake medium was 
aspirated, the cells were incubated with 100 µl of test samples for up to 145 min at 
37°C. The experiments were terminated by aspirating the test samples and washing 
the cells three times with ice-cold PBS. To each well was added 100 µl of uptake 
medium, and the cells were solubilized 1h later with 100 µl/well of 0.2 M 




reader (Spectra Fluor, Tecan Group Ltd., Männedorf, Switzerland; λexc 485 nm, λemi 
535 nm) calibrated with FITC-sCT and FITC-Mal-sCT samples (0.05 to 2.5 µM) 
dissolved in 1:1 v/v of uptake medium and the lysate of control cells. Cell-associated 
FITC-sCT and FITC-Mal-sCT were expressed as a percent of the respective initial 
amounts administered to each well (mean ± SD, n = 6).  
 
3.2.7 In vivo hypocalcemic activity  
Pharmacodynamic response of Mal-sCT in Wistar female rats was evaluated using 
methods similar to those described in Section 2.2.7. sCT and Mal-sCT for 
subcutaneous injection were separately dissolved in normal saline at 0.114 and 0.145 
mg/ml (equivalent to 0.114 mg/ml), respectively. Control rats were injected with 
normal saline.  To study the peroral activity of the peptides, the rats were fasted for 
12-16 h before they were administered by intragastric gavage with 5.0 mg/kg of sCT 
or 6.4 mg/kg of Mal-sCT (equivalent to 5.0 mg/kg sCT) in distilled water.  Blood 
samples were collected by saphenous vein puncture with a Microvette® CB300LH 
(Sarstedt, Germany) and were processed and analyzed as described in Section 2.2.7.  
 
Plasma calcium versus time graphs were constructed, and the linear trapezoidal 
method was applied to determine the AAIC. Relative pharmacological bioavailability, 
F, was calculated according to Equation 2:   
D(oral)
AAIC(oral)F =   ÷ 
Dmin/max
Emax                (2) 




administered, Dmin/max was the minimum dose required for maximum calcium 
lowering effect, and Emax was the hypocalcemic activity at this dose. Emax and 
Dmin/max for subcutaneously administered sCT had the values of 426.8 mg.min/dL 
and 10.2 ng/rat (100-250g), respectively (132). Since the absolute bioavailability of 
sCT following subcutaneous injection was 16.1% in a rat model (132), the absolute 
pharmacological bioavailability for the orally administered peptides was calculated as 
F × 16.1%.  
 
3.2.8 Pharmacokinetics profile 
LC-MS method development  
Plasma samples containing Mal-sCT were processed in the same manner as Lipeo-
sCT and REAL-sCT plasma samples (Section 2.2.8.2). The effect of incubation time 
on the relative recovery of Mal-sCT from the extraction media and the standardization 
of Mal-sCT plasma samples were performed in parallel with the Lipeo-sCT, REAL-
sCT and sCT samples. However, assay of Mal-sCT was carried out in the LC-MS 
rather than in the HPLC.  
 
With regards to the MS settings, preliminary results showed a distribution of the H+ 
adduct ions of Mal-sCT at 873.5 (M+5H+, 20%), 1091.4 (M+4H+, 100%) and 1454.5 
(M+3H+, 7%). The most abundant peak was at 1091.4, which would yield the 
strongest response at 1091.5 when analysed later in the MRM mode. This was further 
fragmented to give a daughter ion with a strong signal at 115.1. Thus the ion pair of 




settings are shown in Table 6. 
Table 6 Optimum MS parameters under MRM mode for the determination of Mal-sCT in rat 
plasma samples 
Q1 Mass (amu) Q3 Mass (amu) Dwell (msec) DP EP CEP CE 
1091.5 115.1 150 140  7.5  50.8 51.0 




Drug administration and blood sampling  
Three Wistar female rats weighing 180 to 220 g were each administered with 0.44 
µmol/kg (1.90 mg/kg) of Mal-sCT (1.90 mg/ml in saline) via subcutaneous injection. 
Blood samples were collected as described via saphenous vein puncture and analyzed 
as described in Section 2.2.8 with above-described MS settings.  
 
Area under the plasma concentration-time curve (AUC) was calculated using the 
trapezoidal rule as follows:  
AUC=∑ ΔAUC (tn~tn+1) = ∑ [ 21  (Cn+Cn+1)×(tn~tn+1)], where ΔAUC (tn~tn+1) was the 
AUC from tn (the nth time point) to tn+1((the (n+1)th time point), while Cn and  Cn+1 
were the respective plasma Mal-sCT concentration at tn and tn+1.  
 
3.2.9 Statistical Analyses 
Results are expressed as mean ± standard deviation. Plasma calcium and cellular 
uptake data were analyzed by one-way ANOVA, with post-hoc Tukey’s tests  and 




at a p value of 0.05 (SPSS 12.0, SPSS Inc., Chicago, IL). 
 
3.3 Results  
3.3.1 Synthesis  
The synthesis pathways for the water-soluble lipid, Pal-Lys-Mal (IV), and the 
subsequent conjugation of sCT with Pal-Lys-Mal are shown in Figure 33 A. Pal-Lys-
Mal was synthesized by palmitoylation of ε-maleimido-lysine (III) with Pal-Suc. ε-
maleimido-lysine was obtained by deprotection of  ε-maleimido α-Boc lysine (II), 
which was derived by attaching a maleimido group at the ε-amine of α-Boc-lysine via 
an imide-amide intermediate (201). The presence of the maleimido groups was readily 
confirmed by 1H-NMR (single peak 6.70 ppm) and 13C-NMR (134 ppm) spectra. 
 
Conjugation of Pal-Lys-Mal with sCT was conducted by one-pot synthesis (Figure 33 
B). The intra-disulfide bond of sCT was reduced by TCEP to form thiols in an 
aqueous environment at pH 7.0 and, without separation, further reacted with the 
maleimido group of the lipid to yield the thiol-ether bond of Mal-sCT. Despite the 
mild conditions of synthesis, the conjugation process was very efficient, giving a high 
yield (83%) of the purified conjugate.  
 
The ESI-MS spectrum (Figure 35) of the conjugate showed an array of main peaks at 
873.5 (17%), 1091.4 (100%) and 1454.5 (7%), which agreed well with the calculated 
m/z values for Mal-sCT: 873.1 (M+5H+), 1091.1 (M+4H+) and 1454.5 (M+3H+), 




compound with higher lipophilicity than sCT.   
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Figure 36 HPLC chromatograph of (A) sCT and (B) Mal-sCT  
  
3.3.2 Morphology  
TEM results showed that Mal-sCT, like Lipeo-sCT, had a tendency to aggregate into 
large particles (Figure 37), a sharp contrast to sCT (Figure 10 C). While this was 
suggestive of a greater propensity of Mal-sCT to form agglomerates, it should again 




been introduced during sample drying. 
 
Figure 37 TEM micrographs of Mal-sCT, 10,000x. Samples were prepared by mixing 2 μl of Mal-
sCT solution (0.5 mM in water) with 1 μl of 1% phosphotungstic acid solution for 1 min in a 
TEM grid. Scale bar, 500 nm. 
 
3.3.3 Particle size 
Figure 38 shows the mean particle size measured by dynamic light scattering analyses 
of sCT and Mal-sCT in distilled water. The sCT data had earlier been discussed in 
Section 2.3.4. sCT existed mainly as monomers in distilled water in the concentration 
range of 220 to 1000 µM, and the particle size of sCT could not be accurately 
measured below the critical concentration of 220 µM. By comparison, Mal-sCT (MW 
4.36 KDa) had mean radii of 3.1 to 3.6 nm (peak 2 at 1000 µM and 11µM was 
ignored because of its negligible contribution based on mass percentage) over a wide 
concentration range of 11.2 to 1000 µM (Table 7). The particle size range was 
equivalent to a calculated MW of between 46.02 and 66.37 KDa. Further dilution of 
the Mal-sCT solution to 2.5 µM resulted in a hydrodynamic radius of 1.3 nm, 




Mal-sCT in aqueous solutions might have transited from aggregated to monomeric 
states when diluted from 11.2 to 2.5 µM.  
















1000 497 Peak  1 3.58 0.59  99.9  66.4
  Peak  2 9.43 0  0.1  641.1
224 140 Peak  1 3.30 0.62  100.0  3.25
54 35 Peak  1 3.16 0.30  100.0  49.55
11 23 Peak  1 3.06 0  99.8  46.02
  Peak  2 28.03 7.3  0.2  8207






















Figure 38 Particle size as a function of concentration of sCT and Mal-sCT in water, as measured 
by dynamic light scattering. Data represent mean ± polydispersity of at least 20 scans. 
 
3.3.4 Stability 
Figure 39 shows the degradation profiles of sCT and Mal-sCT in the diluted intestinal 
solutions. Degradation of sCT was almost complete within 5 min, the degradation data 




Mal-sCT was less well defined by first order kinetics (Y = 100e-0.43X, R2=0.84).  
However, there were no significant differences in the percent remaining between sCT 



























Figure 39 Degradation of sCT and Mal-sCT by diluted rat intestinal solution. 40 µM sCT and 
Mal-sCT were incubated separately with the diluted intestinal solution (45 µg protein /ml) at 
37ºC in a shaking water bath operating at 50 rpm. 
 
After 15 min of incubation in the liver juice, approximately 1% of sCT was detected, 
indicating a rapid degradation of the peptide by the liver enzymes (Figure 40). When 
the incubation period was prolonged to 30 min, there was negligible amount of sCT 
remaining, and the peptide became undetectable after 45 min of incubation. In 
comparison, Mal-sCT showed a slower rate of liver metabolism, with 86.4% of the 
conjugate remaining after 15 min of incubation in the liver juice. Even when the 
incubation period was prolonged to 90 min, about 10% of the conjugate remained 
detectable in the juice. The degradation data for sCT and Mal-sCT fitted a first order 
degradation profile to give the following respective equations: Y=100e-0.231 t (R2=0.91) 
and Y=100e -0.0195 t (R2=0.92), where Y represents the percent remaining after 





















Figure 40 Degradation profiles of sCT and Mal-sCT when incubated with fresh liver juice. Liver 
juice was the turbid supernatant obtained by centrifuging a mixture of homogenized rat liver (7.5 
g) and 7.5 ml of MEM (with 5% FBS) at 2000 rpm. Curve fitting was based on first order kinetics. 
 
3.3.5 Peptide conformation 
As has been discussed in Section 2.3.6, CD analysis indicated that sCT in water 
showed no apparent secondary structure (Figure 41), but assumed a helical 
conformation upon the addition of increasing concentrations of TFE, an organic 
solvent with low dielectric constant. In contrast, Mal-sCT exhibited comparable CD 
spectra whether it was dissolved in water or in aqueous solutions of TFE (Figure 41 
B). The CD spectra of Mal-sCT suggested a helical structure for the conjugate that 















































Figure 41 Circular dichroism spectra of (A) sCT and (B) Mal-sCT in aqueous solutions 
containing different concentrations of trifluoroethanol (TFE). Peptides were analyzed at a 
concentration of 0.10 mM. 
 
3.3.6 Cellular Uptake by Caco-2 Cells  
Initial uptake of FITC-sCT and FITC-Mal-sCT by the Caco-2 cell monolayers was 
rapid, with subsequent uptake occurring at slower rates (Figure 42). At all time points, 
the cellular uptake of FITC-Mal-sCT was about 2-fold higher than that of FITC-sCT. 
For example, at 145 min of incubation, the cell-associated FITC-sCT was equivalent 
to 2.08% of the initial load, while the corresponding figure for FITC-Mal-sCT was 
























Figure 42 Cell-associated FITC-sCT and FITC-Mal-sCT as a function of incubation time with 
Caco-2 cell monolayers. HBSS (pH 7.4) served as transport medium and the loading dose of 
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Figure 43 Plasma calcium level of rats administered with Vehicle (normal saline), sCT and Mal-
sCT by subcutaneous injection. sCT and Mal-sCT, dissolved in normal saline at 0.114 mg/ml and 
0.145 mg/ml (equivalent to 0.114 mg/ml sCT) respectively, were dosed at  200 µl/rat (200g). Data 






3.3.7 In vivo hypocalcemic activity 
The in vivo bioactivity of Mal-sCT was evaluated by measuring its ability to lower 
plasma calcium levels after subcutaneous injection (Figure 43) or intragastric gavage 
(Figure 44) in the rat model. Rats dosed with the vehicle served as negative controls, 
while those administered with equivalent sCT dose were positive controls. Baseline 
plasma calcium levels were not significantly different between the rats in the control 
































Figure 44 Plasma calcium level of 6 individual rats after intragastric gavage with sCT (A) and 
Mal-sCT (B).  sCT and Mal-sCT were administered respectively as 2.5 mg/ml and 3.2 mg/ml 
(equivalent to 2.5 mg/ml sCT) solutions in water. Doses administered for sCT and Mal-sCT were 





Compared to the vehicle, Mal-sCT administered subcutaneously at a dose of 0.145 
mg/kg (equivalent to 0.114 mg/kg sCT) was observed to cause a significant lowering 
of the plasma calcium level at 2h post-injection (Figure 43). The plasma calcium level 
remained at low levels from 2 to 12h post-injection. Subcutaneous sCT at the same 
dose produced comparable results to Mal-sCT, causing a significant lowering of the 
plasma calcium levels from 1 to 12 h post-injection. However, Mal-sCT appeared to 
give more variable outcomes, as evidenced by the wider error bars for the plasma 
calcium levels at 8 and 12 h post-injection.   
 
The biological activities of peroral sCT and Mal-sCT were also compared. All 6 rats 
given sCT (dose 5.0 mg/kg) by intragastric gavage showed significantly lower plasma 
calcium levels at 1 to 2 h post-administration (p<0.001), and a return of the calcium 
levels to baseline at 4h post-administration (Figure 44 A). In contrast, the mean 
plasma calcium data obtained for peroral Mal-sCT were not statistically different from 
baseline levels. However, while consistent outcomes were observed for all the rats in 
the sCT group, the outcomes were not uniform across the 6 rats in the peroral Mal-
sCT treatment group (Figure 44 B). The majority of the rats (4 out of 6) did not 
exhibit a lowering in plasma calcium level following the administration of Mal-sCT, 
but two rats in the group showed low calcium levels, about 6.5 mg/dL, from 2 to 12 h 
post-administration.  
 
The pharmacodynamic responses attributed to peroral sCT and Mal-sCT was 




mg.min/dL (n=6) was not statistically different from that for peroral Mal-sCT at 1254 
± 1829 mg.min/dL (n=6). Mean relative and absolute pharmacological bioavailability 
(BA) for sCT were calculated to be 0.0069% and 0.0011%, respectively. These values 
were approximately 26-fold less than that reported for sCT delivered directly into the 
rat duodenum at a similar dose (132), suggesting that the peptide was significantly 
degraded in the gastric fluid. Mean relative pharmacological BA for peroral Mal-sCT 
was 0.015%, about 2 fold higher than that for peroral sCT. However, the accuracy of 
the BA value for Mal-sCT is compromised by the large variation in plasma calcium 
data obtained. 
 
3.3.8 Pharmacokinetics profile  
LC-MS method development  
It had previously been observed that sCT, REAL-sCT and Lipeo-sCT were not stable 
in plasma containing the extraction medium (Section 2.3.8). Mal-sCT showed similar 
instability with a rapid degradation rate in IPA-ACN precipitated plasma solutions 
(Figure 45). In about 93 min, 44.4% of the Mal-sCT initial load was degraded and at 
283 min, only 10.7 % of the Mal-sCT was left. On the basis of these results, the LC-
MS analysis of Mal-sCT was performed immediately after the plasma samples were 
processed.  
 
Using the tandem MS mode, blank plasma samples showed a clean baseline. Plasma 
samples spiked with Mal-sCT showed an elution peak at 13.4 min (Figure 46). The 




to Mal-sCT, probably because the smaller aggregated particle size of Mal-sCT 
facilitiated its dissolving into the mobile phase. There was no peak interference 
between samples spiked with sCT and those spiked with Mal-sCT, indicating that sCT 
could be simultaneously determined in a Mal-sCT sample which had reverted back to 


























Figure 45 Effect of incubation time on the relative recovery of Mal-sCT. The samples were 
obtained as clear supernantent after centrifugation of the plasma samples, which were diluted 
with equal volume of water and precipitated with 4 times of its volume with IPA-ACN (v/v 1:1). 











Calibration of the LC-MS was performed with plasma samples spiked with known 
quantities of Mal-sCT. Table 8 shows a comparison of peak areas of Mal-sCT 
extracted from plasma and water, both samples being processed in the same way. 
Peptide recovery, based on the ratio of mean peak area of Mal-sCT in plasma to the 
mean peak area of Mal-sCT in water, was a respectable 73.1% (n=4). In the 
concentration range of 5.0 to 300 nM, RSD for peak area of Mal-sCT in plasma was 
in the acceptable range of 10.6 to 29.8% (n=2~4). In addition, mean peak area was 
linearly correlated with the concentration of Mal-sCT in plasma (Figure 47), 
indicating that the LC-MS peak area could be used to quantify Mal-sCT concentration 
in plasma samples.  
Table 8 LC-MS peak areas for standard solutions of Mal-sCT in plasma and in water. The 
recovery was calculated based on the peak area of Mal-sCT in plasma relative to the peak area of 
Mal-sCT in water. 
Mal-sCT in plasma Mal-sCT in water Conc. 
(µM) n Peak area ± SD n Peak area ± SD 
Recovery Mean recovery(± SD) 
100.0 2 3485 ± 1039 3 4136.7 ± 900 84.2% 
50.0 4 1790 ± 190 3 2290 ± 165 78.2% 
10.0 2 277 ± 41.7 3 468 ± 114 59.2% 
5.0 4 471 ± 78.6 2 666 ± 67 70.8% 
73.1 % 
































Mal-sCT (1.91 mg/ml in saline) injected subcutaneously at a dose of 0.44 µmol/kg 
was detectable in the blood of the rats at 10 min (Figure 48). There was a gradual 
build up of plasma Mal-sCT over the next 230 min to reach a concentration of 207 nM, 
and the maintenance of this plasma concentration over the time frame of 240 to 360 
min. When compared with plasma concentration of rats injected subcutaneously with 
sCT or REAL-sCT, the plasma Mal-sCT concentration in 90-360 min was comparable 
to the level of plasma sCT measured in the first 10-20 min (Figure 27), and the plasma 
Mal-sCT concentration profile was parallel to that of the plasma REAL-sCT 
concentration measured throughout 360 min (Figure 28). At all time points measured, 





























   
Figure 48 Plasma Mal-sCT concentration in Wistar female rats after a single SC injection of 1.91 
mg/kg of Mal-sCT (equivalent to 1.50 mg/kg sCT). Data represents mean ± SD, n=3. 
 




rule to be 68,828.8±22863.7 nM.min (n=3), while AUC of sCT from 0 min to infinity 
was 6,837.9 ± 2715.3 nM.min (n=3), indicating AUC of Mal-sCT was at least 10 
times as much as AUC of sCT.  
 
3.4 Discussion 
Lipid modification of peptides has gained prominence in recent years for improving 
peptide drug deliverability (119, 121, 125, 205, 206). Chemical methods for 
lipidization usually target the free ε-amine of lysine or the N-terminal amine. These 
methods inevitably involved the use of noxious organic solvents, such as chloroform 
and dimethylformamide, which are hardly favorable for maintaining peptide drug 
stability (207, 208). In addition, solvent removal is mandatory, requiring complicated 
post-processing (200). On this basis, the ability to conjugate a lipid to a peptide drug 
in an aqueous media is highly desirable.  
 
A water-soluble lipid, cysteine 2-pyridine disulfide derivative of palmitic acid, has 
previously been applied to the lipidization of protein drugs via a reversible disulfide 
bond (90, 93). Ionization of the carboxyl group at cysteine at neutral pH significantly 
improved the aqueous solubility of the lipid, thereby allowing the conjugation process 
to be performed in an aqueous environment. The disulfide bond between the lipid and 
the peptide was designed to break down under reductive conditions, e.g. in the liver, 
to generate the peptide drug in vivo (93). Our hypothesis was that a non-reversible, 
aqueous-based lipid conjugation at the disulfide bond was also feasible, and that it 
would confer greater benefits in terms of presenting consistent stability to the peptide 




peptide. To evaluate the hypothesis, sCT was used as the model compound to produce 
the analog, Mal-sCT. 
 
Using straightforward synthesis procedures, Mal-sCT could be obtained at high purity 
and yield. More importantly, the lipid modification did not compromise the 
hypocalcemic activity of the peptide, thereby confirming that the disulfide moiety in 
sCT was not critical for its biological activity. HPLC analysis did not show the 
appearance of sCT when Mal-sCT was incubated with the liver juice, suggesting that 
the thio-ether bond in Mal-sCT was stable under reductive conditions. The implication 
is that the in vivo hypocalcemic activity of Mal-sCT could be attributed to the analog 
itself, not to the parent compound. This was further confirmed by the pharmacokinetic 
experiments, in which sCT was not detected in the plasma of any of the rats 
administered subcutaneously with Mal-sCT. Yet at sCT equivalent dose of 0.114 
mg/kg, Mal-sCT showed comparable hypocalcemic activity to sCT following 
subcutaneous injection in the rat model. Although the data might also suggest 
comparable bone resorption activities for the two compounds, it should be noted that 
the plasma calcium level has a threshold value because of homeostasis (132). 
Therefore, differences in bone resorption activity between two compounds, 
particularly at high doses, might not be reflected by significantly different plasma 
calcium levels (94) despite reports on a direct correlation between plasma calcium 
level and bone resorption activity (70, 209). In view of the higher AUC obtained for 
Mal-sCT compared with sCT, further studies, e.g. a comparison of ED50 values, will 
have to be conducted to establish whether subcutaneously injected Mal-sCT is 





The CD data provided an interesting correlation of sCT activity to its conformation. 
sCT was shown to exhibit a highly labile conformation in an aqueous medium, 
changing from random coil to helical structure as the polarity of the medium was 
decreased. By comparison, the conformation of Mal-sCT was independent of the 
polarity of the medium, the peptide maintaining a helical structure in aqueous media 
containing 0 – 50% of TFE. This has significant implications because the manifold 
conformations of sCT in aqueous solutions have not allowed its active conformation 
to be resolved to date (27). Mal-sCT is the first irreversible sCT analog to show a 
robust helical structure in aqueous solutions, and by inference of its comparable 
hypocalcemic activity in vivo, would suggest that the helical sCT is a biologically 
active molecule.  
 
The dynamic light scattering data suggested that Mal-sCT formed aggregates over the 
concentration range of 11 to 1000 µM in water (Figure 38). This is not a unique 
phenomenon, because other lipidated peptides, e.g. insulin conjugated with myristoyl 
or deoxycholic acid (121, 210), as well as Lipeo-sCT and REAL-sCT, have also 
shown aggregation behavior in water. Micellization of the amphiphilic Mal-sCT was 
likely to be promoted in water through the segregation of the dual lipid chains to form 
a microenvironment of low dielectric constant. The propensity of Mal-sCT to 
aggregate in water probably underpinned its enhanced stability in the liver juice, since 
the aggregates will limit enzyme access to individual Mal-sCT molecules. In contrast, 
sCT existed predominantly as monomers in aqueous media and it was rapidly 




showed negligible hepatic first-pass elimination of sCT following portal venous 
injection into beagle dogs (161). The contradiction may have arisen from the higher 
concentration of liver enzymes in the present study or to the difference in accessibility 
to intracellular (liver juice) and extracellular (portal vein passage) peptidases. 
 
Transformation of sCT to Mal-sCT improved its resistance to degradation by hepatic 
peptidases (Figure 40). Although it might be argued that the enhancement in stability 
was not encouraging, this level was in agreement with some reports, e.g. the 
lipidization of desmopressin was shown to cause 11.5-fold resistance to enzyme 
degradation (93). On the other hand, Mal-sCT showed comparable degradation rate to 
sCT in the diluted intestinal fluid, suggesting that the aggregated state of Mal-sCT did 
not confer protection against the intestinal peptidases. This is not unusual, for the 
lipidization of peptide drugs does not always result in protection against enzyme 
degradation. In one study, the lipidization of insulin was shown to decrease the 
peptide stability in intestinal fluid by 1.9 fold (195). Nevertheless, the failure of Mal-
sCT to resist degradation in the intestinal fluid does bring into question the practicality 
of synthesizing Mal-sCT. However, as the same lipidization process does not often 
bring about equitable enzyme stability for different peptides (195, 211), it is 
conceivable that the novel synthetic pathway that was developed in this study may 
still prove useful for stabilizing other peptides to enzyme degradation.  
 
Mal-sCT showed 2-fold greater cellular uptake compared to sCT in the Caco-2 cell 
model (Figure 42). The greater cellular association of Mal-sCT is not surprising given 




and Mal-sCT solutions (5 µM) to avoid uptake saturation. At this concentration, both 
sCT and Mal-sCT should exist as monomers based on the particle size measurements. 
Therefore the higher cellular uptake of Mal-sCT could not be attributed to an 
aggregation phenomenon.  
 
A comparison of pharmacokinetic data indicated a prolonged absorption phase (up to 
240 min) for subcutaneously injected Mal-sCT (Figure 48), relative to the short Tmax 
of 10 min obtained for similarly administered sCT. Tmax for sCT was faster than the 
values of 30~60 min reported by Sinko's laboratory for sCT injected subcutaneously 
at doses of 1 to 100 µg/rat (132). The discrepancy could be caused by dose differences, 
the high dose employed in our experiments resulting in greater concentration gradients 
that facilitated sCT absorption from the injection site. Absorption of Mal-sCT was 
slower by comparison, probably due to hydrophobic interaction of the peptide with the 
local adipose tissue or albumin in subcutis (147), and its aggregation into larger 
particles at the injection site. A slower rate of elimination might further prolong the 
absorption phase of Mal-sCT compared to that of sCT. Other non-reversible lipidized 
peptides have been reported to have prolonged absorption phases, e.g. NN304 or ε-
LysB29-myristoyl, des(B30) human insulin had Tmax of 4 to 6 h after subcutaneous 
injection at 0.15 to 0.60 U/kg in human voluteers (212). Likewise, REAL-sCT, which 
was absorbed as a lipidized peptide, showed similar pharmacokinetic profile to Mal-
sCT after subcutaneous injection. 
 
The oral BA of Mal-sCT dissolved in water was determined in the present study. 




uptake (90) or both (205, 211) of lipidized peptide drugs, there is little data on their in 
vivo activity. Often, the higher oral bioavailability of the peptides was alluded to 
based on the in vitro data (90, 94, 121, 205, 211), and what little in vivo data available 
on these conjugates were derived with specially designed pharmaceutical formulations 
(94). In view of its greater resistance to liver metabolism and stronger cellular 
association, Mal-sCT was anticipated to have greater oral bioavailability than sCT. 
This was not evident from the in vivo data. Mal-sCT, delivered by intragastric gavage 
as dissolved molecules in water at equivalent sCT dose and concentration, did not 
produce mean plasma calcium levels that were significantly different from the 
baseline level at all the time points measured. In contrast, peroral sCT solution at the 
same dose was observed to significantly lower the plasma calcium level of the rats to 
20% at 1h post-administration, and to maintain this level for the next 1-3 h.  
 
Wide variation in within-group outcome was seen with peroral Mal-sCT, with 4 out of 
6 rats not responding, while 2 rats showed a highly favorable outcome in which the 
plasma calcium level was reduced by up to 40% from the baseline level for a 
prolonged period of time of up to 10h (Figure 44 B).  Several factors may explain the 
variation. Firstly, the oral route of administration is known to produce significant 
within-group variations in BA, in particular for compounds with very low oral BA. 
Nonetheless, the pharmacodynamic responses for all the rats in the sCT treatment 
group were highly comparable. Mal-sCT, however, had a propensity to aggregate in 
aqueous media. Aggregation of Mal-sCT into larger particles in the GIT could give 
rise to variable absorption profiles (213, 214). Depending on the stability of the 




absorption would occur predominantly through the M cells of the Peyer's patch, a 
route that tends to give highly variable BA  (215).  
 
The variation in pharmacodynamic response might also result from factors other than 
absorption (216). This is because Mal-sCT also produced greater variability in plasma 
calcium levels compared to sCT when it was administered to the rats by subcutaneous 
injection (Figure 43). Such pharmacological variation has not been reported for other 
non-reversible lipid-conjugates, such as insulin (119, 121, 217), indicating that the 
increase in lipophilicity of the molecule was not an influencing factor. Mal-sCT 
appeared to have a more rigid conformation in water, and this could have limited its 
capacity to bind with certain receptor phenotypes. Calcitonin receptors in human (218, 
219) and in the rat (220-223) are known to show genetic polymorphisms. The 
calcitonin receptor was hypothesized to bind with sCT, and its analogues, in a 2-step 
process that involved the peptide backbone/receptor interaction followed by the 
peptide side-chain/receptor interaction (220, 224, 225). sCT is proposed to adopt an 
extended conformation to participate in the first reaction, followed by a restructuring 
into the helical conformation for the subsequent reaction due to the decreased polarity 
at the membrane interface (192). Mal-sCT lacks this flexibility; its rigid helical 
conformation might favor the second reaction, but would hinder the peptide from 
making the initial interaction with the receptor. The therapeutic outcome of peroral 
Mal-sCT could be further complicated by the genetic polymorphisms of metabolic 
enzymes (226). More experiments have to be conducted to provide a better 





In conclusion, we have reported a novel method for conjugating a water-soluble lipid 
to sCT to generate a novel, non-reversible, water-soluble lipid-sCT conjugate at high 
yield. This conjugate, denoted as Mal-sCT, showed higher lipophilicity and a stable 
helix structure in aqueous solutions of varying degrees of polarity. Compared with 
sCT, the conjugate had a stronger tendency to form aggregates, was more resistant to 
enzyme degradation, and exhibited stronger cellular association. Biological activity 
was not compromised by the lipid conjugation, as Mal-sCT produced comparable 
hypocalcemic activity to sCT when injected subcutaneously into the rat model. The 
biological activity of peroral Mal-sCT was, however, inconclusive due to wide within-





Section  4 sCT co-conjugated with lipid and 






PEGylation has evolved to become an established method to enhance the enzyme 
stability of peptide drugs (99). The PEG chains emanating from a peptide molecule 
have been shown to bind strongly with water molecules to form an effective shield 
against enzyme approach. PEGylation is also employed to prolong the systemic 
circulating time of a peptide, as the significant molecular size of the PEGylated 
peptide impeded excretion by renal filtration (101). In addition, a recent study on 
PEGylated poly(caprolactone)-b-poly(ethylene oxide) (PCL-b-PEO) showed that the 
PCL-b-PEO micellar nanocontainers were efficiently transported across the cell 
membrane into the Golgi apparatus and  mitochondria of PC12 (rat 
pheochromocytoma cells) and NIH/3T3 (NIH Swiss mouse embryo cells) cells (107).  
 
In previous experiments of this project, novel lipid conjugates of sCT, namely Lipeo-
sCT and Mal-sCT, have been shown to produce hypocalcemic activity comparable to 
that of sCT in vivo. While the lipid conjugates were more stable than sCT in intestinal 
or hepatic milieu, the level of stability was less than ideal, which undoubtedly 
contributed to their poor bioactivity upon oral administration in the rats. This section 
explored the feasibility of improving the oral deliverability of sCT by co-conjugating 
the peptide with lipid and PEG, the hypothesis being that PEGylation could further 
improve the stability and oral bioactivity of lipidized sCT. PEGylation has already 
been reported to increase the stability of calcitonin in rat nasal mucosa and colonic 




hypothesized that lipidized peptides might also be transported across absorptive cells 
as nanosized containers when conjugated with PEG.  
 
sCT consists of 32 amino acids, a proline amide at residue 32 and an N-terminal 
disulfide bridge between residues 1 and 7.  Previous experiments with Mal-sCT have 
indicated that sCT bioactivity was not affected by conjugation with a lipid via a non-
reversible thioether bond at cysteine 1 and cysteine 7. Rather, the lipid conjugation 
had promoted peptide stability in liver juice and peptide association with cell 
membrane. In studies by other laboratories, PEG-modification of sCT at lysine 18 has 
also been shown to enhance oral and nasal bioavailability (143, 227). On the basis of 
these data, we hypothesized that sCT might be co-conjugated with PEG and lipid at 
the lysine and cysteine moieties, respectively, without sacrificing its bioactivity.  
 
Nevertheless, conjugation at multiple sites of a peptide chain with lipid and PEG 
molecules does run a high risk of compromised or even loss of peptide bioactivity 
(102, 228, 229). In consideration of this, a novel strategy was developed, which might 
also be applicable to other PEGylated or lipidized drug molecules. This strategy 
employed the ε-maleimido-lysine molecule as an anchor linker to simultaneously bind 
the sCT, PEG and lipid together to form a triblock system (Figure 49). The anchor 
linker ensured all 3 molecules remained exposed for biological interactions so that 







Lipid PEG  
Figure 49 Schematic representation showing a novel strategy to co-conjugate PEG and a lipid to a 
drug 
 
This section describes the synthesis and characterization of sCT co-conjugated with 
PEG and lipid using the two strategies outlined in the previous paragraphs. For the 
first strategy, where PEG was to be conjugated at the lysine moieties, Mal-sCT was 
used as the base molecule for conjugation with one or two PEG chains, the final 
compounds denoted as 1PEG-Mal-sCT and 2PEG-Mal-sCT, respectively. For the 
second strategy, the same lipid as had been conjugated in Mal-sCT, i.e. Pal-Lys-Mal 
(Compound IV, Section 3.2.1), was used to produce the triblock sCT-lipid-PEG 
system. This allowed the characteristics and bioactivity of the 3 PEGylated lipidized 
sCT conjugates to be compared with Mal-sCT to delineate the effects of PEGylation. 
To our knowledge, this is the first report of a peptide drug co-conjugated with both 
PEG and lipid for oral delivery. 
 
4.2 Materials and Methods 
mPEG propylamine (mPEG-amine) (MW 5000, SUNBRIGHT MEPA-50H) was from 
NOF Corporation (Tokyo, Japan), mPEG-Succinimidyl Propionate (mPEG-Suc) (MW 
5000) was from Nektar Therapeutics Corporation (Huntsville, AL, USA). All other 






1PEG-Mal-sCT and 2PEG-Mal-sCT 
Figure 50 shows the synthesis pathways for 1PEG-Mal-sCT and 2PEG-Mal-sCT. 
Mal-sCT and mPEG-Suc, at molar ratios of 1:1.2, 1:3.6 or 1:7.3, were dissolved in 
200 µl of DMF, and 0.6 µl of TEA was added with stirring for 20 min. The reaction 
mix was added to 1 ml of saturated ammonium acetate buffer and subjected to 
Tricine-SDS-PAGE, using protocols described in Section 2.2.2. 1PEG-Mal-sCT and 
2PEG-Mal-sCT were identified by Matrix-Assisted Laser Desorption/Ionization 
Time-Of-Flight mass spectrometry (MALDI-TOF MS), then purified and dried as 
described in Section 2.2.1 for the preparation of Lipeo-sCT. The yield was calculated 
based on the peak area of 1PEG-Mal-sCT, 2PEG-Mal-sCT to the total peak area of all 
the sCT conjugates in HPLC chromatograph. Purity was confirmed by HPLC analysis, 






































































Figure 50 Synthesis pathway for 1PEG-Mal-sCT and 2PEG-Mal-sCT. Mal-sCT was conjugated 
with one PEG chain at either Lys 11 or Lys 18 to produce 1PEG-Mal-sCT, while 2PEG-Mal-sCT 





Voyager-DE STR MALDI-TOF mass spectrometer (Applied Biosystems, CA, USA) 
was used for the identification of the PEGylated lipidized sCT derivatives. m/z data of 
samples were automatically acquired in the linear mode by using the Linear Method 
(accelerating voltage: 20 kV, laser intensity: 2400-2600, acquisition mass range: 
1000~25000). Samples (0.5 μL, approximately 20 µg/ml) dissolved in a solvent 
containing 50% of ACN-IPA in water with 0.1% of TFA, were spotted on a 96×2 well 
plate with 0.5 µl of a saturated solution of sinapinic acid in ACN. Samples were 
analyzed after they are dried, and the final spectrum was the average of at least 200 
scans. 
 
To further confirm the site(s) of PEGylation of 1PEG-Mal-sCT and 2PEG-Mal-sCT, 
the peptides at 20 µM were incubated with 2.5 µM of trypsin overnight. The 
fragments were analyzed by HPLC using the conditions described in Section 2.2.5, 
and compared with the HPLC chromatographs of similarly processed sCT and Mal-
sCT samples. The rationale for this analysis was as follows. A comparison of the 
HPLC chromatographs between sCT and Mal-sCT indicated that Mal-sCT was 
digested to give fragments corresponding to Thr26~Pro32, Leu19~Arg25 and 
Leu12~Lys18 (elution times of 6.8, 9.4 and 8.7 min, respectively) (Figure 12 A). 
Another peak corresponding to Cys1~Lys11 was flushed out later at 39 min. If PEG 
conjugation of Mal-sCT had occurred at Lys11 and Lys18, the peak area for 
Leu19~Arg 24 would be reduced, but not the peak area for Thr25~Pro32. If PEG was 
conjugated at only Lys11 and not Lys18, the peak area for Leu19~Arg24 should not 




conjugation of PEG, whether at the site of Lys11 or Lys18. Therefore, PEG 
conjugation at Lys11 and/or Lys18 could be confirmed by comparing the peak area 
ratio of Leu19~Arg24 to Thr25~Pro32 in digested Mal-sCT with that of the digested 
PEGylated Mal-sCT. This method was used to estimate the relative quantity of 1PEG-
Mal-sCT conjugated at Lys11, denoted as 1PEG(11)-Mal-SCT, and those conjugated 
at Lys18 (1PEG(18)-Mal-sCT) in a  sample.  
 
Mal-PL-sCT  
Mal-PL-sCT was synthesized according to the scheme shown in Figure 51.  
Preparation of Pal-Lys-Mal (I) has been described in Section 3.2.1. To synthesize 
PEGylated Mal-Lys-Pal (PEG-Lipid) (II) (Figure 51), α-palmitoyl-ε-maleimido lysine 
(11.95 mg, 25.7 µmol), N-hydoxy succinimide (1.14 mg, 9.91 µmol) and PEG amine 
(117.56 mg, 22.6 µmol based on average MW of 5197) were stirred vigorously with 
131.5 mg of DCC in 1.5 ml of CH2Cl2 for 18 h under argon protection. The reaction 
mixture was filtered and the clear solution was eluted in a silica-gel column (10×250 
mm) with CHCl3 –CH3OH stepwise gradients from 100:1 to 100:5. The fractions were 
monitored by silica-gel thin layer chromatography (TLC) (Merck, Darmstadt, 
Germany), in the solid and mobile (solvent: CHCl3:CH3OH in the volume ratio of 
10:1) phases, with PEG-amine as reference. Those fractions containing the pure target 
were pooled together for solvent evaporation. The yield was 96.74 mg (17.1 µmol; 
75.8%). The target was identified using the BRUKER NMR-300 with CDCl3 as 








































Figure 51 Synthesis pathway of Mal-PL-sCT 
  
Synthesis of Mal-PL-sCT (III) was similar to that of Mal-sCT (Section 3.2.1). Briefly, 
24.34 mg of sCT, 85.57 mg of PEG-lipid and 12 mg of TECP were stirred overnight 
in a 15 ml-mixture of dimethylformamide (DMF) and water (2:1) under argon. The 
reaction mixture was analyzed with Tricine-SDS-PAGE with Bio-Rad molecular 
markers (mixed with sCT) as reference samples (156). Purification was carried out in 
the C-18 semi-preparative column attached to the HPLC system as described in 
Section 2.2.1, and the purified sample was freeze-dried. The yield was 80.29 mg 
(80.2%). Mal-PL-sCT was identified by MALDI-TOF MS, using methods similar to 
those described for 1PEG-Mal-sCT and 2PEG-Mal-sCT. Conjugate purity was further 




Sections 2.2.2 and 3.2.1, respectively.  
 
4.2.2 Morphology 
The morphology of 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-PL-sCT was visualized 
by transmission electron microscopy (JEOL JEM-2010, Japan) as described in Section 
2.2.3.  
 
4.2.3 Particle size 
Particle size was determined according to the method described in Section 2.2.4. 
Samples were dissolved in distilled water at 11 µM for 1PEG-Mal-sCT and Mal-PL-
sCT, but at a lower concentration of 2.5 µM for 2PEG-Mal-sCT due to its 
significantly higher photon count. 
 
4.2.4 Stability  
Stability of the PEG-modified peptides was determined in intestinal fluid in parallel 
experiments with other conjugates as described in Section 2.2.5.  
 
4.2.5 Peptide conformation 
Peptide conformation was determined by circular dichroism (CD) using the method 





4.2.6 In vivo hypocalcemic activity 
The in vivo bioactivity of the PEGylated lipidized sCT conjugates was characterized 
using similar method as described in Section 3.2.7. The 3 conjugates were dissolved 
in normal saline to the same molar concentration of 0.033 mM, which corresponded to 
0.331 mg/ml for 1PEG-Mal-sCT, 0.508 mg/ml for 2PEG-Mal-sCT and 0.510 mg/ml 
for Mal-PL-sCT. Mal-sCT and sCT samples, prepared in the same way to 0.033 mM, 
served as controls. The subcutaneous dose for all the peptides was equivalent to 0.114 
mg/kg of sCT.  Blood collection, processing and analysis were carried out according 
to the proceduces described in Section 3.2.7. 
 
Oral activities of 1PEG-Mal-sCT and Mal-PL-sCT were studied in parallel with sCT, 
Lipeo-sCT, REAL-sCT and Mal-sCT, according to the protocols described in Section 
2.2.7. The PEGylated conjugates were dissolved in water to give 2.50 mg/ml sCT 
equivalent concentration (6.81 mg/ml of 1PEG-mal-sCT and 11.56 mg/ml of Mal-PL-
sCT) and administered to Wistar femal rats at a dose equivalent to 5.0 mg/kg of sCT. 
The volume received by each rat (∼ 200g) was about 400 µl.  
 
4.3 Results  
4.3.1 Synthesis 
1PEG-Mal-sCT and 2PEG-Mal-sCT 
Tricine SDS-PAGE analysis showed that Mal-sCT readily reacted with mPEG-Suc in 
the reaction conditions employed to yield compounds of higher MW than Mal-










Figure 52 Tricine-SDS-PAGE analysis of the reaction mixture of mPEG-Suc and Mal-sCT at 
mPEG-Suc/Mal-sCT molar ratio of 3.6. 
 
HPLC analysis of the reaction mix showed 2 elution peaks, at 32.8 and 34.8 min, 
respectively. These elution times were faster in comparison with the elution of Mal-
sCT at 36.8 min (Figure 53 A). The compound which eluted at 34.8 min (Figure 53 B) 
was identified by MALDI-TOF MS to possess a single but widely dispersed peak at 
9.9 KDa (Figure 54 A), equivalent to Mal-sCT (4.4 KDa)  conjugated with 1 unit of 
mPEG-Suc (5.1 KDa). This suggests that the compound was 1PEG-Mal-sCT. The 
other compound, which eluted at 32.8 min (Figure 53 C), was identified by MALDI-
TOF MS to have a dominant MW of 15.0 KDa (Figure 54 B), equivalent to Mal-sCT 
(4.4K) conjugated with 2 units of mPEG-Suc, or 2PEG-Mal-sCT. The HPLC (or 
MALDI-TOF) peaks for the PEGylated Mal-sCT conjugates were broader than those 



















The molar ratio of mPEG-Suc to Mal-sCT in the synthesis pot was found to affect the 
yield of the PEGylated Mal-sCT conjugates. As shown in Figure 55, when PEG-Suc 
and Mal-sCT were reacted at the molar ratio of 1.2, 1PEG-Mal-sCT (yield 18%) was 
synthesized but not 2PEG-Mal-sCT. Increasing the molar ratio to 3.6 and 
subsequently to 7.3 favoured the synthesis of 2PEG-Mal-sCT, which was obtained at 
successively higher yields of 31% and 43%, respectively. Conversely, while the 
mPEG-Suc:Mal-sCT molar ratio of 3.6 yielded a higher amount of 1PEG-Mal-sCT 
(42%), a further increase in the weight ratio to 7.3 was not desirable for the synthesis 
of this compound, the yield of which dropped to 32%. Such results were suggestive of 
a 2-step reaction process, whereby 1PEG-Mal-sCT was first generated followed by its 
















Figure 55 Yields of 1PEG-Mal-sCT and 2PEG-Mal-sCT in relation to the molar ratio of mPEG-
Suc to Mal-sCT used for synthesis 
 
Analysis of the digested 1PEG-Mal-sCT was complicated by the presence of multi-
components. The fragments were identified by comparing the digestion fragments of 




Leu12~Lys18, Leu19~Arg24 and Cys1~Lys11, they were respectively flushed out at 
6.8 min, 8.7min, 9.4 and 39 min as described in Section 2.2.5. After degradation of 
1PEG-Mal-sCT with trypsin, there was no Leu12~Lys18 fragment , the reason may be 
that either Lys11 or Lys18 was conjugated with PEG and PEG was not conjugated to 
Mal-sCT at the amine at Cys1.  
 
The PEG attachment site in 1PEG-Mal-sCT was confirmed by HPLC analysis 
following trypsin digestion, as outlined in Section 4.2.1. The analysis was complicated 
by the presence of multi-components, making the quantification of the relative 
contents of 1PEG-Mal-sCT attached at Lys11 (denoted as 1PEG(11)-Mal-sCT) and 
Lys 18 (1PEG(18)-Mal-sCT) at best estimates. Following the digestion of 1PEG-Mal-
sCT with trypsin, the HPLC peak corresponding to Leu12~Lys18 was no longer 
apparent, suggesting that either Lys11 and/or Lys 18 had been conjugated. All other 
HPLC peaks were similar to those obtained for Mal-sCT, thus also confirming that 
PEG was not conjugated at the N-terminal of Cys1. With regards to the Thr25~Pro32 
and Leu19~Arg24 fragments, it may be argued that the former was a by-product of 
digested 1PEG(11)-Mal-sCT and 1PEG(18)-Mal-sCT, but the Leu19~Arg24 fragment 
could only be contributed by digested 1PEG(11)-Mal-sCT. Since the peak area ratios 
for the Leu19~Arg24 and Thr25~Pro32 fragments for Mal-sCT (parent compound) 
following digestion was 1.51, the percentage of 1PEG(11)-Mal-sCT and 1PEG(18)-
Mal-sCT in 1PEG-Mal-sCT could therefore be calculated, respectively, as 
Pro32) ~ (Thr25 Area
 /1.51Arg24)~(Leu19 Area ×100% and [1- 
32) Pro ~ 25(Thr  Area
 /1.51Arg24)~(Leu19 Area ] x 100%, 





Figure 56 shows the relative amounts of 1PEG(11)-Mal-sCT and 1PEG(18)-Mal-sCT 
obtained as a function of the molar ratio of mPEG-Suc:Mal-sCT used in the synthesis 
reaction. An increase in the molar ratio from 1.2 to 3.6 to 7.3 caused the yield of 
1PEG(11)-Mal-sCT to increase from 29.6% to 43.0% to 72.8%, suggesting a 
corresponding decrease in the yield of 1PEG(18)-Mal-sCT. This suggests that the Lys 
11 and Lys 18 moieties had similar chances of being conjugated with PEG at the 
mPEG-Suc:Mal-sCT molar ratio of 3.6, but conjugation at the Lys11 site was favored 
at higher mPEG-Suc concentration. The addition of increasing amounts of mPEG-Suc 
to DMF could have lowered the dielectric constant of the reaction medium, and 
exposed the more hydrophobic Cys1 ~ Lys11 end of the Mal-sCT molecule for 
reaction with mPEG-Suc. 1PEG-Mal-sCT for subsequent experimentation was 
































PEG at Lys 11 PEG at Lys 18
 
Figure 56 Relative contents of 1PEG(11)-Mal-sCT and 1PEG(18)-Mal-sCT as a function of the 
molar ratio of mPEG-Suc:Mal-sCT used for synthesis  
 




In the case of trypsin-digested 2PEG-Mal-sCT, however, only the Thr25~Pro32 
fragment was eluted at 6.9 min, suggesting that both the Lys 11 and Lys 18 sites were 
successfully conjugated. Taken together, the trypsin fragmentation results for 1PEG-
Mal-sCT and 2PEG-Mal-sCT confirmed that the PEG chains were conjugated at 
Lys11 and Lys18, and that the modification was a 2-step process, in which 1PEG-
Mal-sCT was first synthesized and further modified by reaction with another PEG-Suc 
molecule to give 2PEG-Mal-sCT.  
 
Mal-PL-sCT 
 Analysis of the intermediate product, PEG-Lipid, by silica-gel TLC indicated a 
highly purified product with Rf value of 0.26 (Figure 57). Compared with the Rf value 
of 0.11 for the reactant, mPEG-amine, the intermediate product was more lipophilic, 












Figure 57 TLC analysis of the reactant, mPEG-amine, and the intermediate product, PEG-Lipid 
 




6.685 ppm (2H, maleimido-H); 4.390 ppm (1H, lysine-α-H), 2.245ppm (2H, -
COCH2(CH2)13CH3), 2.137 ppm (H2O); 1.2470 ppm (26H, -COCH2 (CH2)13CH3); 
0.8742 ppm (-COCH2(CH2)13CH3); and 3.3-4.0 ppm (476 H, corresponding to 119 -
CH2CH2O-; calculated MW of 5236). MALDI-TOF MS spectrum (Figure 59) showed 
a mono-dispersed peak with average MW of 5557.9, which would correspond to PEG-
amine (MW 5197) conjugated with Mal-Lys-Pal (MW 464). These results indicate 












































































































































































































Figure 58 NMR Spectrum of PEG-Lipid 
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Reaction between sCT and PEG-Lipid was clean. Tricine-SDS-PAGE analysis 
suggested the generation of a main product having MW between 25 and 37 KDa 
(Figure 60, Lane 1). Further purification resulted in a highly purified compound 
(Figure 60, Lane 3), as was also confirmed by HPLC analysis. The PEGylated 
lipidized sCT, denoted as Mal-PL-sCT, was flushed out from the C-18 column at 
31.58 min (Figure 61 A), slightly faster than 2PEG-Mal-sCT (Figure 53 C), probably 
because the relatively hydrophilic Lys11 and Lys18 moieties were retained in Mal-
PL-sCT. MALDI-TOF MS spectrum (Figure 61 B) showed a dominant mono-
dispersed peak at MW 15.1 KDa and minor peaks at 5 and 9 KDa. The dominant peak 
corresponded to a molecule of sCT (3.4 KDa) conjugated with 2 molecules of PEG-
Lipid (average MW 5.6 KDa), while the minor peaks could be representative of 
impurities. Given the tendency of lower MW compounds to show higher MS response, 
and taking into consideration the Tricine-SDS-PAGE and HPLC data, the impurities 




















Figure 60 Tricine-SDS-PAGE analysis of the reaction mixture (Lane 1), molecular markers 
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Figure 61 HPLC chromatograph (A) and MALDI-TOF MS spectrum (B) for Mal-PL-sCT  
 
 
Interestingly, Tricine-SDS-PAGE analyses of 1PEG-Mal-sCT, 2PEG-Mal-sCT and 
Mal-PL-sCT (Figure 62) showed bands that corresponded to MW twice or more that 
of the respective compounds. 1PEG-Mal-sCT yielded a band at 15 KDa, while 2PEG-
Mal-sCT and Mal-PL-sCT showed bands corresponding to 25 - 37 KDa. A possible 
reason for the higher apparent MW could be the association of water molecules to the 




















Figure 62 Tricine-SDS-PAGE analysis of purified 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-PL-
sCT alongside MW markers  
 
4.3.2 Morphology 
Figure 63 shows the TEM micrographs of 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-
PL-sCT. There were no apparent differences in the morphology of the PEGylated 
lipidized sCT, with all 3 peptides showing aggregation into regular patterns. The 
aggregation behaviour appeared to be more uniform than that of Mal-sCT and other 











Figure 63 TEM micrographs of 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-PL-sCT. Samples were 
prepared by mixing 2 μl of peptide solution (0.5 mM in water) with 1 μl of 1% phosphotungstic 
acid solution for 1 min in a TEM grid. (A) 1PEG-Mal-sCT, 50,000x; (B) 2PEG-Mal-sCT, 50,000x; 





4.3.3 Particle size 
Figure 64 and Table 9 summarized the particle size distribution data of 1PEG-Mal-
sCT, 2PEG-Mal-sCT and Mal-PL-sCT in distilled water as measured by DLS 
analyses. 1PEG-Mal-sCT at 11.4 µM had mean particle radius of 34.4 ± 17.5 nm 
while Mal-PL-sCT at the same concentration measured 28.9 ± 9.4 nm in radius. 
Particle size of 2PEG-Mal-sCT cannot be determined at this concentration as the 
photon count exceeded the limit of detection. At a more diluted concentration of 2.5 
µM, 2PEG-Mal-sCT was found to form particles with mean radius of 67.7 ± 21.0 nm. 
These particle size ranges were much higher than the particle radius of 1.5~2.5 nm 
expected of the molecular size of the conjugates, and were 10-20 fold higher than the 
particle size ranges of Mal-sCT. The large size of the PEGylated Mal-sCT analogs 
was earlier alluded to by the Tricine-SDS-PAGE data, and might be attributed to 
molecular aggregation and the association of water molecules to the PEG chain(s). 
The viscous drag, in particular, could significantly reduce particle mobility, leading to 
high readings on the DLS instrument.  
Table 9 Particle size as determined by dynamic light scattering analysis of 1PEG-Mal-sCT, 














(K Da)    
1PEG-Mal-sCT 11 277 Peak  1 34.4 17.5 100.0 1.54E+4 
   Peak  2 3049 709.4 0.0 8.20E+8 
2PEG-Mal-sCT 2.5 1624 Peak  1 67.7 21.0 99.4 7.98E+4 
   Peak  2 3134 596.5 0.6 8.76E+8 
Mal-PL-sCT 11 270 Peak  1 28.9 9.4 99.9 2.08E+4 













Figure 64 Particle size distribution as determined by dynamic light scattering analysis of (A)  
1PEG-Mal-sCT  (11.2 µM), (B) 2PEG-Mal-sCT  (2.5 µM) and (C) Mal-PL-sCT (11.2 µM) in 
water.  Data presented as the cumulative results of at least 20 scans. 
 
4.3.4  Peptide conformation 
Figure 65 shows the CD spectra of 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-PL-sCT 




positive peak at 192 nm and 2 negative peaks at 208 and 222 nm, respectively, with 
peak intensity increasing slightly at higher TFE concentration. Mal-sCT exhibited 
similar CD spectra, although peak intensities for Mal-sCT were stronger than those for 
the PEGylated analogs, suggesting that PEG modification might interfere to a certain 
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Figure 65 Circular dichroism spectra of 1PEG-Mal-sCT(A), 2PEG-Mal-sCT(B) and Mal-PL-






Based on the percent peptide load remaining following incubation with diluted rodent 
intestinal fluid, the stability of the peptides could be ranked in the order of sCT < Mal-
sCT < Mal-PL-sCT < 1PEG-Mal-sCT < 2PEG-Mal-sCT. Statistical analysis by a 
paired 2-tailed t test indicated that at 2 to 15 min, 1PEG-Mal-sCT and 2PEG-Mal-sCT 
were significantly more stable than Mal-sCT (p<0.01), but there was no significant 
difference between Mal-PL-sCT and Mal-sCT in percent remaining (p>0.05); 
although there was significant difference in percent remaining at 2 min and 5 min 
between Mal-PL-sCT and sCT based on paired 2-tailed t test (p<0.05). This indicates 
that PEG conjugation at Lys 11 and Lys 18 could confer greater stability on Mal-sCT 
against enzyme degradation. A reason for this could be the predominance of trypsin or 
trypsin-like activity in the intestinal fluid, for the Thr25~Pro32 fragment was observed 
to be the main degradation product for the 3 PEGylated peptide conjugates (HPLC 
chromatographs not shown). Not surprisingly, 2PEG-Mal-sCT was more stable 
(0.05>p≥0.01) than 1PEG-Mal-sCT at 5 and 10 min, as it has been reported that a 
more effective barrier against enzyme approach could be achieved by conjugating a 
peptide with a higher number of PEG chains (232). These data suggest that the 
intestinal stability of Mal-sCT could be improved by PEGylation, and that both the 
site of conjugation and the number of PEG chains could influence the degree of 
protection conferred. Degradation of 2PEG-Mal-sCT was well defined by first order 
kinetics (Y=100e-0.050X, R2 =0.98), Mal-PL-sCT(Y=100e-0.21X, R2 =0.76) and 1PEG-
























Figure 66 Degradation of sCT, Mal-sCT, 1PEG-Mal-sCT, 2 PEG-Mal-sCT and Mal-PL-sCT by 
diluted intestinal solution. 40 µM of sCT and its conjugates were incubated with diluted intestinal 
solution (45 µg protein /ml) at 37ºC (Mean ± SD, n=3). 
 
4.3.6 In vivo hypocalcemic activity 
The in vivo bioactivity of 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-PL-sCT was 
evaluated by measuring their ability to lower plasma calcium levels after 
subcutaneous injection or intragastric gavage in the rat model. Rats dosed with the 
vehicle served as negative controls, while those administered with equivalent sCT 
dose were positive controls. Baseline plasma calcium levels were not significantly 
different between the rats in the control and treatment groups prior to treatment 
initiation. Rats administered with the vehicle by subcutaneous injection also did not 
show significant differences in plasma calcium levels before and after dosing.  
 
1PEG-Mal-sCT was comparable to Mal-sCT in bioactivity (Figure 67), producing 
statistically significant (p<0.05) hypocalcemic activity at 2, 4, 8, 12 and 18 h after 
subcutaneous injection into the rat (Figure 68). However, 1PEG-Mal-sCT was less 




extent than sCT at 4 and 8 h post-injection (Figure 68). 1PEG-Mal-sCT was 
nevertheless more active than 2PEG-Mal-sCT, which did not change the plasma 
calcium level significantly post-injection, suggesting a lack of intrinsic hypocalcemic 























Figure 67 Plasma calcium level of rats administered with Mal-sCT and 1PEG-Mal-sCT by 
subcutaneous injection. Mal-sCT and 1PEG-Mal-sCT dissolved in normal saline at 0.145 mg/ml 
and 0.331 mg/ml (equivalent to 0.114 mg/ml of sCT) respectively, were dosed at 200 µl/rat (200g). 























Vehicle sCT 1PEG-Mal-sCT 2PEG-Mal-sCT
 
Figure 68 Plasma calcium level of rats administered with Vehicle (normal saline), sCT, 1PEG-
Mal-sCT and 2PEG-Mal-sCT by subcutaneous injection. sCT, 1PEG-Mal-sCT and 2PEG-Mal-
sCT, dissolved in normal saline at 0.114 mg/ml, 0.331 mg/ml and 0.508 mg/ml (equivalent to 0.114 





Hypocalcemic activity of Mal-PL-sCT was evaluated in a separate experiment with 
sCT and vehicle as controls (Figure 69). Although Mal-PL-sCT after subcutaneous 
injection produced significantly lower plasma calcium levels in the rat compared to 
the vehicle at 2 to 8 h post-injection, these levels were significantly higher than those 
observed in the sCT control group. The implication was that Mal-PL-sCT, like 1PEG-
























Figure 69 Plasma calcium level of rats administered with Vehicle (normal saline), sCT and Mal-
PL-sCT by subcutaneous injection. sCT and Mal-PL-sCT, dissolved in normal saline at 0.114 
mg/ml and 0.508 mg/ml (equivalent to 0.114 mg/ml of sCT) respectively, were dosed at  200 µl/rat 
(200g). Data represent mean ± SD, n = 6.  
 
The bioactivities of 1PEG-Mal-sCT and Mal-PL-sCT were further evaluated via the 
peroral route, with vehicle and sCT as controls. As was observed before (Section 
2.3.7), all 6 rats given sCT (dose 5.0 mg/kg) by intragastric gavage showed 
significantly lower plasma calcium levels at 1 to 2 h post-administration (p<0.001) 
(Figure 18), the plasma calcium returning to baseline levels 4h post-administration. In 




A) or Mal-PL-sCT (Figure 70 B) did not show significantly lower plasma calcium 
levels from baseline values. On this basis, it may be concluded that 1PEG-Mal-sCT 
and Mal-PL-sCT were not active when administrated perorally as simple aqueous 




























































Figure 70 Plasma calcium level of 6 individual rats after intragastric gavage with (A) 1PEG-Mal-
sCT and (B) Mal-PL-sCT. 1PEG-Mal-sCT and Mal-PL-sCT, dissolved in water at 6.81 mg/ml 
and 11.6 mg/ml (equivalent to as 2.5 mg/ml sCT), were dosed at 13.6 mg/kg and 23.2 mg/kg 






The main aim of the experiments in this section was to determine whether PEGylation 
could improve the oral deliverability of Mal-sCT, a non-reversible lipidized sCT 
analog. For this purpose, 3 different PEGylated Mal-sCT compounds were 
synthesized and characterized. 1PEG-Mal-sCT and 2PEG-Mal-sCT were synthesized 
by conjugating PEG chains to the Lys11 and/or Lys18 in the Mal-sCT molecule. The 
site of conjugation was influenced by the molar ratio of mPEG-Suc:Mal-sCT 
employed for the reaction, a higher ratio favouring the conjugation of the initial PEG 
chain at Lys 11, followed by conjugation of another PEG chain at Lys 18. Mal-PL-
sCT was synthesized by conjugating PEG at the ε-maleimido-lysine linker of Mal-
sCT to give a triblock system. This was a novel conjugation strategy, whereby the 
PEG and lipid molecules were both linked to sCT via a common thioether bond. To 
our knowledge, the maleimido intermediate compound synthesized in this study is the 
first PEG-linked lipid that chemically reacts with disulfide bonds. The functionalized 
lipid not only retained its lipophilicity, but reacted with sCT in an impressive manner 
under reductive condition to produce the target conjugate at high yield.  
 
All 3 peptides were successfully purified and positively identified by MALDI-TOF 
MS (Figure 54, Figure 61 B). Relative hydrophilicity, ranked by the rate of elution 
from the HPLC column, was in the order of Mal-PL-sCT >2PEG-Mal-sCT > 1PEG-
Mal-sCT > Mal-sCT. Like Mal-sCT, the PEGylated Mal-sCT analogs showed a 
propensity to aggregate in aqueous media. However, the radius of the aggregated 
particles, as measured by DLS, was much larger than the aggregated particles of Mal-




but also to the formation of a solvent sheath through the binding of water molecules to 
the PEG molecules. For this reason, all the PEGylated Mal-sCT showed enhanced 
stability against intestinal digestion in comparison with sCT. Conjugation of Mal-sCT 
with 2 PEG chains was particularly effective in this respect, with 2PEG-Mal-sCT 
exhibiting the highest stability, followed by 1PEG-Mal-sCT and Mal-PL-sCT. The 
degradation data followed non-linear kinetics, which did not agree with a report that 
showed PEG-conjugated sCT to have linear enzyme degradation kinetics (106), and 
probably reflected the aggregated status of the PEGylated Mal-sCT in this study.  
 
In vivo experiments suggested that 1PEG-Mal-sCT and Mal-PL-sCT had intrinsic 
hypocalcemic activity, but they failed to lower plasma calcium levels to the same 
extent as sCT when administered by subcutaneous injection. 2PEG-Mal-sCT, on the 
other hand, completely lacked hypocalcemic bioactivity when it was administered by 
subcutaneous injection in the rat model. The data for 2PEG-Mal-sCT was, however, 
consistent with that of another report that showed sCT to exhibit a complete loss of 
activity when both of its lysine groups were conjugated with a 2 KDa-PEG chain 
(102).  
 
The relatively low bioactivity of 1PEG-Mal-sCT and Mal-PL-sCT might be ascribed 
to the high MW PEG used. sCT conjugated with a 2 KDa-PEG has been shown to 
retain its bioactivity, while lower bioactivity was observed when the MW of the PEG 
chain was increased to 5 or 12 KDa (102). In the present study, a 5 KDa-PEG 
molecule was employed for conjugation, which could make it difficult for the 




could also explain why the conjugation of an additional PEG chain, as in the case of 
2PEG-Mal-sCT rendered the molecule totally ineffective. Aggregation of the 
PEGylated Mal-sCT into lipid cores with extending PEG chains could further 
compound the problem of binding efficiently with receptors. In addition, the decrease 
in activity is also likely due to that the active conformation has been disturbed because 
of the bulky PEG or PEG-lipid as shown in: Mal-sCT has high helicity than 1PEG-
Mal-sCT and Mal-PL-sCT as more intense peaks were observed at 192nm, 208 nm 
and 222nm for Mal-sCT. In addition, the Lys11 and Lys18 moieties could well be 
important for the hypocalcemic activity of Mal-sCT, despite reports that the oral and 
nasal bioavailability of sCT was enhanced by PEG modification at Lys 18 (143, 227).  
 
1PEG-Mal-sCT and Mal-PL-sCT administered by intragastric gavage were not 
effective in lowering the plasma calcium level in the rat.  A possible explanation for 
this lack of activity could be the lower intrinsic hypocalcemic activity of Mal-sCT 
following PEGylation. However the lower bioactivity could be compensated by the 
greater stability of the PEGylated peptides against intestinal degradation (Figure 66). 
Other factors, e.g. the mucoadhesive properties of PEG molecules (233-235) could 
further limit the transportation of 1PEG-Mal-sCT and Mal-PL-sCT molecules across 
the intestinal epithelium. Understanding the transport mechanisms of Mal-sCT before 
and after PEGylation might aid in the development of better strategies to facilitate its 









This study set out to investigate the hypothesis that lipid conjugation, with and 
without PEG modification, could stabilize and improve the oral deliverability of 
peptide drugs. With salmon calcitonin (sCT) as the model peptide, 6 lipidized 
conjugates, of which 5 were novel compounds, were synthesized and evaluated. The 6 
conjugates comprised of 2 reversible lipid conjugates, REAL-sCT and Lipeo-sCT; one 
non-reversible lipid conjugate, Mal-sCT; and 3 PEGylated conjugates of Mal-sCT, 
namely 1PEG-Mal-sCT, 2PEG-Mal-sCT and Mal-PL-sCT.  
 
Lipeo-sCT was designed to be similar to REAL-sCT, a proven bioactive peptide with 
two palmitic acid molecules covalently conjugated to sCT via reversible disulfide 
bonds. In Lipeo-sCT, the anionic lipids were substituted with C16E3OH, the 
hypothesis being that an amphiphilic, non-anionic lipid could better enhance the 
interaction of the peptide with cell membrane to promote its permeability. Lipeo-sCT 
and REAL-sCT were successfully synthesized by similar 4-step reactions, and their 
identities confirmed by ESI-MS analysis. Mal-sCT was designed to be a non-
reversible conjugate in which two palmitic acid chains were conjugated to sCT by 
thioether bonds via a maleimido-lysine linker. The rationale was that a non-reversible 
lipid conjugate might be better able to fulfill the benefits of lipidization in vivo. Mal-
sCT was synthesized at a very high yield (83%) using a novel aqueous-based lipid 
conjugation method, and positively identified by ESI-MS. Two classes of PEGylated 
Mal-sCT were synthesized to evaluate the hypothesis that PEGylation could further 
improve the stability and permeability of Mal-sCT in the GIT. 1PEG-Mal-sCT and 
2PEG-Mal-sCT belonged to the first class, and they were Mal-sCT conjugated with 




in a stepwise manner, with 1PEG-Mal-sCT first generated followed by its reaction 
with another PEG molecule to give 2PEG-Mal-sCT. Identity of the peptides was 
provided by MALDI-TOF MS data, and the sites of conjugation were confirmed by 
HPLC analysis of tryspin-degraded fragments. Lysine 11 was the preferred 
conjugation site when higher ratios of PEG to Mal-sCT were used as reactants, 
although a high PEG content also promoted subsequent conjugation at the lysine 18 
site to give 2PEG-Mal-sCT. Mal-PL-sCT formed the second class of PEGylated Mal-
sCT evaluated, and it was synthesized by conjugating PEG to the ε-maleimido-lysine 
linker of Mal-sCT to give a triblock system. The synthesis involved the generation of 
a novel PEG-lipid with a maleimido group, which was linked to sCT via a thio-ether 
bond similar to that employed in Mal-sCT. 
 
Despite the differences in lipid chemistry, the 6 lipidized sCT conjugates shared 
certain similar characteristics. Unlike sCT, whose labile conformation changed from 
random coil to helical structure as the polarity of the medium decreased, the lipidized 
peptides had a relatively stable helical conformation that was independent of the 
polarity of the solvent. The conformational stability might have resulted from a lipid-
imposed sterical hindrance on peptide chain mobility. The stabilization effect was not 
unduly influenced by lipid chemistry or the site of lipid conjugation employed in the 
study. This finding has significant implications because the manifold conformations of 
sCT in aqueous solutions have not allowed its active conformation to be resolved. 
Since 5 out of the 6 lipidized sCT conjugates possessed intrinsic hypocalcemic 
activity in the rat model, it would, by inference, suggest that that helical sCT is a 





Analysis by DLS and TEM suggested that all 6 lipidized conjugates had a propensity 
to form aggregates over a broad concentration range in aqueous media. The capacity 
to self-aggregate was not surprising given the amphiphilic nature of the lipidized sCT 
compounds. Aggregate formation would protect the lipidized peptides against 
degradation in the trypsin, rat intestinal and rat liver solutions. The mechanism of 
protection was elucidated through the LC-MS identification of trypsin-digested 
fragments of Lipeo-sCT and REAL-sCT. Trypsin-mediated degradation of the two 
lipidized peptides proceeded in a step-wise, unidirectional manner, with initial 
cleavage of the peptides occurring at a position furthest from the conjugated lipid sites 
of cysteine 1 and cysteine 7. Such a degradation profile is envisaged to be facilitated 
by peptide aggregation, as the orientation of the conjugated lipids towards the 
aggregate core would direct the sCT backbone chain outwards, rendering the amino 
acids furthest from the core most vulnerable to enzyme attack. Further supporting data 
were provided by the correlations between peptide stability and aggregate size. Of the 
6 lipidized peptides, Mal-sCT formed the smallest aggregates and was the least stable 
in rodent intestinal juice. The PEGylated Mal-sCT analogs, in particular 2PEG-Mal-
sCT, formed the largest aggregates and they were the most stable peptides in the 
rodent intestinal juice. By comparison, the monomeric sCT was cleaved 
simultaneously by trypsin at multiple sites, and it was even less stable than Mal-sCT 
in the rodent liver juice.  
 
Aside from aggregation status, the stability of the sCT analogs appeared also to be 




formed aggregates of comparable sizes, the more lipophilic Lipeo-sCT showed greater 
resistance to degradation in the rodent intestinal fluid. It was also interesting that the 
enhancement in stability was observed in both the reversible and non-reversible 
lipidized sCT. In the case of Lipeo-sCT and REAL-sCT, which were rapidly 
converted to sCT in vivo and when incubated in vitro with liver juice, the regenerated 
sCT was observed to persist for a longer period than the unmodified sCT. This 
persistence could not be due to a more stable sCT being generated. Rather, it might 
have resulted from a continual regeneration of sCT from the reversible lipidized sCT 
analogs. This depot effect, which indirectly prolonged the circulatory half life of sCT 
in vivo, was possible only if the backbone amino acid sequence of the lipidized sCT 
conjugates was not fragmented and that intact sCT was released following chemical 
reduction. 
 
Except for 2PEG-Mal-sCT, which was inactive, varying degrees of hypocalcemic 
activity were observed when the lipidized peptides were subcutaneously injected into 
female Wistar rats. Of the active lipidized peptides, Mal-sCT and Lipeo-sCT were the 
most promising, eliciting comparable levels of hypocalcemia to sCT at equivalent 
subcutaneous doses, while the PEGylated analogs were the least potent. The 
pharmacodynamic data therefore correlated inversely with the stability data, the 
implication being that peptides that had been stabilized to a greater extent by 
lipidization (and PEGylation) also tended to possess lower intrinsic activity. This 
observation was in agreement with other studies (119, 123), and it underscored the 
dilemma posed by lipidation, where the peptide was prevented not only from 





Despite the comparable hypocalcemic activity, Lipeo-sCT differed from Mal-sCT in 
showing prolonged activity. A prolonged activity was also observed for REAL-sCT, 
the other reversible lipidized sCT analog, but not for the PEGylated Mal-sCT 
compounds. As alluded to in the previous paragraph, the prolonged action of Lipeo-
sCT and REAL-sCT was likely due to a depot effect in which the reversible lipidized 
sCT served as a reservoir to gradually release intact sCT into the circulation. This 
pharmacokinetic profile was confirmed through the development of a novel LC-MS 
method capable of quantifying the lipidized conjugates and regenerated sCT 
simultaneously in a plasma sample. The plasma concentration-time curve of sCT (1.5 
mg/kg) showed only the elimination phase, indicating a rapid absorption of the 
injected peptide, which was then rapidly degraded to a sub-detectable level after in 2.5 
h. The plasma concentration-time curves of the lipidized peptides showed a prolonged 
absorption phase that lasted up to 2.5 hours followed by constant plasma peptide 
concentration that lasted up to 4.0 h. sCT generated from REAL-sCT and Lipeo-sCT 
also persisted longer than the subcutaneously injected sCT. 
 
Interestingly, Lipeo-sCT and REAL-sCT produced different pharmacokinetic profiles 
although the two reversible lipidized sCT shared similar characteristics. Rats injected 
subcutaneously with Lipeo-sCT (1.90 mg/kg) were found not to have detectable levels 
of Lipeo-sCT in circulation. Instead, the plasma samples tested positive for sCT, 
which increased in concentration to a Cmax of  16.2 at 1.5 h followed by a plateauing 
of the concentration to 5.9~7.0 nM for at least 480 min. The pharmacokinetic profile 




However, sCT regeneration in vivo was likely to be mediated by liver metabolism, as 
both Lipeo-sCT and REAL-sCT were reduced to sCT by incubation with the rodent 
liver juice. Thus, an apparent absence of plasma Lipeo-sCT could also implicate a 
highly rapid turnover of absorbed Lipeo-sCT into sCT. Conversely, rats injected with 
an equivalent dose of REAL-sCT (1.81 mg/kg) had detectable levels of REAL-sCT 
and sCT in the circulation, the concentration of sCT correlating with that of REAL-
sCT for at least 6 h. This would suggest that REAL-sCT was absorbed into the 
circulation following subcutaneous absorption, and the plasma REAL-sCT was 
converted to sCT following liver metabolism.  
 
While the depot effect might play a role in prolonging the activity of Lipeo-sCT and 
REAL-sCT in vivo, the lipidized peptides themselves might also have contributed to 
the observed hypocalcemia. This hypothesis was based on several observations. 
Firstly, as equivalent doses of sCT and lipidized peptides were administered, the 
hypocalcemic effect exhibited by the lipidized peptides should be smaller than that of 
sCT given that not all of the lipidized peptide dose was converted to sCT upon 
immediate administration. This was not seen. Instead, Lipeo-sCT and REAL-sCT 
lowered the plasma calcium to comparable levels as the injected sCT. Secondly, the 
non-reversible Mal-sCT was also bioactive despite its inability to regenerate sCT in 
vivo. Since the lipid chemistry in Mal-sCT was similar to that in REAL-sCT, it would 
not be inconceivable for REAL-sCT to possess intrinsic bioactivity as well.  
 
Administration of the lipidized peptides was associated with large inter-individual 




related to the rigid helical structure of the lipidized peptides, in particular for the non-
reversible analogs, such as Mal-sCT, 1PEG-Mal-sCT and Mal-PL-sCT. Such 
pharmacological variation has not been reported for other non-reversible lipid-
conjugates, such as insulin (119, 121, 217), indicating that the increase in lipophilicity 
was not the influencing factor. Calcitonin receptors in the rat (220-223) are known to 
show genetic polymorphisms and were hypothesized to bind with sCT, and its 
analogues, in a 2-step process that involved the peptide backbone/receptor interaction 
followed by the peptide side-chain/receptor interaction (220, 224, 225). sCT is 
proposed to adopt an extended conformation to participate in the first reaction, 
followed by a restructuring into the helical conformation for the subsequent reaction 
due to the decreased polarity at the membrane interface (192). Mal-sCT and 
PEGylated conjugates lack this flexibility; their rigid helical conformations might 
favor the second reaction, but would hinder the peptides from making the initial 
interaction with the receptor. Inter-individual variation in hypocalcemic activity was 
also noted for REAL-sCT and Lipeo-sCT. This supported the hypothesis that the 
observed hypocalcemia induced by these two peptides was produced both by the 
regenerated sCT (which did not cause significant inter-individual variation in response) 
and the lipidized peptides per se.   
 
Unlike sCT, which showed some hypocalcemic activity after oral administration at a 
dose of 5.0 mg/kg in the rats, equivalent doses of peroral lipidized sCT analogs failed 
to elicit statistically significant hypocalcemia. The poor oral activities of Lipeo-sCT, 
REAL-sCT, Mal-sCT, 1PEG-Mal-sCT and Mal-Pl-sCT could be attributed to their 




aggregates in aqueous media might have also compromised their permeation through 
the intestinal epithelium. Further studies, possibly with radiolabeled analogs, would be 
necessary to verify this, as the subcutaneously injected REAL-sCT and Mal-sCT were 
successfully absorbed into the circulation. What is evident was that PEGylation 
further decreased the bioactivity of Mal-sCT, and was therefore not deemed desirable.  
 
In summary, the project has demonstrated that lipidization was a useful tool for 
enhancing the stability of sCT against liver and intestinal enzymes by inducing self-
aggregation of the peptide in aqueous media.  While the aggregation behaviour did not 
appear to affect the intrinsic hypocalcemic activity of the lipidized peptides, it could 
have compromised the permeation of the peptides across the absorptive intestinal 
membrane for none of the lipidized peptides showed significant hypocalcemic activity 





In the current project, 6 lipidized conjugates of sCT were synthesized and evaluated. 
The lipidized conjugates showed a strong propensity to aggregate in aqueous media, 
and the aggregation behaviour was proposed as the mechanism for their enhanced 
stability against enzymatic degradation. However, we also hypothesized that the 
aggregation behaviour hampered the permeation of the peptides through the intestinal 
epithelium, causing them to have poor hypocalcemic activity when administered 
orally. Future studies could employ methods to control peptide aggregation in order to 
verify its role on the secondary structure, enzyme stability, cellular uptake and 
pharmacokinetic profile of the lipidized peptides. Permeation studies on surrogate 
intestinal cell lines, e.g. the Caco-2 cell monolayers, could also be conducted. 
Radiolabelled or fluorophore-labeled analogs would be to be prepared to permit the 
quantitation of small amounts of lipidized sCT and sCT that had permeated through 
the surrogate intestinal epithelium. 
 
In this project, Mal-PL-sCT was synthesized through a new conjugation strategy. This 
strategy conjugated a maleimide functionalized PEG-lipid, a novel compound, to the 
disulfide bond of sCT via a non-reversible thioether bond. A similar strategy could be 
employed to produce reversible analogs of Mal-PL-sCT. This is because a comparison 
of REAL-sCT with Mal-sCT has shown REAL-sCT to have a more advantageous 
pharmacodynamic profile, including prolonged action and smaller inter-individual 
responses. It would be interesting to evaluate whether the reversible conjugation of the 




oral routes of administration.  
 
Mal-sCT, Lipeo-sCT and REAL-sCT showed comparable hypocalcemic activity to 
sCT at a sCT comparable dose of 0.145 mg/kg. This dose was deemed too high to 
allow potency differentiation based on the intensity of hypocalcemic activity. Further 
animal experiments could be carried out using lower doses of the lipidized peptides. 
In addition, peptide treatment by oral and subcutaneous route of administration could 
be performed on the same animal to eliminate compounding factors attributed to inter-
individual response. This will enable a better understanding of the factors that 
influenced peptide bioavailability.   
 
In the present study, the in vitro cytotoxicity profiles of Mal-sCT and PEG-Mal-sCT 
were not established. It is important that future experiments include a systematic 
evaluation of the toxicity profile of these maleimide derivatives of sCT. 
 
Another area of study could be an investigation into the effect of formulation on the 
oral bioavailability of the lipidized peptides. In this study, REAL-sCT has been shown 
to have poor bioactivity when administered orally in distilled water. An earlier report 
has, however, indicated that this lipidized peptide had acceptable bioavailability when 
administered orally as an o/w emulsion (94). Lipeo-sCT, Mal-sCT, 1PEG-Mal-sCT 
and Mal-PL-sCT could be reformulated, either as o/w emulsions or as oily solutions 
or dispersion, to determine whether formulation variables have an impact on the oral 






   
1. P. Langguth, V. Bohner, J. Heizmann, H. P. Merkle, S. Wolffram, G. L. 
Amidon, and S. Yamashita. The challenge of proteolytic enzymes in intestinal 
peptide delivery. Journal of Controlled Release 46: 39-57 (1997). 
 
2. K. Ikesue, P. Kopeckova, and J. Kopecek. Degradation of proteins by guinea 
pig intestinal enzymes. International Journal of Pharmaceutics 95: 171-179 
(1993). 
 
3. R. J. Schilling and A. K. Mitra. Degradation of insulin by trypsin and alpha-
chymotrypsin. Pharm Res 8: 721-7 (1991). 
 
4. A. Bernkop-Schnurch. The use of inhibitory agents to overcome the enzymatic 
barrier to perorally administered therapeutic peptides and proteins. J Control 
Release 52: 1-16 (1998). 
 
5. R. H. Lu, P. Kopeckova, and J. Kopecek. Degradation and aggregation of 
human calcitonin in vitro. Pharm Res 16: 359-67 (1999). 
 
6. Y. Aoki, M. Morishita, K. Asai, B. Akikusa, S. Hosoda, and K. Takayama. 
Region-dependent role of the mucous/glycocalyx layers in insulin permeation 
across rat small intestinal membrane. Pharm Res 22: 1854-62 (2005). 
 
7. Y. Aoki, M. Morishita, and K. Takayama. Role of the mucous/glycocalyx 
layers in insulin permeation across the rat ileal membrane. Int J Pharm 297: 
98-109 (2005). 
 
8. A. M. Ugolev, L. F. Smirnova, N. N. Iezuitova, N. M. Timofeeva, N. M. 
Mityushova, V. V. Egorova, and E. M. Parshkov. Distribution of some 
adsorbed and intrinsic enzymes between the mucosal cells of the rat small 
intestine and the apical glycocalyx separated from them. FEBS Letters 104: 
35-38 (1979). 
 
9. P. Langguth, H. P. Merkle, and G. L. Amidon. Oral absorption of peptides: the 




metkephamid. Pharm Res 11: 528-35 (1994). 
 
10. J. Heizmann, P. Langguth, A. Biber, R. Oschmann, H. P. Merkle, and S. 
Wolffram. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic 
and intestinal brush-border enzymes. Peptides 17: 1083-9 (1996). 
 
11. J. P. Bai and L. L. Chang. Transepithelial transport of insulin: I. Insulin 
degradation by insulin-degrading enzyme in small intestinal epithelium. 
Pharm Res 12: 1171-5 (1995). 
 
12. J. P. Bai. Subcellular distribution of proteolytic activities degrading bioactive 
peptides and analogues in the rat small intestinal and colonic enterocytes. J 
Pharm Pharmacol 46: 671-5 (1994). 
 
13. G. A. Kullak-Ublick and M. B. Becker. Regulation of drug and bile salt 
transporters in liver and intestine. Drug Metab Rev 35: 305-17 (2003). 
 
14. F. P. Guengerich. Cytochrome P450: what have we learned and what are the 
future issues? Drug Metab Rev 36: 159-97 (2004). 
 
15. N. Kobayashi, N. Yamamura, M. Kamagata, A. Kurihara, and T. Ikeda. In 
vitro metabolism of human and salmon calcitonins in rat liver and kidney 
evaluated by liquid chromatography-tandem mass spectrometry. Xenobiotica 
30: 655-64 (2000). 
 
16. B. M. Liederer, K. T. Phan, H. Ouyang, and R. T. Borchardt. Significant 
differences in the disposition of cyclic prodrugs of opioid peptides in rats and 
guinea pigs following IV administration. J Pharm Sci 94: 2676-87 (2005). 
 
17. J. R. Pappenheimer. Role of pre-epithelial "unstirred" layers in absorption of 
nutrients from the human jejunum. J Membr Biol 179: 185-204 (2001). 
 
18. R. E. Fahim, G. G. Forstner, and J. F. Forstner. Heterogeneity of rat goblet-cell 
mucin before and after reduction. Biochem J 209: 117-24 (1983). 
 
19. A. W. Larhed, P. Artursson, and E. Bjork. The influence of intestinal mucus 
components on the diffusion of drugs. Pharm Res 15: 66-71 (1998). 
 




membrane-bound heparan sulphate proteoglycan. Biochem J 311 ( Pt 2): 561-5 
(1995). 
 
21. I. Matthes, F. Nimmerfall, J. Vonderscher, and H. Sucker. [Mucus models for 
investigation of intestinal absorption mechanisms. 4. Comparison of mucus 
models with absorption models in vivo and in situ for prediction of intestinal 
drug absorption]. Pharmazie 47: 787-91 (1992). 
 
22. A. W. Larhed, P. Artursson, J. Grasjo, and E. Bjork. Diffusion of drugs in 
native and purified gastrointestinal mucus. J Pharm Sci 86: 660-5 (1997). 
 
23. A. Varki. Sialic acids as ligands in recognition phenomena. Faseb J 11: 248-
55 (1997). 
 
24. O. N. Kovbasnjuk and K. R. Spring. The apical membrane glycocalyx of 
MDCK cells. J Membr Biol 176: 19-29 (2000). 
 
25. M. Goldberg and I. Gomez-Orellana. Challenges for the oral delivery of 
macromolecules. Nat Rev Drug Discov 2: 289-95 (2003). 
 
26. M. D. Donovan, G. L. Flynn, and G. L. Amidon. Absorption of polyethylene 
glycols 600 through 2000: the molecular weight dependence of gastrointestinal 
and nasal absorption. Pharm Res 7: 863-8 (1990). 
 
27. G. Camenisch, J. Alsenz, H. van de Waterbeemd, and G. Folkers. Estimation 
of permeability by passive diffusion through Caco-2 cell monolayers using the 
drugs' lipophilicity and molecular weight. Eur J Pharm Sci 6: 317-24 (1998). 
 
28. H. Gao, F. Wang, and E. J. Lien. Hydrophobic contribution constants of amino 
acid residues to the hydrophobicities of oligopeptides. Pharm Res 12: 1279-83 
(1995). 
 
29. P. S. Burton, R. A. Conradi, N. F. Ho, A. R. Hilgers, and R. T. Borchardt. 
How structural features influence the biomembrane permeability of peptides. J 
Pharm Sci 85: 1336-40 (1996). 
 
30. R. H. Muller, S. Runge, V. Ravelli, W. Mehnert, A. F. Thunemann, and E. B. 
Souto. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) 





31. Y. Mo and L. Y. Lim. Mechanistic study of the uptake of wheat germ 
agglutinin-conjugated PLGA nanoparticles by A549 cells. J Pharm Sci 93: 20-
8 (2004). 
 
32. B. Rihova. Receptor-mediated targeted drug or toxin delivery. Adv Drug Deliv 
Rev 29: 273-289 (1998). 
 
33. A. Bernkop-Schnurch and M. K. Marschutz. Development and in vitro 
evaluation of systems to protect peptide drugs from aminopeptidase N. 
Pharmaceutical Research 14: 181-185 (1997). 
 
34. Y. Birk. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor 
from soybeans. International Journal Of Peptide And Protein Research 25: 
113-131 (1985). 
 
35. R. B. Shah and M. A. Khan. Protection of salmon calcitonin breakdown with 
serine proteases by various ovomucoid species for oral drug delivery. J Pharm 
Sci 93: 392-406 (2004). 
 
36. V. Agarwal, S. Nazzal, I. K. Reddy, and M. A. Khan. Transport studies of 
insulin across rat jejunum in the presence of chicken and duck ovomucoids. J 
Pharm Pharmacol 53: 1131-8 (2001). 
 
37. D. Grob. PROTEOLYTIC ENZYMES: III. FURTHER STUDIES ON 
PROTEIN, POLYPEPTIDE, AND OTHER INHIBITORS OF SERUM 
PROTEINASE, LEUCOPROTEINASE, TRYPSIN, AND PAPAIN. J. Gen. 
Physiol. 33: 103-124 (1949). 
 
38. C. W. Garner, Jr. and F. J. Behal. Human liver aminopeptidase. Role of metal 
ions in mechanism of action. Biochemistry 13: 3227-33 (1974). 
 
39. R. B. Shah, A. Palamakula, and M. A. Khan. Cytotoxicity evaluation of 
enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of 
salmon calcitonin. J Pharm Sci 93: 1070-82 (2004). 
 
40. Å. Krogdahl, B. Leat, and J. J. OLLI. Soybean proteinase inhibitors affect 
intestinal trypsin activities and amino acid digestibilities in rainbow trout 






41. J. E. Reseland, H. Holm, M. B. Jacobsen, T. G. Jenssen, and L. E. Hanssen. 
Proteinase inhibitors induce selective stimulation of human trypsin and 
chymotrypsin secretion. J Nutr 126: 634-42 (1996). 
 
42. R. N. Melmed, A. A. A. El-Aaser, and S. J. Holt. Hypertrophy and hyperplasia 
of the neonatal rat exocrine pancreas induced by orally administered soybean 
trypsin inhibitor. Biochimica et Biophysica Acta (BBA) - General Subjects 421: 
280-288 (1976). 
 
43. M. Otsuki, A. Ohki, Y. Okabayashi, I. Suehiro, and S. Baba. Effect of 
synthetic protease inhibitor camostate on pancreatic exocrine function in rats. 
Pancreas 2: 164-169 (1987). 
 
44. Y. C. Ge and R. G. Morgan. The effect of trypsin inhibitor on the pancreas and 
small intestine of mice. The British Journal Of Nutrition 70: 333-345 (1993). 
 
45. E. S. Swenson, W. B. Milisen, and W. Curatolo. Intestinal permeability 
enhancement: efficacy, acute local toxicity, and reversibility. Pharm Res 11: 
1132-42 (1994). 
 
46. Y. Watanabe, Y. Matsumoto, N. Hori, H. Funato, and M. Matsumoto. 
Enhanced rectal absorption of insulin in rabbits from hollow-type 
suppositories containing insulin and glyceryl-1-monooctanoate. Chem Pharm 
Bull (Tokyo) 39: 3007-12 (1991). 
 
47. K. Ichikawa, I. Ohata, M. Mitomi, S. Kawamura, H. Maeno, and H. Kawata. 
Rectal absorption of insulin suppositories in rabbits. J Pharm Pharmacol 32: 
314-8 (1980). 
 
48. S. Takatsuka, T. Morita, A. Koguchi, Y. Horikiri, H. Yamahara, and H. 
Yoshino. Synergistic absorption enhancement of salmon calcitonin and 
reversible mucosal injury by applying a mucolytic agent and a non-ionic 
surfactant. Int J Pharm (2006). 
 
49. Z. Ma and L. Y. Lim. Uptake of Chitosan and Associated Insulin in Caco-2 
Cell Monolayers: A Comparison Between Chitosan Molecules and Chitosan 
Nanoparticles. Pharm Res. 20: 1812-1819 (2003). 
 
50. J. Smith, E. Wood, and M. Dornish. Effect of Chitosan on Epithelial Cell Tight 





51. M. Thanou, J. C. Verhoef, P. Marbach, and H. E. Junginger. Intestinal 
absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the 
permeability and absorption properties of the somatostatin analogue in vitro 
and in vivo. J Pharm Sci 89: 951-7 (2000). 
 
52. B. I. Florea, M. Thanou, H. E. Junginger, and G. Borchard. Enhancement of 
bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows 
linear in vitro/in vivo correlation. J Control Release 110: 353-61 (2006). 
 
53. A. Fasano, B. Baudry, D. W. Pumplin, S. S. Wasserman, B. D. Tall, J. M. 
Ketley, and J. B. Kaper. Vibrio cholerae produces a second enterotoxin, which 
affects intestinal tight junctions. Proc Natl Acad Sci U S A 88: 5242-6 (1991). 
 
54. D. S. Cox, S. Raje, H. Gao, N. N. Salama, and N. D. Eddington. Enhanced 
permeability of molecular weight markers and poorly bioavailable compounds 
across Caco-2 cell monolayers using the absorption enhancer, zonula 
occludens toxin. Pharm Res 19: 1680-8 (2002). 
 
55. A. Fasano and S. Uzzau. Modulation of intestinal tight junctions by Zonula 
occludens toxin permits enteral administration of insulin and other 
macromolecules in an animal model. J Clin Invest 99: 1158-64 (1997). 
 
56. N. G. Schipper, S. Olsson, J. A. Hoogstraate, A. G. deBoer, K. M. Varum, and 
P. Artursson. Chitosans as absorption enhancers for poorly absorbable drugs 2: 
mechanism of absorption enhancement. Pharm Res 14: 923-9 (1997). 
 
57. F. A. Dorkoosh, C. A. Broekhuizen, G. Borchard, M. Rafiee-Tehrani, J. C. 
Verhoef, and H. E. Junginger. Transport of octreotide and evaluation of 
mechanism of opening the paracellular tight junctions using superporous 
hydrogel polymers in Caco-2 cell monolayers. J Pharm Sci 93: 743-52 (2004). 
 
58. M. Thanou, J. C. Verhoef, J. H. Verheijden, and H. E. Junginger. Intestinal 
absorption of octreotide using trimethyl chitosan chloride: studies in pigs. 
Pharm Res 18: 823-8 (2001). 
 
59. A. Fasano, C. Fiorentini, G. Donelli, S. Uzzau, J. B. Kaper, K. Margaretten, X. 
Ding, S. Guandalini, L. Comstock, and S. E. Goldblum. Zonula occludens 
toxin modulates tight junctions through protein kinase C-dependent actin 
reorganization, in vitro. J Clin Invest 96: 710-20 (1995). 
 




and A. Yamamoto. Effectiveness and toxicity screening of various absorption 
enhancers using Caco-2 cell monolayers. Biological & Pharmaceutical 
Bulletin 21: 615-620 (1998). 
 
61. H. E. Hofland, J. A. Bouwstra, J. C. Verhoef, G. Buckton, B. Z. Chowdry, M. 
Ponec, and H. E. Junginger. Safety aspects of non-ionic surfactant vesicles: a 
toxicity study related to the physicochemical characteristics of non-ionic 
surfactants. J Pharm Pharmacol 44: 287-94 (1992). 
 
62. D. Dimitrijevic, A. J. Shaw, and A. T. Florence. Effects of some non-ionic 
surfactants on transepithelial permeability in Caco-2 cells. J Pharm Pharmacol 
52: 157-62 (2000). 
 
63. G. P. Martin and C. Marriott. Membrane damage by bile salts: the protective 
function of phospholipids. J Pharm Pharmacol 33: 754-9 (1981). 
 
64. E. S. Swenson, W. B. Milisen, and W. Curatolo. Intestinal Permeability 
Enhancement: Structure-Activity and Structure-Toxicity Relationships for 
Nonylphenoxypolyoxyethylene Surfactant Permeability Enhancers. 
Pharmaceutical Research 11: 1501-1504 (1994). 
 
65. E. Scott Swenson and W. J. Curatolo. (C) Means to enhance penetration : (2) 
Intestinal permeability enhancement for proteins, peptides and other polar 
drugs: mechanisms and potential toxicity. Advanced Drug Delivery Reviews 8: 
39-92 (1992). 
 
66. A. Leone-Bay, K. K. Ho, R. Agarwal, R. A. Baughman, K. Chaudhary, F. 
DeMorin, L. Genoble, C. McInnes, C. Lercara, S. Milstein, D. O'Toole, D. 
Sarubbi, B. Variano, and D. R. Paton. 4-[4-[(2-
Hydroxybenzoyl)amino]phenyl]butyric acid as a novel oral delivery agent for 
recombinant human growth hormone. J Med Chem 39: 2571-8 (1996). 
 
67. A. Leone-Bay, M. Sato, D. Paton, A. H. Hunt, D. Sarubbi, M. Carozza, J. 
Chou, J. McDonough, and R. A. Baughman. Oral delivery of biologically 
active parathyroid hormone. Pharm Res 18: 964-70 (2001). 
 
68. A. Leone-Bay, D. R. Paton, B. Variano, H. Leipold, T. Rivera, J. Miura-
Fraboni, R. A. Baughman, and N. Santiago. Acylated non-alpha-amino acids 
as novel agents for the oral delivery of heparin sodium, USP. J Control 





69. S. J. Milstein, H. Leipold, D. Sarubbi, A. Leone-Bay, G. M. Mlynek, J. R. 
Robinson, M. Kasimova, and E. Freire. Partially unfolded proteins efficiently 
penetrate cell membranes--implications for oral drug delivery. J Control 
Release 53: 259-67 (1998). 
 
70. T. Buclin, M. Cosma Rochat, P. Burckhardt, M. Azria, and M. Attinger. 
Bioavailability and biological efficacy of a new oral formulation of salmon 
calcitonin in healthy volunteers. J Bone Miner Res 17: 1478-85 (2002). 
 
71. Z. Shen and S. Mitragotri. Intestinal patches for oral drug delivery. Pharm Res 
19: 391-5 (2002). 
 
72. K. Whitehead, Z. Shen, and S. Mitragotri. Oral delivery of macromolecules 
using intestinal patches: applications for insulin delivery. J Control Release 98: 
37-45 (2004). 
 
73. S. Eiamtrakarn, Y. Itoh, J. Kishimoto, Y. Yoshikawa, N. Shibata, M. 
Murakami, and K. Takada. Gastrointestinal mucoadhesive patch system (GI-
MAPS) for oral administration of G-CSF, a model protein. Biomaterials 23: 
145-52 (2002). 
 
74. S. L. Tao, M. W. Lubeley, and T. A. Desai. Bioadhesive poly(methyl 
methacrylate) microdevices for controlled drug delivery. J Control Release 88: 
215-28 (2003). 
 
75. H. L. Luessen, G. Borchard, A. de Boer, H. Junginger, K. Kolter, V. 
Schehlmann, and A. Sanner. Use of (meth) acrylic acid/maleic acid 
copolymers for improving mucosal permeability. In U. S. P. a. T. Office (ed) 
(U. S. P. a. T. Office, ed), BASF Aktiengesellschaft, (1999). 
 
76. F. A. Dorkoosh, J. C. Verhoef, G. Borchard, M. Rafiee-Tehrani, and H. E. 
Junginger. Development and characterization of a novel peroral peptide drug 
delivery system. J Control Release 71: 307-18 (2001). 
 
77. F. A. Dorkoosh, J. C. Verhoef, J. H. Verheijden, M. Rafiee-Tehrani, G. 
Borchard, and H. E. Junginger. Peroral absorption of octreotide in pigs 
formulated in delivery systems on the basis of superporous hydrogel polymers. 
Pharm Res 19: 1532-6 (2002). 
 
78. F. A. Dorkoosh, G. Borchard, M. Rafiee-Tehrani, J. C. Verhoef, and H. E. 




porcine intestine ex-vivo: assessment of drug transport, morphology effect, 
and mechanical fixation to intestinal wall. Eur J Pharm Biopharm 53: 161-6 
(2002). 
 
79. F. A. Dorkoosh, M. P. Stokkel, D. Blok, G. Borchard, M. Rafiee-Tehrani, J. C. 
Verhoef, and H. E. Junginger. Feasibility study on the retention of superporous 
hydrogel composite polymer in the intestinal tract of man using scintigraphy. J 
Control Release 99: 199-206 (2004). 
 
80. S. Sakuma, Y. Ishida, R. Sudo, N. Suzuki, H. Kikuchi, K.-i. Hiwatari, A. 
Kishida, M. Akashi, and M. Hayashi. Stabilization of salmon calcitonin by 
polystyrene nanoparticles having surface hydrophilic polymeric chains, against 
enzymatic degradation. International Journal of Pharmaceutics 159: 181-189 
(1997). 
 
81. A. M. Lowman, M. Morishita, M. Kajita, T. Nagai, and N. A. Peppas. Oral 
delivery of insulin using pH-responsive complexation gels. J Pharm Sci 88: 
933-7 (1999). 
 
82. H. Ichikawa and N. A. Peppas. Novel complexation hydrogels for oral peptide 
delivery: in vitro evaluation of their cytocompatibility and insulin-transport 
enhancing effects using Caco-2 cell monolayers. J Biomed Mater Res A 67: 
609-17 (2003). 
 
83. K. Nakamura, R. J. Murray, J. I. Joseph, N. A. Peppas, M. Morishita, and A. 
M. Lowman. Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of 
network morphology on insulin delivery characteristics. J Control Release 95: 
589-99 (2004). 
 
84. M. Morishita, T. Goto, K. Nakamura, A. M. Lowman, K. Takayama, and N. A. 
Peppas. Novel oral insulin delivery systems based on complexation polymer 
hydrogels: Single and multiple administration studies in type 1 and 2 diabetic 
rats. J Control Release 110: 587-94 (2006). 
 
85. D. Shah and W. C. Shen. Transcellular delivery of an insulin-transferrin 
conjugate in enterocyte-like Caco-2 cells. J Pharm Sci 85: 1306-11 (1996). 
 
86. C. Q. Xia, J. Wang, and W. C. Shen. Hypoglycemic effect of insulin-
transferrin conjugate in streptozotocin-induced diabetic rats. J Pharmacol Exp 





87. Y. Bai, D. K. Ann, and W. C. Shen. Recombinant granulocyte colony-
stimulating factor-transferrin fusion protein as an oral myelopoietic agent. 
Proc Natl Acad Sci U S A 102: 7292-6 (2005). 
 
88. A. Widera, Y. Bai, and W. C. Shen. The transepithelial transport of a G-CSF-
transferrin conjugate in Caco-2 cells and its myelopoietic effect in BDF1 mice. 
Pharm Res 21: 278-84 (2004). 
 
89. C. J. Lim and W. C. Shen. Comparison of monomeric and oligomeric 
transferrin as potential carrier in oral delivery of protein drugs. J Control 
Release 106: 273-86 (2005). 
 
90. H. M. Ekrami, A. R. Kennedy, and W. C. Shen. Water-soluble fatty acid 
derivatives as acylating agents for reversible lipidization of polypeptides. 
FEBS Lett 371: 283-6 (1995). 
 
91. J. Wang, D. Shen, and W. C. Shen. Preparation, purification, and 
characterization of a reversibly lipidized desmopressin with potentiated anti-
diuretic activity. Pharm Res 16: 1674-9 (1999). 
 
92. J. Wang and W. C. Shen. Gastric retention and stability of lipidized Bowman-
Birk protease inhibitor in mice. Int J Pharm 204: 111-6 (2000). 
 
93. J. Wang, D. Wu, and W. C. Shen. Structure-activity relationship of reversibly 
lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm Res 
19: 609-14 (2002). 
 
94. J. Wang, D. Chow, H. Heiati, and W. C. Shen. Reversible lipidization for the 
oral delivery of salmon calcitonin. J Control Release 88: 369-80 (2003). 
 
95. L. Yuan, J. Wang, and W. C. Shen. Reversible lipidization prolongs the 
pharmacological effect, plasma duration, and liver retention of octreotide. 
Pharm Res 22: 220-7 (2005). 
 
96. J. Wang, D. J. Hogenkamp, M. Tran, W. Y. Li, R. F. Yoshimura, T. B. 
Johnstone, W. C. Shen, and K. W. Gee. Reversible lipidization for the oral 
delivery of leu-enkephalin. J Drug Target 14: 127-36 (2006). 
 
97. O. Cohen, C. Kronman, T. Chitlaru, A. Ordentlich, B. Velan, and A. 




acetylcholinesterase by polyethylene glycol on its circulatory longevity. 
Biochem J 357: 795-802 (2001). 
 
98. K. D. Hinds and S. W. Kim. Effects of PEG conjugation on insulin properties. 
Adv Drug Deliv Rev 54: 505-30 (2002). 
 
99. J. M. Harris and R. B. Chess. Effect of pegylation on pharmaceuticals. Nat Rev 
Drug Discov 2: 214-21 (2003). 
 
100. J. Ramon, V. Saez, R. Baez, R. Aldana, and E. Hardy. PEGylated interferon-
alpha2b: a branched 40K polyethylene glycol derivative. Pharm Res 22: 1374-
86 (2005). 
 
101. J. M. Harris, N. E. Martin, and M. Modi. Pegylation: a novel process for 
modifying pharmacokinetics. Clin Pharmacokinet 40: 539-51 (2001). 
 
102. K. C. Lee, M. O. Park, D. H. Na, Y. S. Youn, S. D. Lee, S. D. Yoo, H. S. Lee, 
and P. P. DeLuca. Intranasal delivery of PEGylated salmon calcitonins: 
hypocalcemic effects in rats. Calcif Tissue Int 73: 545-9 (2003). 
 
103. P. Calceti, S. Salmaso, G. Walker, and A. Bernkop-Schnurch. Development 
and in vivo evaluation of an oral insulin-PEG delivery system. Eur J Pharm 
Sci 22: 315-23 (2004). 
 
104. H. L. Luessen, J. C. Verhoef, G. Borchard, C. M. Lehr, A. G. de Boer, and H. 
E. Junginger. Mucoadhesive polymers in peroral peptide drug delivery. II. 
Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic 
enzyme trypsin. Pharm Res 12: 1293-8 (1995). 
 
105. V. M. Leitner, G. F. Walker, and A. Bernkop-Schnurch. Thiolated polymers: 
evidence for the formation of disulphide bonds with mucus glycoproteins. Eur 
J Pharm Biopharm 56: 207-14 (2003). 
 
106. D. H. Na, Y. S. Youn, E. J. Park, J. M. Lee, O. R. Cho, K. R. Lee, S. D. Lee, S. 
D. Yoo, P. P. DeLuca, and K. C. Lee. Stability of PEGylated salmon calcitonin 
in nasal mucosa. J Pharm Sci 93: 256-61 (2004). 
 
107. R. Savic, L. Luo, A. Eisenberg, and D. Maysinger. Micellar nanocontainers 





108. C. M. Chin, M. Gutierrez, J. G. Still, and G. Kosutic. Pharmacokinetics of 
modified oral calcitonin product in healthy volunteers. Pharmacotherapy 24: 
994-1001 (2004). 
 
109. N. Ekwuribe, M. Ramaswamy, and J. S. Rajagopalan. Amphiphilic drug-
oligomer conjugates with hydroyzable lipophile components and methods for 
making and using the same. In U. S. P. a. T. Office (ed), United States Patent 
and Trademark Office (U. S. P. a. T. Office, ed), Nobex Corporation, US, 
2001. 
 
110. A. Cataliotti, J. A. Schirger, F. L. Martin, H. H. Chen, P. M. McKie, G. 
Boerrigter, L. C. Costello-Boerrigter, G. Harty, D. M. Heublein, S. M. 
Sandberg, K. D. James, M. A. Miller, N. B. Malkar, K. Polowy, and J. C. 
Burnett, Jr. Oral human brain natriuretic peptide activates cyclic guanosine 
3',5'-monophosphate and decreases mean arterial pressure. Circulation 112: 
836-40 (2005). 
 
111. M. A. Miller, N. B. Malkar, D. Severynse-Stevens, K. G. Yarbrough, M. J. 
Bednarcik, R. E. Dugdell, M. E. Puskas, R. Krishnan, and K. D. James. 
Amphiphilic conjugates of human brain natriuretic Peptide designed for oral 
delivery: in vitro activity screening. Bioconjug Chem 17: 267-74 (2006). 
 
112. C. A. DiCostanzo, M. C. Moore, M. Lautz, M. Scott, B. Farmer, C. A. Everett, 
J. G. Still, A. Higgins, and A. D. Cherrington. Simulated first-phase insulin 
release using Humulin or insulin analog HIM2 is associated with prolonged 
improvement in postprandial glycemia. Am J Physiol Endocrinol Metab 289: 
E46-52 (2005). 
 
113. S. Clement, P. Dandona, J. G. Still, and G. Kosutic. Oral modified insulin 
(HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II 
clinical trial. Metabolism 53: 54-8 (2004). 
 
114. M. Kipnes, P. Dandona, D. Tripathy, J. G. Still, and G. Kosutic. Control of 
postprandial plasma glucose by an oral insulin product (HIM2) in patients with 
type 2 diabetes. Diabetes Care 26: 421-6 (2003). 
 
115. S. V. Komarova, J. B. Shum, L. A. Paige, S. M. Sims, and S. J. Dixon. 
Regulation of osteoclasts by calcitonin and amphiphilic calcitonin conjugates: 
role of cytosolic calcium. Calcif Tissue Int 73: 265-73 (2003). 
 
116. C. Price. NOBEX Corporation: Crossing Barriers for Better Drug Delivery. 





117. A. Yamamoto, Y. Morishita, S. Sugishita, T. Hayami, N. Okada, T. Fujita, and 
S. Muranishi. Enhanced permeability of phenylalanyl-glycine (Phe-Gly) across 
the intestinal membranes by chemical modification with various fatty acids. 
Drug Metab Pharmacokinet 18: 23-32 (2003). 
 
118. A. V. Kabanov, A. V. Ovcharenko, N. S. Melik-Hubarov, A. I. Bannikov, V. 
Alakhov, V. I. Kiselev, P. G. Sveshnikov, O. I. Kiselev, A. V. Levashov, and 
E. S. Severin. Fatty acid acylated antibodies against virus suppress its 
reproduction in cells. FEBS Lett 250: 238-40 (1989). 
 
119. M. Hashimoto, K. Takada, Y. Kiso, and S. Muranishi. Synthesis of palmitoyl 
derivatives of insulin and their biological activities. Pharm Res 6: 171-6 
(1989). 
 
120. G. A. Brunner, G. Sendhofer, A. Wutte, M. Ellmerer, B. Sogaard, A. 
Siebenhofer, S. Hirschberger, G. J. Krejs, and T. R. Pieber. Pharmacokinetic 
and pharmacodynamic properties of long-acting insulin analogue NN304 in 
comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 108: 
100-5 (2000). 
 
121. S. Lee, K. Kim, T. S. Kumar, J. Lee, S. K. Kim, D. Y. Lee, Y. K. Lee, and Y. 
Byun. Synthesis and biological properties of insulin-deoxycholic acid 
chemical conjugates. Bioconjug Chem 16: 615-20 (2005). 
 
122. N. A. Lockwood, J. R. Haseman, M. V. Tirrell, and K. H. Mayo. Acylation of 
SC4 dodecapeptide increases bactericidal potency against Gram-positive 
bacteria, including drug-resistant strains. Biochem J 378: 93-103 (2004). 
 
123. F. Delie, P. Couvreur, D. Nisato, J. B. Michel, F. Puisieux, and Y. Letourneux. 
Synthesis and in vitro study of a diglyceride prodrug of a peptide. Pharm Res 
11: 1082-7 (1994). 
 
124. M. Ellmerer, M. Hamilton-Wessler, S. P. Kim, M. K. Dea, E. Kirkman, A. 
Perianayagam, J. Markussen, and R. N. Bergman. Mechanism of action in 
dogs of slow-acting insulin analog O346. J Clin Endocrinol Metab 88: 2256-
62 (2003). 
 
125. S. Havelund, A. Plum, U. Ribel, I. Jonassen, A. Volund, J. Markussen, and P. 
Kurtzhals. The mechanism of protraction of insulin detemir, a long-acting, 





126. G. Saito, J. A. Swanson, and K. D. Lee. Drug delivery strategy utilizing 
conjugation via reversible disulfide linkages: role and site of cellular reducing 
activities. Adv Drug Deliv Rev 55: 199-215 (2003). 
 
127. M. Azria. The calcitonins : physiology and pharmacology, Karger, Basel ; 
New York, 1989. 
 
128. M. Zaidi, A. M. Inzerillo, B. S. Moonga, P. J. Bevis, and C. L. Huang. Forty 
years of calcitonin--where are we now? A tribute to the work of Iain Macintyre, 
FRS. Bone 30: 655-63 (2002). 
 
129. M. V. Ray, P. Van Duyne, A. H. Bertelsen, D. E. Jackson-Matthews, A. M. 
Sturmer, D. J. Merkler, A. P. Consalvo, S. D. Young, J. P. Gilligan, and P. P. 
Shields. Production of recombinant salmon calcitonin by in vitro amidation of 
an Escherichia coli produced precursor peptide. Biotechnology (N Y) 11: 64-70 
(1993). 
 
130. D. Guggi and A. Bernkop-Schnurch. In vitro evaluation of polymeric 
excipients protecting calcitonin against degradation by intestinal serine 
proteases. Int J Pharm 252: 187-96 (2003). 
 
131. M. D. Taylor and G. L. Amidon. Peptide-based drug design : controlling 
transport and metabolism, American Chemical Society, Washington, DC, 
1995. 
 
132. P. J. Sinko, C. L. Smith, L. T. McWhorter, W. Stern, E. Wagner, and J. P. 
Gilligan. Utility of pharmacodynamic measures for assessing the oral 
bioavailability of peptides. 1. Administration of recombinant salmon calcitonin 
in rats. J Pharm Sci 84: 1374-8 (1995). 
 
133. D. Guggi, A. H. Krauland, and A. Bernkop-Schnurch. Systemic peptide 
delivery via the stomach: in vivo evaluation of an oral dosage form for salmon 
calcitonin. J Control Release 92: 125-35 (2003). 
 
134. C. Prego, M. Garcia, D. Torres, and M. J. Alonso. Transmucosal 
macromolecular drug delivery. J Control Release 101: 151-62 (2005). 
 
135. D. Guggi, C. E. Kast, and A. Bernkop-Schnurch. In vivo evaluation of an oral 
salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. 





136. M. Garcia-Fuentes, C. Prego, D. Torres, and M. J. Alonso. A comparative 
study of the potential of solid triglyceride nanostructures coated with chitosan 
or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm 
Sci 25: 133-43 (2005). 
 
137. C. Prego, M. Fabre, D. Torres, and M. J. Alonso. Efficacy and mechanism of 
action of chitosan nanocapsules for oral Peptide delivery. Pharm Res 23: 549-
56 (2006). 
 
138. C. Prego, D. Torres, E. Fernandez-Megia, R. Novoa-Carballal, E. Quinoa, and 
M. J. Alonso. Chitosan-PEG nanocapsules as new carriers for oral peptide 
delivery Effect of chitosan pegylation degree. J Control Release 111: 299-308 
(2006). 
 
139. K. H. Song, S. J. Chung, and C. K. Shim. Enhanced intestinal absorption of 
salmon calcitonin (sCT) from proliposomes containing bile salts. J Control 
Release 106: 298-308 (2005). 
 
140. S. Sakuma, N. Suzuki, R. Sudo, K.-i. Hiwatari, A. Kishida, and M. Akashi. 
Optimized chemical structure of nanoparticles as carriers for oral delivery of 
salmon calcitonin. International Journal of Pharmaceutics 239: 185-195 
(2002). 
 
141. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima. pH-sensitive 
microsphere delivery increases oral bioavailability of calcitonin. J Control 
Release 98: 1-9 (2004). 
 
142. H. Sang Yoo and T. Gwan Park. Biodegradable nanoparticles containing 
protein-fatty acid complexes for oral delivery of salmon calcitonin. J Pharm 
Sci 93: 488-95 (2004). 
 
143. S. Mansoor, Y. S. Youn, and K. C. Lee. Oral delivery of mono-PEGylated sCT 
(Lys18) in rats: regional difference in stability and hypocalcemic effect. 
Pharm Dev Technol 10: 389-96 (2005). 
 
144. T. Fujita, T. Fujita, K. Morikawa, H. Tanaka, O. Iemura, A. Yamamoto, and S. 
Muranishi. Improvement of intestinal absorption of human calcitonin by 
chemical modification with fatty acids: Synergistic effects of acylation and 





145. Y. Onuki, M. Morishita, and K. Takayama. Formulation optimization of 
water-in-oil-water multiple emulsion for intestinal insulin delivery. J Control 
Release 97: 91-9 (2004). 
 
146. M. Morishita, M. Kajita, A. Suzuki, K. Takayama, Y. Chiba, S. Tokiwa, and T. 
Nagai. The dose-related hypoglycemic effects of insulin emulsions 
incorporating highly purified EPA and DHA. Int J Pharm 201: 175-85 (2000). 
 
147. J. Markussen, S. Havelund, P. Kurtzhals, A. S. Andersen, J. Halstrom, E. 
Hasselager, U. D. Larsen, U. Ribel, L. Schaffer, K. Vad, and I. Jonassen. 
Soluble, fatty acid acylated insulins bind to albumin and show protracted 
action in pigs. Diabetologia 39: 281-8 (1996). 
 
148. Y. Wang, H. Dou, C. Cao, N. Zhang, J. Ma, J. Mao, and H. Wu. Solution 
structure and biological activity of recombinant salmon calcitonin S-sulfonated 
analog. Biochem Biophys Res Commun 306: 582-9 (2003). 
 
149. R. C. Orlowski, R. M. Epand, and A. R. Stafford. Biologically potent 
analogues of salmon calcitonin which do not contain an N-terminal disulfide-
bridged ring structure. Eur J Biochem 162: 399-402 (1987). 
 
150. B. Bjellqvist, B. Basse, E. Olsen, and J. E. Celis. Reference points for 
comparisons of two-dimensional maps of proteins from different human cell 
types defined in a pH scale where isoelectric points correlate with polypeptide 
compositions. Electrophoresis 15: 529-39 (1994). 
 
151. G. Drin, S. Cottin, E. Blanc, A. R. Rees, and J. Temsamani. Studies on the 
internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 
278: 31192-201 (2003). 
 
152. M. E. Lindgren, M. M. Hallbrink, A. M. Elmquist, and U. Langel. Passage of 
cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem 
J 377: 69-76 (2004). 
 
153. H. J. Ryser and R. Hancock. Histones and basic polyamino acids stimulate the 
uptake of albumin by tumor cells in culture. Science 150: 501-3 (1965). 
 
154. M. Pooga, C. Kut, M. Kihlmark, M. Hallbrink, S. Fernaeus, R. Raid, T. Land, 
E. Hallberg, T. Bartfai, and U. Langel. Cellular translocation of proteins by 





155. J. Carlsson, H. Drevin, and R. Axen. Protein thiolation and reversible protein-
protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new 
heterobifunctional reagent. Biochem J 173: 723-37 (1978). 
 
156. H. Schagger and G. von Jagow. Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis for the separation of proteins in the range 
from 1 to 100 kDa. Anal Biochem 166: 368-79 (1987). 
 
157. S. Sunita, H. Zhenxing, J. Swaathi, M. Cygler, A. Matte, and J. Sivaraman. 
Domain organization and crystal structure of the catalytic domain of E.coli 
RluF, a pseudouridine synthase that acts on 23S rRNA. J Mol Biol 359: 998-
1009 (2006). 
 
158. J. C. Van Loon. Analytical atomic absorption spectroscopy : selected methods, 
Academic Press, New York, 1980. 
 
159. L. J. Deftos. Immunoassay for human calcitonin. I. Method. Metabolism 20: 
1122-8 (1971). 
 
160. L. J. Deftos, A. E. Bury, J. F. Habener, F. R. Singer, and J. T. Potts, Jr. 
Immunoassay for human calcitonin. II. Clinical studies. Metabolism 20: 1129-
37 (1971). 
 
161. Y. Hee Lee, G. D. Leesman, V. Makhey, H. Yu, P. Hu, B. Perry, J. P. Sutyak, 
E. J. Wagner, L. M. Falzone, W. Stern, and P. J. Sinko. Regional oral 
absorption, hepatic first-pass effect, and non-linear disposition of salmon 
calcitonin in beagle dogs. Eur J Pharm Biopharm 50: 205-11 (2000). 
 
162. M. Miyazaki, S. Nakade, K. Iwanaga, K. Morimoto, and M. Kakemi. 
Estimation of bioavailability of salmon calcitonin from the hypocalcemic 
effect in rats (I): pharmacokinetic-pharmacodynamic modeling based on the 
endogenous Ca regulatory system. Drug Metab Pharmacokinet 18: 350-7 
(2003). 
 
163. M. Hinchcliffe, I. Jabbal-Gill, and A. Smith. Effect of chitosan on the 
intranasal absorption of salmon calcitonin in sheep. J Pharm Pharmacol 57: 
681-7 (2005). 
 
164. P. J. Lowe and C. S. Temple. Calcitonin and insulin in isobutylcyanoacrylate 
nanocapsules: protection against proteases and effect on intestinal absorption 





165. C. W. Cooper, T. C. Peng, J. F. Obie, and S. C. Garner. Calcitonin-like 
immunoreactivity in rat and human pituitary glands: histochemical, in vitro, 
and in vivo studies. Endocrinology 107: 98-107 (1980). 
 
166. K. H. Song, H. M. An, H. J. Kim, S. H. Ahn, S. J. Chung, and C. K. Shim. 
Simple liquid chromatography-electrospray ionization mass spectrometry 
method for the routine determination of salmon calcitonin in serum. J 
Chromatogr B Analyt Technol Biomed Life Sci 775: 247-55 (2002). 
 
167. T. Mosmann. Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods 65: 
55-63 (1983). 
 
168. D. Gerlier and N. Thomasset. Use of MTT colorimetric assay to measure cell 
activation. J Immunol Methods 94: 57-63 (1986). 
 
169. M. Ferrari, M. C. Fornasiero, and A. M. Isetta. MTT colorimetric assay for 
testing macrophage cytotoxic activity in vitro. J Immunol Methods 131: 165-
72 (1990). 
 
170. Y. Mo and L. Y. Lim. Paclitaxel-loaded PLGA nanoparticles: potentiation of 
anticancer activity by surface conjugation with wheat germ agglutinin. J 
Control Release 108: 244-62 (2005). 
 
171. K. Shao, Q. Hou, W. Duan, M. L. Go, K. P. Wong, and Q. T. Li. Intracellular 
drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release 
115: 150-7 (2006). 
 
172. T. Okada, T. Sawada, and K. Kubota. Deferoxamine enhances anti-
proliferative effect of interferon-gamma against hepatocellular carcinoma cells. 
Cancer Lett 248: 24-31 (2007). 
 
173. H. S. Hwang, D. W. Kim, and S. S. Kim. Structure-activity relationships of the 
human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative 
activity and cellular internalization. Biochem J 395: 165-72 (2006). 
 
174. M. Huang, E. Khor, and L. Y. Lim. Uptake and cytotoxicity of chitosan 
molecules and nanoparticles: effects of molecular weight and degree of 





175. F. A. Dorkoosh, D. Setyaningsih, G. Borchard, M. Rafiee-Tehrani, J. C. 
Verhoef, and H. E. Junginger. Effects of superporous hydrogels on 
paracellular drug permeability and cytotoxicity studies in Caco-2 cell 
monolayers. Int J Pharm 241: 35-45 (2002). 
 
176. P. V. Paranjpe, Y. Chen, V. Kholodovych, W. Welsh, S. Stein, and P. J. Sinko. 
Tumor-targeted bioconjugate based delivery of camptothecin: design, 
synthesis and in vitro evaluation. J Control Release 100: 275-92 (2004). 
 
177. F. Greco, M. J. Vicent, N. A. Penning, R. I. Nicholson, and R. Duncan. HPMA 
copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell 
lines. J Drug Target 13: 459-70 (2005). 
 
178. Q. Cai and Z. R. Zhang. Lectin-mediated cytotoxicity and specificity of 5-
fluorouracil conjugated with peanut agglutinin (5-Fu-PNA) in vitro. J Drug 
Target 13: 251-7 (2005). 
 
179. B. Hallgas, T. Patonay, A. Kiss-Szikszai, Z. Dobos, F. Hollosy, D. Eros, L. 
Orfi, G. Keri, and M. Idei. Comparison of measured and calculated 
lipophilicity of substituted aurones and related compounds. J Chromatogr B 
Analyt Technol Biomed Life Sci 801: 229-35 (2004). 
 
180. V. Keil-Dlouha, N. Zylber, J. M. Imhoff, N. T. Tong, and B. Keil. Proteolytic 
activity of pseudotrypsin. FEBS Letters 16: 291-295 (1971). 
 
181. V. V. Keil-Dlouha, N. Zylber, N. Tong, and B. Keil. Cleavage of glucagon by 
alpha- and beta-trypsin. FEBS Lett 16: 287-290 (1971). 
 
182. K. C. Lee, S. C. Moon, M. O. Park, J. T. Lee, D. H. Na, S. D. Yoo, H. S. Lee, 
and P. P. DeLuca. Isolation, characterization, and stability of positional 
isomers of mono-PEGylated salmon calcitonins. Pharm Res 16: 813-8 (1999). 
 
183. M. Zhao, C. Hartke, A. Jimeno, J. Li, P. He, Y. Zabelina, M. Hidalgo, and S. 
D. Baker. Specific method for determination of gefitinib in human plasma, 
mouse plasma and tissues using high performance liquid chromatography 
coupled to tandem mass spectrometry. Journal of Chromatography B 819: 73-
80 (2005). 
 
184. H. F. Gilbert. Thiol/disulfide exchange equilibria and disulfide bond stability. 





185. M. Jemal and D. J. Hawthorne. Quantitative determination of BMS-186716, a 
thiol compound, in rat plasma by high-performance liquid chromatography-
positive ion electrospray mass spectrometry after hydrolysis of the methyl 
acrylate adduct by the native esterases. J Chromatogr B Biomed Sci Appl 698: 
123-32 (1997). 
 
186. J. Z. Yang, W. Chen, and R. T. Borchardt. In vitro stability and in vivo 
pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-
Leu-OH (DADLE), and its cyclic prodrugs. J Pharmacol Exp Ther 303: 840-8 
(2002). 
 
187. Sigma-Adrich. MSDS form of  THYROCALCITONIN SALMON  
 
188. B. Smedsrod, H. Pertoft, S. Gustafson, and T. C. Laurent. Scavenger functions 
of the liver endothelial cell. Biochem J 266: 313-27 (1990). 
 
189. R. W. Jansen, G. Molema, G. Harms, J. K. Kruijt, T. J. van Berkel, M. J. 
Hardonk, and D. K. Meijer. Formaldehyde treated albumin contains 
monomeric and polymeric forms that are differently cleared by endothelial and 
Kupffer cells of the liver: evidence for scavenger receptor heterogeneity. 
Biochem Biophys Res Commun 180: 23-32 (1991). 
 
190. E. P. Feener, W. C. Shen, and H. J. Ryser. Cleavage of disulfide bonds in 
endocytosed macromolecules. A processing not associated with lysosomes or 
endosomes. J Biol Chem 265: 18780-5 (1990). 
 
191. T. J. Van Berkel, Y. B. De Rijke, and J. K. Kruijt. Different fate in vivo of 
oxidatively modified low density lipoprotein and acetylated low density 
lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and 
endothelial liver cells. J Biol Chem 266: 2282-9 (1991). 
 
192. A. Motta, A. Pastore, N. A. Goud, and M. A. Castiglione Morelli. Solution 
conformation of salmon calcitonin in sodium dodecyl sulfate micelles as 
determined by two-dimensional NMR and distance geometry calculations. 
Biochemistry 30: 10444-50 (1991). 
 
193. V. Christmann, J. Rosenberg, J. Seega, and C. M. Lehr. Simultaneous in vivo 
visualization and localization of solid oral dosage forms in the rat 






194. M. P. Desai, V. Labhasetwar, E. Walter, R. J. Levy, and G. L. Amidon. The 
mechanism of uptake of biodegradable microparticles in Caco-2 cells is size 
dependent. Pharm Res 14: 1568-73 (1997). 
 
195. H. Asada, T. Douen, Y. Mizokoshi, T. Fujita, M. Murakami, A. Yamamoto, 
and S. Muranishi. Stability of acyl derivatives of insulin in the small intestine: 
relative importance of insulin association characteristics in aqueous solution. 
Pharm Res 11: 1115-20 (1994). 
 
196. J. H. Cort, O. Schuck, J. Stribrna, J. Skopkova, K. Jost, and J. L. Mulder. Role 
of the disulfide bridge and the C-terminal tripeptide in the antidiuretic action 
of vasopressin in man and the rat. Kidney Int 8: 292-302 (1975). 
 
197. S. Gazal, G. Gelerman, O. Ziv, O. Karpov, P. Litman, M. Bracha, M. Afargan, 
and C. Gilon. Human somatostatin receptor specificity of backbone-cyclic 
analogues containing novel sulfur building units. J Med Chem 45: 1665-71 
(2002). 
 
198. M. Afargan, E. T. Janson, G. Gelerman, R. Rosenfeld, O. Ziv, O. Karpov, A. 
Wolf, M. Bracha, D. Shohat, G. Liapakis, C. Gilon, A. Hoffman, D. 
Stephensky, and K. Oberg. Novel long-acting somatostatin analog with 
endocrine selectivity: potent suppression of growth hormone but not of insulin. 
Endocrinology 142: 477-86 (2001). 
 
199. C. Peters, A. Wolf, M. Wagner, J. Kuhlmann, and H. Waldmann. The 
cholesterol membrane anchor of the Hedgehog protein confers stable 
membrane association to lipid-modified proteins. Proc Natl Acad Sci U S A 
101: 8531-6 (2004). 
 
200. J. T. Elliott and G. D. Prestwich. Maleimide-functionalized lipids that anchor 
polypeptides to lipid bilayers and membranes. Bioconjug Chem 11: 832-41 
(2000). 
 
201. O. Keller and J. Rudinger. Preparation and some properties of maleimido acids 
and maleoyl derivatives of peptides. Helv Chim Acta 58: 531-41 (1975). 
 
202. K. Wakisaka, Y. Arano, T. Uezono, H. Akizawa, M. Ono, K. Kawai, Y. 
Ohomomo, M. Nakayama, and H. Saji. A novel radioiodination reagent for 
protein radiopharmaceuticals with L-lysine as a plasma-stable metabolizable 




Chem 40: 2643-52 (1997). 
 
203. G. T. Hermanson. Bioconjugate techniques, Academic Press, San Diego, 1996. 
 
204. Z. Ma and L. Y. Lim. Uptake of chitosan and associated insulin in Caco-2 cell 
monolayers: a comparison between chitosan molecules and chitosan 
nanoparticles. Pharm Res 20: 1812-9 (2003). 
 
205. T. Uchiyama, A. Kotani, H. Tatsumi, T. Kishida, A. Okamoto, N. Okada, M. 
Murakami, T. Fujita, Y. Fujiwara, Y. Kiso, S. Muranishi, and A. Yamamoto. 
Development of novel lipophilic derivatives of DADLE (leucine enkephalin 
analogue): intestinal permeability characateristics of DADLE derivatives in 
rats. Pharm Res 17: 1461-7 (2000). 
 
206. Y. J. Tsai, A. Rottero, D. D. Chow, K. J. Hwang, V. H. Lee, G. Zhu, and K. K. 
Chan. Synthesis and purification of NB1-palmitoyl insulin. J Pharm Sci 86: 
1264-8 (1997). 
 
207. M. Sukumar, S. M. Storms, and M. R. De Felippis. Non-native intermediate 
conformational states of human growth hormone in the presence of organic 
solvents. Pharm Res 22: 789-96 (2005). 
 
208. H. Sah. Protein behavior at the water/methylene chloride interface. J Pharm 
Sci 88: 1320-5 (1999). 
 
209. K. Nishiki, S. Tsuruoka, M. Wakaumi, H. Yamamoto, A. Koyama, and A. 
Fujimura. Dosing time-dependent variation in the hypocalcemic effect of 
calcitonin in rat. Eur J Pharmacol 460: 171-5 (2003). 
 
210. H. B. Olsen and N. C. Kaarsholm. Structural effects of protein lipidation as 
revealed by LysB29-myristoyl, des(B30) insulin. Biochemistry 39: 11893-900 
(2000). 
 
211. E. Yodoya, K. Uemura, T. Tenma, T. Fujita, M. Murakami, A. Yamamoto, 
and S. Muranishi. Enhanced permeability of tetragastrin across the rat 
intestinal membrane and its reduced degradation by acylation with various 
fatty acids. J Pharmacol Exp Ther 271: 1509-13 (1994). 
 
212. L. Heinemann, K. Sinha, C. Weyer, M. Loftager, S. Hirschberger, and T. 




insulin analogue NN304. Diabet Med 16: 332-8 (1999). 
 
213. H. Chen and R. Langer. Oral particulate delivery: status and future trends. Adv 
Drug Deliv Rev 34: 339-350 (1998). 
 
214. Y. V. Frenkel, A. D. Clark, Jr., K. Das, Y. H. Wang, P. J. Lewi, P. A. Janssen, 
and E. Arnold. Concentration and pH dependent aggregation of hydrophobic 
drug molecules and relevance to oral bioavailability. J Med Chem 48: 1974-83 
(2005). 
 
215. E. C. Lavelle, S. Sharif, N. W. Thomas, J. Holland, and S. S. Davis. The 
importance of gastrointestinal uptake of particles in the design of oral delivery 
systems. Advanced Drug Delivery Reviews 18: 5-22 (1995). 
 
216. G. Levy. Impact of pharmacodynamic variability on drug delivery(1). Adv 
Drug Deliv Rev 33: 201-206 (1998). 
 
217. H. Mei, C. Yu, and K. K. Chan. NB1-C16-insulin: site-specific synthesis, 
purification, and biological activity. Pharm Res 16: 1680-6 (1999). 
 
218. I. Zofkova, K. Zajickova, and M. Hill. Postmenopausal serum androstenedione 
levels are associated with the calcitonin receptor gene polymorphism T1377c. 
A pilot study. J Endocrinol Invest 27: 442-4 (2004). 
 
219. V. Braga, A. Sangalli, G. Malerba, M. Mottes, S. Mirandola, D. Gatti, M. 
Rossini, M. Zamboni, and S. Adami. Relationship among VDR (BsmI and 
FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover 
markers, and sex hormones in men. Calcif Tissue Int 70: 457-62 (2002). 
 
220. H. Nakamuta, R. C. Orlowski, and R. M. Epand. Evidence for calcitonin 
receptor heterogeneity: binding studies with nonhelical analogs. 
Endocrinology 127: 163-9 (1990). 
 
221. J. M. Hilton, S. Y. Chai, and P. M. Sexton. In vitro autoradiographic 
localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain. 
Neuroscience 69: 1223-37 (1995). 
 
222. P. M. Sexton, S. Houssami, J. M. Hilton, L. M. O'Keeffe, R. J. Center, M. T. 
Gillespie, P. Darcy, and D. M. Findlay. Identification of brain isoforms of the 





223. M. Ikegame, M. Rakopoulos, H. Zhou, S. Houssami, T. J. Martin, J. M. 
Moseley, and D. M. Findlay. Calcitonin receptor isoforms in mouse and rat 
osteoclasts. J Bone Miner Res 10: 59-65 (1995). 
 
224. G. Siligardi, B. Samori, S. Melandri, M. Visconti, and A. F. Drake. 
Correlations between biological activities and conformational properties for 
human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD 
spectroscopy. Eur J Biochem 221: 1117-25 (1994). 
 
225. S. Houssami, D. M. Findlay, C. L. Brady, T. J. Martin, R. M. Epand, E. E. 
Moore, E. Murayama, T. Tamura, R. C. Orlowski, and P. M. Sexton. 
Divergent structural requirements exist for calcitonin receptor binding 
specificity and adenylate cyclase activation. Mol Pharmacol 47: 798-809 
(1995). 
 
226. M. O. Goodarzi, K. D. Taylor, X. Guo, M. J. Quinones, J. Cui, X. Li, T. Hang, 
H. Yang, E. Holmes, W. A. Hsueh, J. Olefsky, and J. I. Rotter. Variation in the 
gene for muscle-specific AMP deaminase is associated with insulin clearance, 
a highly heritable trait. Diabetes 54: 1222-7 (2005). 
 
227. B. S. Shin, J. H. Jung, K. C. Lee, and S. D. Yoo. Nasal absorption and 
pharmacokinetic disposition of salmon calcitonin modified with low molecular 
weight polyethylene glycol. Chem Pharm Bull (Tokyo) 52: 957-60 (2004). 
 
228. T. L. Cheng, B. M. Chen, L. Y. Chan, P. Y. Wu, J. W. Chern, and S. R. 
Roffler. Poly(ethylene glycol) modification of beta-glucuronidase-antibody 
conjugates for solid-tumor therapy by targeted activation of glucuronide 
prodrugs. Cancer Immunol Immunother 44: 305-15 (1997). 
 
229. B. N. Manjula, A. G. Tsai, M. Intaglietta, C. H. Tsai, C. Ho, P. K. Smith, K. 
Perumalsamy, N. D. Kanika, J. M. Friedman, and S. A. Acharya. Conjugation 
of multiple copies of polyethylene glycol to hemoglobin facilitated through 
thiolation: influence on hemoglobin structure and function. Protein J 24: 133-
46 (2005). 
 
230. P. Bailon, A. Palleroni, C. A. Schaffer, C. L. Spence, W. J. Fung, J. E. Porter, 
G. K. Ehrlich, W. Pan, Z. X. Xu, M. W. Modi, A. Farid, W. Berthold, and M. 
Graves. Rational design of a potent, long-lasting form of interferon: a 40 kDa 
branched polyethylene glycol-conjugated interferon alpha-2a for the treatment 





231. Y. S. Youn, J. Y. Jung, S. H. Oh, S. D. Yoo, and K. C. Lee. Improved 
intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: 
stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic 
efficacy. J Control Release 114: 334-42 (2006). 
 
232. C. Monfardini, O. Schiavon, P. Caliceti, M. Morpurgo, J. M. Harris, and F. M. 
Veronese. A branched monomethoxypoly(ethylene glycol) for protein 
modification. Bioconjug Chem 6: 62-9 (1995). 
 
233. L. Serra, J. Domenech, and N. A. Peppas. Design of poly(ethylene glycol)-
tethered copolymers as novel mucoadhesive drug delivery systems. Eur J 
Pharm Biopharm (2005). 
 
234. M. Morishita, T. Goto, K. Nakamura, A. M. Lowman, K. Takayama, and N. A. 
Peppas. Novel oral insulin delivery systems based on complexation polymer 
hydrogels: Single and multiple administration studies in type 1 and 2 diabetic 
rats. J Control Release (2005). 
 
235. M. Morishita, T. Goto, N. A. Peppas, J. I. Joseph, M. C. Torjman, C. Munsick, 
K. Nakamura, T. Yamagata, K. Takayama, and A. M. Lowman. Mucosal 
insulin delivery systems based on complexation polymer hydrogels: effect of 
particle size on insulin enteral absorption. J Control Release 97: 115-24 (2004). 
 
 
 
 
